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Abstract 
 
Cancers receive nutrients, convey waste and metastasise by a dynamic vasculature. 
Heterogeneous vessels are created by angiogenesis and vasculogenesis. The 
endothelium, via the angiogenic switch, is central to both processes. Assessing its 
activities in colorectal cancer (CRC) has promising applications, more so recently for 
monitoring anti-angiogenic therapies. However no single marker has translated to 
clinical care and many are altered in other tumours and non-cancer disorders. 
Hence, the ‘endotheliome’, the multifactorial assessment of endothelial activity and 
its subset, the ‘angiome’ (angiogenic activity), are proposed. I hypothesised and 
tested that together, circulating cellular and plasma biomarkers are more important 
determinants of stage, prognosis, and treatment outcomes than a single test. 
 
An improved and validated flow cytometry assay quantified circulating endothelial 
cells (CECs, displaced from blood vessels) and endothelial progenitor cells (EPCs, 
for vasculogenesis). The plasma markers, measured by ELISA, were: von Willebrand 
factor (vWf, for endothelial damage/turnover), soluble E-selectin (for endothelial 
adhesion in tumour migration), vascular endothelial growth factor (VEGF) and 
angiogenin (for the ‘angiogenic switch’). Markers were prospectively quantified in 
CRC participants before treatment and compared to non-cancer controls. They were 
tested against the tumour’s clinico-pathological features. The assays were repeated 
3 and 6 months after surgery or, where applicable, before and after adjuvant therapy.  
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CECs and EPCs were highest in CRC and correlated to VEGF only. Both increased 
in a linear trend with CRC stage and differentiation. Angiogenin was diagnostic of 
CRC and vWf detected metastatic disease. All markers fell after surgery but varied 
after adjuvant treatment. Only lower CD34+CD45- cells identified responders to anti-
angiogenic therapy. Mathematical models, incorporating pre-treatment CEC, EPC 
and angiogenin levels with CRC stage, predicted progression within 2 years. 
 
In summary, the endotheliome and angiome are important to understanding the 
vascular biology of CRC staging and prognosis. Clinically, they are crucial 
determinants of outcomes and may therefore aid decisions on therapeutic strategies.  
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Chapter 1 
Introduction 
 
 
1.1 General introduction 
 
After cardiovascular disease, cancer is the second greatest burden on human health. 
With approximately 13% of all deaths (7.4 million), it is the leading cause of mortality 
worldwide (1). In the UK, colorectal cancer (CRC) is responsible for 16,000 of the 
150,000 cancer deaths annually, and is the second most common cause after lung 
cancer. It remains the third most frequently occurring with 38,000 new cases per 
year, the second most common in women after breast cancer and, likewise in men, 
third after prostate and lung cancer (2, 3).  
 
With over a hundred new cases per day, CRC places a great demand on resources 
for diagnosis, counselling, specialist treatment (i.e. surgery, radiotherapy and 
chemotherapy), specialist services (e.g. stoma care, palliative services), and follow-
up typically over five years. Furthermore, advances in treatment will eventually push 
cancer into the realms of chronic diseases, similar to diabetes or rheumatoid arthritis 
(4). A greater burden on health economics is likely from better therapies and, 
consequentially, the long-term surveillance required. Already in a relatively short 
period earlier diagnosis and improved treatment doubled the 5-year survival rate to 
over 50% within the last 30 years (3, 5). 
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However, CRC is characterised by a high mortality rate, mainly from diagnosis or 
presentation at an advanced stage, which justified screening policies (6). A number 
of strategies were available to screen average risk populations ranging from low cost 
faecal occult blood test (FOBT) to more invasive and costly flexible sigmoidoscopy, 
colonoscopy or virtual CT-colonoscopy (7). Currently the UK offers screening 
colonoscopy after a positive routine FOBT between the ages of 60 to 74 years (6, 8). 
Only 20 of 1000 FOBTs are positive, of which 2 will have cancer at colonoscopy. 
There are no diagnostic or prognostic biomarkers that are simple, easily accessible, 
and relatively inexpensive with good sensitivities and specificities. Although a number 
of potential markers existed, test performances before, during and after treatment 
were generally inconsistent and poorly defined. More expensive assays for genomics 
and, more recently, serum proteonomics are promising technologies. However 
antibody assays (e.g. ELISA) and flow cytometry (FC) were usually easier, faster, 
inexpensive, reproducible, accessible and minimally invasive (9).  
 
Fundamentally, cancer is characterized by abnormal cell proliferation, invasion and 
metastasis, all of which are orchestrated by a complex interplay of genetic factors, 
cytokines and growth mediators. Crucially all depend on a good blood supply to 
convey growth mediators to cancer cells, facilitate invasion and metastasize. The 
endothelium (EC) is the gateway to these processes but disturbances of homeostatic 
functions, such as haemostasis, barrier to tumour invasion, vasomotor activity, to 
name a few, were known in CRC (10-13). 
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Perturbation of EC activity is established in CRC, as reflected in changes to 
biomarkers expressed by blood vessels in the tumour and those secreted into the 
peripheral circulation (14, 15). Some, for example plasma vWf, correlated to disease 
progression and survival (16). More cells with EC morphology and phenotype were 
found in the peripheral blood (PB) of CRC participants, and other solid organ 
tumours, than in healthy controls (17). Logically, research is aimed to expand 
treatment options for CRC that stopped EC activity in angiogenesis. For example, the 
antibody to vascular endothelial growth factor (VEGF), Bevacizumab, extended 
survival by at least 6 months in metastatic CRC (2, 18).  A marker of its effectiveness 
would be useful, hence a number of EC surrogates were suggested (19). The origins 
of these cells are heavily debated. They may arise from existing normal and/ or 
tumour vasculature, (known as mature circulating endothelial cells or CECs) or 
represent endothelial progenitor cells (EPCs) derived from stem cells (probably from 
the bone marrow) that may contribute to neovascularisation (17, 20, 21). 
 
Other EC derived markers were suggested for their clinical and prognostic value in 
CRC but to date no single test has translated to clinical care and many were altered 
in other tumours and non-cancer disorders (10, 22-24). I therefore theorised that 
measuring a combination of biomarkers reflective of the EC’s many functions are 
more important determinants of stage, prognosis, and treatment outcomes than any 
single test. Therefore EC activity in CRC is worthy of further study and to prove its 
importance my thesis structure is outlined below. 
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Thesis Overview 
 
Chapter 1 first considers an overview of vascular biology of the endothelium (EC). 
The primary importance of ECs in cancer is explored in section 1.2 and in 
angiogenesis in Section 1.3. From these, two neologisms of the assessment of EC 
activity are introduced, that is the endotheliome and angiome. In section 1.4, CRC is 
discussed, specifically the pathophysiology and clinical management. Section 1.5 
supports the importance of the endotheliome and angiome in CRC. In the final 
introductory section (1.6), aspects of the cell biology of CRC, angiogenesis and the 
EC are outlined in ‘what we know’ and ‘what we don’t know’. From these, original 
hypotheses are formulated and the details of their investigations are provided. 
  
In the second chapter, (a) patient and control recruitment, (b) laboratory and clinical 
materials and (c) methodology, and (d) statistical methods for analysis are described. 
In the third chapter the findings of each study on EC activity in CRC are presented. 
The cross-sectional findings tested whether EC activity is indeed abnormal in CRC 
when compared to the three proposed control groups.  The EC markers relative to 
disease stage are then investigated. The longitudinal studies tested the changes of 
the markers after surgery with or without adjuvant therapy. All markers are then 
analysed for their predictive value of disease recurrence and survival at two years. 
 
In the final chapter the results are discussed and the conclusions are formulated. 
Finally, studies beyond the remit of this thesis are proposed for future investigations.  
1.2 The Endotheliome: The biology of the EC 
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1.2 Vascular biology and the endothelium (EC) 
 
The role of the EC in human physiology (and, ultimately, pathophysiology) sparked 
much debate. Before electron microscopy, many thought that the innermost layer of 
the blood vessel, barely visible under light microscopy, was functionless. The 
observations of Mallory in 1898 (25) of endothelial-like cells in the blood of patients 
with typhoid fever prompted Sabin and Doan in 1926 (26) to conclude that: 
 
“.... desquamated endothelium is practically a constant constituent of blood, is not 
identical to monocytes, and numbers are increased in many pathological conditions”   
 
 
 
 
 
 
 
 
 
Figure 1: Plate from the Journal of Experimental Medicine, 1898. 
Mallory described this as fibrin in a vein but was later suggested by Sabin in 1926 to 
be a CEC (26). The CEC was therefore proposed as a valuable tool to measure 
disease activity and prognosis. 
CEC? 
 
Endothelial 
cell of the vein 
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This probably is the first recognition of circulating ECs in peripheral blood (PB) as 
markers of disease processes such as inflammation, infection and cancer. Over the 
last 3 decades much discovery on its physiology lent to the understanding these 
roles. Broadly, pathological EC activity either promoted both neo-vascular (and neo-
lymphatic) formation (e.g. in cancer and rheumatoid arthritis) or restricted vessel 
growth (e.g. in atherosclerosis). While the tools to assess these activities, directly or 
indirectly, are under intense research, many were not translated to clinical use.  They 
included circulating plasma and cellular markers, physiological studies and 
radiological techniques. Many EC-derived markers e.g. von Willibrand factor (vWf), 
nitric oxide (NO), were elevated in CRC but their clinical value was inconclusive. 
Recently CECs and EPCs were proposed for monitoring anti-angiogenic therapy (19, 
28). However, clinical application was hindered by the lack of standardised 
methodology, inconsistent definitions, and inconclusive findings.  
 
Therefore, assessment EC activity in CRC deserved further study. I proposed no 
single marker could yield useful information. This is probably why no EC marker of 
diagnosis or prognosis exists in mainstream practice. To support this concept, the 
current understanding of EC biology is reviewed. I aim to demonstrate their 
importance as crucial determinants of CRC staging, treatment outcomes and 
progression. I introduce the multifactorial assessment of EC activity, called the 
endotheliome and angiome. That is, the endothelium, appended to 'endotheliome' 
measures endothelial function as a whole (-ome). This is parallel to other ‘-omes’, 
such as the cytome, which considers the total functions of a single cell and 
1.2 The Endotheliome: The biology of the EC 
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proteomics for protein expression. The angiome, as a subset of the endotheliome, 
assesses angiogenic activity. The endotheliome and angiome are measures of EC 
activity that reflect the tumour microenvironment. I hypothesised they may add to or 
may be better than the current methods of assessing CRC prognosis and outcomes. 
 
 
1.2.1 The physiological functions of the EC and changes in CRC 
 
Multicellular organisms establish a circulating network to deliver nutrients, remove 
waste products and as a means for inter-organ communication (13). Human 
vasculature comprises of blood and lymphatic vessels all lined by ECs. Vascular ECs 
are ‘ubiquitous’ from the innermost lining of the heart to the smallest capillaries. It is 
visible on routine histology as a monolayer of flattened nuclei and is the largest organ 
in the body. In an adult it has 1-6x1013 cells, weighs approximately 1kg and covers a 
surface area of approximately 4000 to 7000 m2 (29).  Ultrastructurally, each cell is 
anchored to the underlying basal lamina and attached to each other by adhesion 
junctions, which prevents diffusion between cells (30).  
 
The EC’s biological properties primarily are to simultaneously maintain tissue 
homeostasis (with oxygen and nutrients), vessel wall permeability, appropriate blood 
flow and lumen patency. These functions are regulated by intricate paracrine, 
endocrine and autocrine activities of a vast number of mediators some of which are 
directly secreted by the EC. It has anti-oxidant and anti-inflammatory properties, 
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trafficked leukocyte adhesion and migration, prevents smooth muscle proliferation 
and migration, and regulats platelet adhesion and aggregation (29).  
 
Though a single layer, its position as the innermost lining of blood vessels requires 
the EC to respond to a number of stresses and signals. It itself produces a variety of 
signalling molecules that exert autocrine and paracrine effects which regulate 
vascular tone, cell to cell and cell to basement membrane adhesion, haemostasis, 
thrombo-resistance, smooth muscle proliferation and inflammation (31). These 
physiological roles are summarised in Figure 2. 
 
 
Figure 2: The heterotrophic functions of the EC in vascular homeostasis. 
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Overall, Sawada et al described the EC as a ‘gate’ e.g. to metastasis, and a ‘fence’ to 
the egress of molecules aided by transport proteins (32). Neovessels in cancers are 
derived by angiogenesis from pre-existing host microvessels, primarily venules, but 
heterogeneity within tumours differs significantly from the organised structure within 
normal tissues (33). They are microscopically distinguishable by their irregular 
thickness, aberrant basement membrane, deficient pericytes and loosely associated 
ECs (34). Movement across the normal EC barrier is usually highly controlled, mainly 
by caveolae invaginations of scaffolding proteins to form vesicles (transcellular 
transport) and selective transport of essential macromolecules across tight junctions 
(paracellular transport) (35). In tumours these activities are significantly increased 
and further facilitated by larger EC fenestrations varying from 10 to 1000nm (36). A 
higher proportion of ECs (from angiogenesis), pericyte deficiency and basement 
changes also enhances vascular permeability.  Overlapping margins, excessive EC 
sprouting and overall loss of the barrier function superseded the normal monolayer 
with tight junctions(33). Tumour cells often filled the spaces by ‘mimicking’ ECs (37). 
The wide intercellular gaps leak blood, fibrin and fluid into the interstitial space, which 
raises the intra-tumour pressure and lowers the pH (38). The irregular EC lining 
impairs blood flow resulting in hypoxia and hypoperfusion (39). Overall ECs are 
unable to fulfil their duties to supply nutrients and remove waste products, thus 
creating the microenvironment for tumour cells to grow (40).  
 
With fundamental structural changes to blood vessels, the EC becomes highly active 
or ‘dysregulated’ to its demands. It is not surprising therefore that a number of its 
1.2 The Endotheliome: The biology of the EC 
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biomarkers, summarised in figure 4, were altered in CRC and spanned the range of 
its functions: haemostasis, vasomotor control, inflammation and angiogenesis.  
 
 
Figure 4: EC-derived factors of homeostasis altered in CRC. 
 
 
All factors listed above are elevated and correlated to poorer outcomes in CRC. Some, such as 
bradykinin and NO worked through mediators of inflammation (IL-6) to facilitate tumour growth. 
 
 
These functions and their changes in CRC are examined next.  
  
1.2 The Endotheliome: The biology of the EC 
11 
	
1.2.1.1 The role of EC-derived mediators in CRC 
 
Vasoactive mediators in CRC 
 
Normally, changes in shear stress, blood pressure and oxygen tension stimulate the 
release of EC-derived mediators of blood flow to improve organ perfusion by still 
unknown mechanisms (41). The equilibrium between vasodilatation and 
vasoconstriction to immediate local demands is controlled by the interaction between 
these mediators and the vascular smooth muscle, the latter often deficient in tumour 
blood vessels. A number of mediators interact with the EC but very few are produced 
by the EC directly. Normal pathways are summarily dependent or independent of the 
potent vasodilator nitric oxide (NO).  In response to shear stress NO is released by 
the activity of nitric oxide synthase in ECs or eNOS on L-arginine and oxygen (42). 
NO diffuses into the blood vessel wall and increases cGMP (through the activation of 
guanylate cyclase), a potent mediator of smooth muscle relaxation.  
 
In cancer, levels of eNOS are increased by chaotic blood flow, nutrient demands and 
VEGF, the key promotor of angiogenesis (43-45). Ziche et al showed that VEGF 
would be otherwise ineffective without an intact NO/cGMP pathway (46). There were 
no in vitro studies on vasoactivity of the heterogeneous vessels in tumours. However, 
the lack of muscular coats, poorer vasoconstrictive control and increased but 
sluggish blood flow were the more likely consequences. Also, other dichotomous 
effects on tumour growth were reported. That is, on one hand NO may modulate 
angiogenesis, cell cycle invasion and metastasis (47) but on the other, inhibit DNA 
1.2 The Endotheliome: The biology of the EC 
12 
	
synthesis and regulate tumour cell apoptosis  (48). Higher levels of NO (and VEGF) 
were linked to poorer disease free survival (DFS) in CRC (49). However, the assay’s 
reliability is uncertain given the short half-life of NO and its concentration is estimated 
indirectly by measuring the breakdown product, nitrite, with the Griess method. 
 
ECs also produce the vasodilator bradykinin, which is a potent vasodilator for long 
term tissue perfusion and vascular remodelling (50). Only recently in vivo studies 
revealed it increased IL-6 levels (linked to angiogenesis), contributed to invasion and 
migration of CRC cells (51). Similarly endothelin-1/endothelin A receptor (ETAR) axis 
promoted metastasis in SW480 and SW620 cell lines (52). However the clinical value 
in CRC prognosis of both IL-6 and endothelin require further evaluation. 
 
Thromboxane A2 and prostacyclin are both potent vasomodulators with short half-
lives and plasma levels are therefore estimated indirectly by measuring metabolite 
levels. Both are highly expressed in CRC cells from increased COX-2 activity, an 
enzyme established as a key promoter of the adenoma-carcinoma transformation 
and angiogenesis (53). They also have antagonistic coagulation functions; this and 
other EC biomarkers of haemostasis are discussed next. 
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The role of haemostasis factors in CRC 
 
The interplay of the coagulation cascade and its antagonists is complex; ECs 
express a variety of proteins involved in these pathways but the vast majority are 
produced in the liver (54). Coagulation proteins bind to their specific EC protease-
activated receptors to transduce the expression of genes for coagulation, as well as 
angiogenesis, leucocyte adhesion, and regulation of the vascular tone. Tissue factor 
(TF) is a glycoprotein pro-coagulant receptor for factor VII expressed by sub-
endothelial cells and inhibited by tissue factor pathway inhibitor synthesized by and 
bound to the surface of ECs. TF is typically not expressed on ECs themselves except 
in cancer and inflammatory disorders (55, 56). 
 
Briefly, TF activated factor X, which then combines with factor Va to convert 
prothrombin to thrombin (57). Thrombin is both anticoagulant and pro-coagulant. 
Thrombomodulin expressed on EC surfaces is the major physiological buffer to 
thrombin. It blocks sites on thrombin that bind to fibrinogen, platelets and factor V. 
The thrombin-thrombomodulin complex activated protein C pathway that was 
augmented by the EC protein C receptor (EPCR). Activated protein C must 
dissociate from EPCR before binding to protein S, an anticoagulant to factor Va. (57, 
58). TF expression in CRC tissue was certainly correlated to overall survival (OS) but 
plasma levels were immeasurable (55).  Thrombomodulin was also higher in the 
tumour and plasma but were not correlated to disease progression (59).  
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The majority of vWf is derived from ECs in two forms: dimers that are secreted into 
the plasma and sub-endothelial matrix, and granular multimer stored in Weibel 
Palade bodies for rapid mobilization during clotting (60). Bound vWf stabilized factor 
VIII and was a cofactor for platelet binding to exposed extracellular matrix in injured 
vessel walls. Blann et al dubbed vWf as the ‘gold standard’ of EC activity when 
measured in plasma, as the contribution from sub-endothelial cells and ∝-granules of 
megakaryocytes was likely to be minimal (61). Significantly higher levels were 
correlated to CRC metastasis and survival (62). More details on vWf are provided 
section 1.5.2 along with the other biomarkers for my study. 
 
Prostacyclin (a platelet aggregation inhibitor) is almost exclusively derived from ECs 
and highly expressed in tumour vessels but circulating levels are difficult to measure 
(63).   Thromboxane A2 was also expressed by COX-2 activity in CRC cells and 
therefore not a sensitive EC biomarker (64). ECs also produce plasminogen activator 
inhibitor (PAI), the main physiological antagonist to plasminogen activators (t-PA, 
also found on ECs, and urokinase-PA) involved in fibrinolysis (54). Disease 
recurrence and poor survival were correlated to high levels expressed in CRC tissue 
no reports were found on relationships with plasma concentrations (65). Hepatocytes 
and smooth muscle of blood vessels are other sources of plasma PAI (66). The 
EPICOR study (long-tErm follow-up of antithrombotic management Patterns In acute 
CORonary syndrome) found that elevated quartile levels were a common risk factor 
to both CRC and cardiovascular disease (67).  
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The role of ECs in inflammation and CRC 
 
Inflammatory processes involving interactions between leukocytes, tumour cells and 
ECs are established in cancer (68). ECs are strategically located at the blood-tissue 
interface to produce and react to various low molecular weight proteins of 
inflammation generically called cytokines (69). While EC-derived products included 
interleukins (-1,-6,-8), colony stimulating factors (CSF), chemokines (CCL-2, -8), 
interferons  and leukotrienes, the vast majority of these are from tumour, and 
associated inflammatory cells such as macrophages and T-cells.  
 
Leucocyte passage regulated by ECs involves attachment, rolling, firm adhesion and 
transmigration (29, 70). Tumour cell migration is thought to mimic this activity but the 
in vitro evidence beyond tumour to EC adhesion was lacking (71). The evidence from 
mice models on colon, breast and lung cancers is that tumour cells stimulated EC 
activation via chemokines (e.g. CCL2) to express E-selection, intercellular adhesion 
molecule (ICAM1) and vascular cell adhesion molecule (VCAM) (72, 73). Further 
CAM expression occurred also with leucocyte interaction and contact with cancer 
integrins (74, 75). VEGF or TGF from the cancer cells signal disruption of VE-
cadherin-b-catenin complex to induce opening of the EC junctions (76). E-selectin 
expression required de novo transcription, hence expressed many hours after 
activation and, in liver metastases, promoted trans-endothelial migration via sialyl 
Lewis ligands on colon cancer cells (77). Uner et al reported serum levels correlated 
to metastatic liver disease and poorer overall survival (78) but further evaluation with 
disease stage and progression is required. 
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Matrix proteins from ECs maintained or laid down the basement membrane of blood 
vessels and, along with the extracellular matrix (ECM), is degraded by proteases 
including MMPs, plasminogen activator and cathepsins (79). MMPs may be 
produced by ECs under the influence of VEGF to penetrate the basement membrane 
for angiogenesis, but most are derived from colon cancer cells (80). A poorer 
prognosis of CRC was correlated to over-expression of membrane-type-1-matrix 
MMP (81). Serum levels of MMP-7 were significantly higher than healthy participants 
and therefore a potential biomarker of the disease (79, 81, 82). 
 
With the activities of the EC in vascular homeostasis and its changes in CRC 
outlined, the methods used to investigate its activity are explored next. 
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1.2.2 Assessing EC activity 
 
Our understanding of vascular biology of EC activity emerged from studies on factors 
secreted into plasma, their physiological action on other cells, the presence of ECs 
within the vascular circulation and the anatomical relationship within tissues.  Broadly 
investigations of EC activity took four forms as outlined in figure 4 and table 1. 
Physiological tests focused mainly on disorders causing disruption or dysfunction e.g. 
cardiovascular disease, rheumatoid arthritis, and obstructive sleep apnoea (22, 83). 
Hence, they were not applicable to cancer. Radiological tests will be discussed briefly 
in section 1.3. Plasma and cellular markers in cancer are discussed next.  
 
 
 
 
 
Figure 4: Summary of methods to assess EC Activity in disease. 
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Table 1: Summary of markers and tests used to assess EC activity in disease. 
 Cancer CVS
A OthersB 
1.  Plasma markers of EC-specific activity 
	 	 	
§ Nitric oxide (46, 64, 84) +	 +	 +	
§ Prostacyclin (64) +	 +	 +	
§ Endothelin-1 (52, 83) +	 +	 +	
§ Bradykinin (85, 86) -	 +	 +	
§ Thromboxane A2 (87, 88) +	 +	 +	
§ Platelet activating factor (54, 88) +	 +	 +	
§ von Willibrand factor (89) +	 +	 +	
§ Plasminogen activator inhibitor (54, 88) +	 +	 +	
§ Soluble thrombomodulin (59, 83) +	 +	 +	
§ Tissue Factor (55, 89) +	 +	 +	
§ E-selectin (22, 90) +	 +	 +	
2.  Circulating cellular markers 
	
	 	
§ CECs (17, 91) +	 +	 +	
§ CPCs (24) +	 +	 +	
§ EPCs (19) +	 +	 +	
§ EMPs (92) +	 +	 +	
3.  Physiological tests 	 	 	
§ Coronary endothelial function (83) -	 +	 +	
§ Flow mediated dilatation (83) -	 +	 +	
§ Pulse wave analysis (83) -	 +	 +	
4. Radiological Tests 	 	 	
§ US Doppler & Duplex Scans (83), +	 +	 +	
§ Computerised TomographyC (93) +	 +	 +	
§ Magnetic Resonance ImagingC (93) +	 +	 +	
 	 	 	
 
A CVS: Cardiovascular diseases.  B Others: Rheumatoid arthritis, obstructive sleep apnoea or diabetes 
mellitus.  C with contrast enhancers. US: Ultrasound. CPC- circulating progenitor cells. EMP: 
endothelial microparticles. CEC: circulating endothelial cells.  EPC: endothelial progenitors. 
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1.2.3 Plasma markers of EC activity in CRC 
 
Unfortunately many EC-derived markers are confined to clinical research, and often 
difficult and/or expensive to measure. They provided information on EC biology but 
their clinical value is limited by assay availability, conflicting results and under-
powering of studies. Nevertheless, there is considerable interest in many cancers 
(61). Table 2 summarises those produced by the EC in CRC as discussed above. 
Angiogenic and growth factors are described in section 1.3 on angiogenesis. 
 
 
 
 
  
 
Figure 6: Markers to assess EC activity in cancer
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Table 2: Potential roles of EC-derived biomarkers in CRC 
 
Factor Role in Colorectal Cancer Ref 
 
Vasodilators 
NO, eNOS Roles include DNA damage, malignant transformation, angiogenesis, 
metastasis, cancer blood flow and immune surveillance. NO may 
enhance radio- and chemo- therapy.  
(94) 
(43) 
(10) 
Prostacyclin 
PGE2 
Both prostanoids produced by COX-2 (highly expressed by both CRC 
cells and ECs) promote tumour proliferation, angiogenesis, and 
metastasis but inhibit apoptosis. 
(95) 
(62) 
(87) 
 
Vasoconstrictors 
Thromboxane A2 A product of COX-2 highly expressed in CRC cells; depletion of 
thromboxane synthetase inhibited tumour proliferation  
(62) 
(87) 
Endothelins Endothelins-1, were also produced by tumour and stromal cells, and 
stimulated tumour growth and progression  
(96) 
 
Procoagulants 
vWf Increased plasma levels occur in colorectal cancer patients though 
recently intracellular levels in ECs of CRC vessels were significantly 
less than those of normal blood vessels. 
(11) 
(23) 
PAI High PAI levels were associated with poor prognosis but are mainly 
produced by tumour cells  
(54) 
Tissue Factor 
 
A primary initiator of blood coagulation, TF was involved in 
hypercoagulability, tumour growth, angiogenesis, and metastasis. 
Elevated TF expression by cancer cells and tumour ECs were 
associated with the expression of mutant K- ras, EGFR or p53. 
(97) 
 
Anti-thrombotics 
Prostacyclin Roles in cancer as above. Primarily it was a potent anti-thrombotic.  
Thrombomodulin 
tPA, heparin 
Both were highly expressed on cancer tissue but only tPA correlated 
to disease progression. Exogenous heparin may promote growth.  
(98) 
 
Matrix Products 
   
MMPs 
 
MMP 1, 3, 7 & 14 were expressed by CRC tissue, associated with 
poor prognosis independently (MMP) of Dukes’ stage. As a 
proteolytic to ECM matrix they increase invasion & metastasis.  
(99) 
(82) 
 
Inflammatory mediators 
Interleukins 
CCLs 
 
E-selectin & 
CAMs 
Abnormal levels of IL-1 & IL-6 were associated with increasing 
tumour size, stage, metastasis and poor prognosis. In tumour-liver 
models CCL2 levels predicted metastasis.  
Cellular Adhesion Molecule, E-selectin and α1β2 Integrin produced by 
ECs are associated with a higher metastatic potential in CRC 
(100) 
 
 
(101) 
   
 
NO- Nitric Oxide; eNOS- nitric oxide synthetase; PAI- Plasminogen Activator Inhibitor; COX-2- 
cyclooxygenase 2; tPA- tissue plasminogen activator; MMP – matrix metalloproteins; 
CCL- chemokine. CAM- cellular adhesion molecules. 
1.2 The Endotheliome: The biology of the EC 
21 
	
1.2.4 Cellular markers of EC activity in CRC 
 
Physiological loss of mature ECs is detectable in plasma as CECs (102). The review 
of Goon et al suggested that these mature mural cells, shed by senescence or 
disease processes, were replaced by angiogenesis from neighbouring cells and/or 
reparative EPCs derived mainly from bone marrow stem cells (92). 
 
 
1.2.4.1 The CEC 
 
Endothelial-like cells were described in peripheral smears for many years. In the 
1970’s their morphology was defined by light microscopy, May–Grünwald Giemsa 
staining, Ficoll density centrifugation and separation. In animal studies vascular 
damage by ovalbumin, trisodium citrate and shock from coliform endotoxemia 
increased the number of CECs (102, 103). In humans this was shown in smoking, 
cardiovascular disease, acute myocardial infarction, immunosuppression, 
hypertension and homocysteinaemia after methionine load (104-108). Hladovec et al 
suggested these cells were anucleate carcasses similar to those from trisodium 
citrate induced vascular damage (108).  
 
The EC phenotypes of the CECs isolated from blood were later defined by indirect 
immunofluoresence by antibodies to intracellular vWf, the prototypical marker of ECs 
(109, 110). However poor specificity highlight the need for a reliable cell surface 
protein. Potential candidates were either non-specific (e.g. adhesion molecules, 
integrins) or were intra-cellular (e.g. tPA, vWf) and therefore relatively inaccessible to 
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monoclonal antibodies without cell permeabilization. In 1991 two groups reported 
antibodies to newly discovered cell surface antigens on ECs (HEC 19 and S-Endo 1) 
and used them to quantify CECs (111, 112). Dignat-George et al subsequently 
characterized their antibody to the CD146 molecule. Solovey et al used a similar 
antibody, P1H12, to detect CECs in sickle cell anaemia (61, 113, 114). 
 
Over the last 20 years various techniques further characterised and isolated CECs. 
Not surprisingly, levels were higher in a number of conditions, including cancer, when 
compared to healthy controls (92). However, results were inconsistent probably from 
the variations in the methodology of isolation and detection. Immunotypes were not 
exclusively specific or sensitive to CECs as they shared surface receptors with other 
cells (see table 3). Recent strategies, theoretically, increased the accuracy of 
detection by the use of more than one monoclonal antibody and the application of 
cell sorters. Nevertheless the relatively small numbers would inevitably result in 
significant inter- and intra-observer variability (61). At publication of this thesis, 
‘accurate’ detection and enumeration remained a challenge. CECs, usually absent in 
the blood of most healthy individuals, were elevated in cancer probably from vascular 
invasion and vessel heterogeneity. It was proposed they were driven from the intima 
and the consequence, not the initiator, of the pathology (61). However it is uncertain 
if they are exclusively from vessels at the source of insult or included those from 
distant sites under the influence of circulating mediators released from the source i.e. 
the entire endothelium is altered by cancer (17, 61). 
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Characterising CECs 
 
In healthy adults there are between 0 to 20 cells per millilitre of PB (115). Given their 
low numbers technical errors in sampling, preparation and analysis were expected. 
Our unit demonstrated that traumatic venesection increased CEC counts, the cells 
themselves having arisen from the site of venepuncture (116). The phenotypic 
expression of CECs was the subject of much debate but despite recommendations of 
Woywodt et al on technical standardization, general consensus was lacking (117). 
Multiple phenotype descriptions, variations in assays and heterogeneity of donors 
accounted for the wide variations in CEC counts reported (See Table 4). As Blann et 
al noted, limitations prevented a meta-analysis of their role in cancer (61). 
 
Alternatively the multiplicity in phenotypes described may reflect sub-populations of 
CECs and therefore the dynamic status of ECs in fulfilling their various functions at 
any given time (17). This argument may justify assays that used more than one 
immunophenotype but highlighted the need for further studies to characterize the 
subsets and, assuming a correlation existed, their corresponding function(s).   
 
Nevertheless, the ideal marker specific to and constantly expressed by all CECs 
remained elusive. A number of phenotypes expressed by ECs were identified and 
many were co-expressed by other cells e.g. leucocytes and platelets, (see table 3).  
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Table 3: Summary of markers used in assays to identify ECs. 
 
Marker Description/ Expression CEC Co expression 
    
CD31a Leucocyte adhesion molecule + Platelets, leucocytes (118, 119) 
CD34 Cell to cell adhesion factor/ 
glycoprotein 
+ HPCs, blood vessel ECs, dendritic 
cells, mast cells (120) 
CD36b Scavenger receptor + Platelets, monocytes and dendritic 
cells (121, 122) 
CD45  Signalling molecule* - Pan-leucocyte (123) 
CD54c I-CAM + Lymphocytes, monocytes (124) 
CD62-E  E-selectin- CAM + None (125) 
CD62-P  P-selectin- CAM + Platelets (125) 
CD90 Thymus cell antigen (+)1 Neurons, stem cells, T-cells, 
melanomas, fibroblasts (126) 
CD105d Mediated angiogenesis and 
oncogenesis 
+ HSCs, monocytes (127) 
CD106e Adhesion molecule for 
leucocytes (VCAM) 
(+)2 Lymphocytes, monocytes, 
eosinophils, basophils (128) 
CD117f Stem cell factor receptor (+)1 HSCs (129) 
CD137 Tumour necrosis factor 
receptor 
+ ECs, DCs, T cells, NK cells, 
granulocytes (130) 
CD144  VE-cadherin- EC adhesion 
glycoprotein 
+ Pan-ECs only (131) 
CD146g EC adhesion molecule + Pericytes, melanomas, gliomas, 
fibroblasts, T cells (132) 
AcLDLj Probe + None (133) 
vWf Von Willibrand factor + Platelets (89) 
UEA-1 Ulex europaeus agglutinin 1 
probe 
+ None (134) 
 
HSC Haematopoietic Stem Cells; j - [Dil-AcLDL] 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-
indocarbocyanine perchlorate;  a -PECAM; b- CR1- collagen receptor 1; c- ICAM-1; d –Endoglin; e -
VCAM-1; f -C-Kitt; g -MelCAM; i -B7-H3. (+)1 Some ECs. (+)2 Upregulated after EC activation.  
* For cell growth, differentiation, mitosis & oncogenesis  
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The majority of assays defined the CEC as bearing the CD146 antigen and not 
haematopoietic (i.e. CD45) or progenitor markers e.g. CD133 (see table 4). Of the 
multitude of surface markers described, ECs were unique in their uptake of Ulex 
Eurpaeus Lectin-1 (UEA-1) and acetylated low-density lipoproteins (Dil Ac-LDL) (132, 
134-136). Hence Woywodt et al advocated their use for CEC validation but lengthy 
and costly multistage assays are significantly practical limitations (117).  
 
Immunomagnetic separation (IMS) with flourochrome labelled CD146 antibodies 
bound to magnetic beads involved identification and/or enumeration by light 
microscopy, electron microscopy, and/or flow cytometry (tables 5 and 7). Lengthy 
batch processing may further compromise the results from cell loss by enrichment, 
apoptosis, lysis of red blood cells, concentration by centrifugation and preparation of 
a mononuclear cell suspension by density centrifugation e.g. Ficoll (117, 137).   
 
Recently, real time PCR identified CD146 genes of human microvascular lung ECs 
(HMVEC-L) and CD144 genes in rectal cancer ECs (138, 139). However, the authors 
reported a higher sensitivity but lower specificity when compared to FC.  
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Table 4: CECs – assay protocols, phenotypes and relationship with cancers 
 
Tumour(s)  Protocol Phenotype 
CEC levels (median & IQR cells/ml of blood) 
Study Cancer Control P< 0.05 
       
Prostate 
Cancer 
n=31 
L, W, FAb & 
FC 
CD45−CD146+ 
CD34+ 
25 a 
(12-52) 
28 a 
(11-43) 
n (140) 
       
       
Breast 
Cancer 
n=160 
L, W, FAb & 
FC 
CD45−CD146+ 
CD34+ 
9.4 a 
(5-12.7) 
7.7 a 
(6-10) 
y (24) 
       
       
Breast 
Cancer 
n=41 
FHDGC, 
CD45 DC & 
FC 
CD45- CD146+ 61 b 
(11-2335) 
7 b 
(2-54) 
y (141) 
       
       
CLL 
n=20 
FAb & FC CD45- CD34+ 
CD146+ 
26.5 a 
(7-89) 
18.5 a 
(4-66) 
y (142) 
       
       
Various 
metastatic 
carcinomas 
n=206 
IMS-CD 146 
& CellTrack® 
DAPI+ CD45- 
CD146+ CD105+ 
111 +/-255 21 +/-18 y (143) 
       
       
GIST 
 n=16 
CFr/T, FAb, 
L,W & FC 
CD45- CD31+ 
P1H12+ CD133- 
1090 d 540 d y (144) 
       
       
MDS 
 n=128 
L, W & FC CD45- CD34+ 
CD146+ CD133- 
5120 d 1530 d y (145) 
       
       
Various 
cancersc 
n=112 
IMS-CD146 
& LM 
CD146+ CD31+ 
vWf+ VEGRF2+ 
399+/-36 d 121+/-16 d y (146) 
       
       
Lymphoma 
(n=30)  & 
Breast 
Cancer 
(n=46) 
FAb L, 
No Wash 
FC 
Active CEC 
CD45- P1H12+ 
CD31+ CD105+ 
CD106+ CD133+ 
6.8e 
(5-8.6) 
1.2 e 
(0.1-2.3)  
y (17) 
    
Resting CEC 
CD45- P1H12+ 
CD31+ CD105-  
CD106- CD133- 
39.1 e 
(16.8-61.4)  
7.9 e 
(4.7-11) 
y 
 
CFU-EC:  colony forming unit-endothelial cell; EOC: endothelial outgrowth cells; CFr/T: controlled 
freezing & thaw procedure;  FAb: Labelling with flourochromes;  L: lysis procedure;  W: wash 
procedure;  LM: light microscopy;  FC; flow cytometry;  ICS: immunocytostaining;  GIST: 
Gastrointestinal Stromal Tumour;  FHDGC: Ficoll-Hypaque density gradient centrifugation;  CD45 DC: 
RosetteSep®Human CD45 Depletion cocktail (StemCell Technologies, Vancouver BC);  MDS- 
Myledysplastic Syndrome;  CellTracks ®system (Immunicon Corp): automated system of cell 
identification and enumeration.  a Median + IQR.  b Median + IQR number of positive events on flow 
cytometry analysis every 600 seconds.  c Breast (n=10), ovarian (n=5), prostate (n=25), colon 
(n=13),head & neck (n=10), renal cell (n=6) cancers. d Events only.  e Median & IQR cells per µL. 
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1.2.4.2 The EPC 
 
In 1997 Asahara et al described cells co-expressing VEGR-2 and CD34 with both EC 
and stem cell characteristics (147). He deduced that bone marrow derived 
progenitors might have a role in neovascularisation by developing into ECs. These 
EPCs have since been characterised by a number of phenotypes (See table 5).  EC 
progenitors were originally defined as VEGF receptor 2-expressing (VEGFR-2) cells 
that were mobilized from the BM by VEGF (148-150). However, co-expression by 
subsets of other blood cells, mainly progenitor cells and mature CECs, raised doubt 
on their origin and function. Alternatively, a spectrum of cells may exist between 
immature haematopoietic stem cells  (HSC) and fully differentiated EC (151).  
 
The most compelling role of EPCs was vascular development or vasculogenesis 
(147). Mesodermal precursors differentiated into ECs to form a primary plexus of 
neovessels. This process, thought to be restricted to prenatal life, was challenged 
when human CD34+ cells from PB, umbilical cord blood and bone marrow of both in 
vitro studies and in vivo mice models differentiated into ECs and blood vessels (147, 
150). These EC precursors were thought to arise from common myeloid progenitors 
and granulocyte/macrophage progenitors and were an intrinsic component of myeloid 
differentiation (152, 153). This discovery added to the theory of vasculogenesis in 
human embryonic development (as no clear evidence existed previously) and 
challenged the traditional concept that ECs proliferated, migrated, and remodelled 
from pre-existing blood vessels at the site of angiogenesis only.  
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EPCs are primarily derived from the haematopoietic stem cell (HSC) pool in bone 
marrow, which also gave rise to myeloid and lymphoid cell lines (figure 7). 
 
Figure 7: Summary of the proposed origins of EPCs. 
 
 
RBC- Red blood cells. NK- natural killer cells. HSC- haematopoietic stem cell 
 
 
EPCs were cultured from monocytes (154), dendritic cells (155) and CECs (156). 
Other origins reported were stromal (mesenchymal) stem cell recruited to tumours 
and cancer stem cells, as both differentiated into vessels with EC phenotype(s) (152, 
157, 158). However there were no reports of this potential from CECs specifically 
shed from heterogeneous vessels of the tumour vasculature (92). 
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EPCs were shown to incorporate in blood vessels of tumours, healing wounds, hind 
limb ischemia, myocardial infarcts and those denuded of ECs (159-161). Likewise, 
bone marrow stem cell recipients had ECs of both donor and recipient phenotypes 
(162). In 2001 Vasa et al suggested EPCs were a ‘backup pool’ from the inverse 
correlation between their numbers and an adverse cardiovascular risk score. 
Remarkably, the functional properties such as cell adherence, migration, invasion 
and vessel formation appear to be attenuated in cardiovascular disease [CVD] (163). 
EPCs were suggested as biomarkers of CVD outcomes, specifically to monitor 
prevention strategies (164). EPC transplantation offered a promising approach to the 
revascularisation of tissues e.g. myocardium, after ischemic events (165). They were 
also proposed as either therapeutic vectors of anti-angiogenic drug delivery and 
targets against angiogenesis-mediated cancer progression (166). 
 
 
Characterising and Enumerating EPCs 
 
At publication of this thesis and like CECs, no clear phenotype of EPCs existed. The 
strategy of designating multiple FC detected surface markers was widely accepted 
but not without its criticisms. Co-expression by other cells (table 5) cast considerable 
doubt on their origins and their proposed EC destiny.  
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Table 5: Markers used in assays for EPCs, HSCs and CECs 
Marker Description EPC HSC CEC Co expression 
      
CD31a Cellular adhesion molecule + + + Platelets, leucocytes (118, 119) 
CD34 Cell to cell adhesion factor/ 
glycoprotein 
+ + + Vascular ECs, dendritic cells, 
mast cells (120) 
CD36b Scavenger receptor ? + + Platelets, monocytes, DCs (121) 
CD44 Cell adhesion and 
migration receptor 
+ + ? Stromal stem cells (167) 
CD45  Signalling molecule - + - Pan-leucocyte (123) 
CD54c Leucocyte adhesion 
molecule 
+ + + Lymphocytes, monocytes (124) 
CD62-E  E-selectin- CAM + - + None (125) 
CD62-P  P-selectin- CAM + - + Platelets (125) 
CD90 Thymus cell antigen + + (+)1 Neurons, stem cells, T-cells, 
melanomas, fibroblasts (126) 
CD105d Mediates angiogenesis and 
oncogenesis 
+ + + HPCs, monocytes (127) 
CD106e Adhesion molecule for 
leucocytes 
(+)2 - (+)2 Lymphocytes, monocytes, 
eosinophils, basophils (128) 
CD117f Stem cell factor receptor + + (+)1 HSCs (129) 
CD133 HCs and nervous system 
marker 
+ + - CRC, glioblastomas, neuronal & 
glial stem cells (164) 
CD137 Tumour necrosis factor 
receptor 
+ + + ECs, DCs, T cells, NK cells, 
granulocytes (130) 
CD144  VE-cadherin- EC adhesion 
glycoprotein 
+ - + Pan-ECs only (131) 
CD146g Melanoma associated 
adhesion molecule 
+ - + Pericytes, melanomas, gliomas, 
fibroblasts, T cells (132) 
CD164 Adhesion glycoprotein + + - HSC precursors (168) 
CD309 VEGFR-2 in angiogenesis  +3 (+)5 - Some HSCs (169) 
AcLDLj Probe + - + None (133) 
vWf Von Willibrand factor + - + Platelets (89) 
UEA-1 Ulex europaeus agglutinin 1 + - + None (134) 
HSC Haematopoeitic Stem Cells; Plts- platelets; KCs- Kupffer cells; DC- dendritic cells;  j - [Dil-AcLDL] 
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate;  a PECAM; b  CR1- collagen 
receptor 1; c ICAM-1; d Endoglin; e VCAM-1; f C-Kit; g MelCAM; h Tie-2 receptor; i B7-H3; (+)1 Some 
ECs; (+)2 Upregulated after EC activation;  (+)3  VEGFR-2 positive EPCs shown in vitro by flow 
cytometry. (-)4  Not yet demonstrated. (+)5  Some haematopoietic stem cell populations.  
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Identifying multiple surface markers produced a complicated list of putative 
immunophenotypes (table 6). Furthermore the identity in many studies was based on 
unselected peripheral blood mononuclear cells (MNC) or small numbers of EPCs 
within the MNC population rather than pure high count specimens. Initial studies on 
cells purified from umbilical cord blood, bone marrow and adult PB revealed cells 
with both CD34+ and VEGFR-2+ surface markers (147, 149). These generated into 
mature ECs in vitro and were the basis of most FC studies. The once widely 
accepted subset CD133+/CD34+/VEGFR2+ cells [markers also expressed by colon 
cancer stem cells (170, 171)] were not directly shown to form ECs in vitro or in vivo, a 
phenomenon considered a pre-requisite to the phenotype validation (61).  
 
There was also uncertainty that the conditions for in vitro differentiation of EPCs into 
ECs occurred naturally. A critical but artificial step of was the introduction of high 
concentrations of the cocktail of angiogenic factors in mice models (172). 
Furthermore, CD133+/CD34+/VEGFR2+ cells were possibly primitive hematopoietic 
progenitors expressing CD45 (pan-leucocytic marker), which lost CD133 as they 
assumed phenotypes typical of mature ECs (173). Instead of EC replacement, they 
may contribute to repair through cytokines to regulate homeostasis, and signal the 
angiogenic switch of native ECs to restore continuity of the monolayer (164). Though 
relatively low, reported levels in PB in healthy participants were inconsistent, ranging 
from 70-210 cells/mL to upwards of 3000–5000 cells/mL, reflecting once again the 
variations in techniques of cell isolation and enumeration. Typically, lower counts 
were found in FC protocols compared to cultured monocytes (151, 174).   
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Table 6: The immunophenotypes of EPCs studied in human disease. 
Reference Subjects Phenotypes 
Peichev 2000 (175) Fetal liver, CB, PB CD34+ CD133+ CD309+  
Gill 2001 (176) PB in trauma CD133+ CD309+   
Burger 2002 (177) CB, BM, PB in CVD CD34+ FGFR1+   
Pelosi 2002 (178) PBMNC culture CD34+ CD309+   
Cogle 2004 (179) BM CD34+ CD45+   
Hildbrand 2004 (180) CB CD11b+ CD34+   
Kondo 2004 (181) PB of smokers CD34+ CD45+ CD133+ CD309+ 
Elsheikh 2005 (182) PBMNC CD14+ CD309+   
Romagnani 2005 (183)  PBMNC CD14+ CD34+   
Delorme 2005 (184) CBMNC CD34+ CD45+ CD146+  
Furstenberger 2006 
(139) PB in breast cancers CD34
+ CD45Low CD309+  
Friedrich 2006 (185) Carotid artery plaques CD34
- CD133+ CD309+  
Westenbrink 2007 
(186) PB in CVD CD34
+ CD45-   
Yip 2007 (187) PB in Stroke CD31+ CD34+ CD62L+  
Allanore 2007 (188) PB in MS CD34+ CD133+   
Martin 2008 (189) PB in OSA CD34+ CD45+ CD133+  
Pircher 2008 (190) PB in cancer CD34+ CD45- CD133+ CD309+ 
Goon 2009 (24) PB in breast cancer CD34+ CD45- CD133+  
Blann 2011 (140) PB in Prostate cancer CD34
+ CD45- CD309+  
CD309=VEGFR-2; PB- peripheral blood; CVD – cardiovascular disease; CB- cord blood; BM- bone 
marrow; PBMNC – peripheral blood mononuclear cells; OSA-Obstructive sleep opnoea; CBMNC cord 
blood mononuclear cells. 
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Asahara et al postulated that vasculogenesis was regulated by a number of 
mediators between the site of neovascularisation and the bone marrow (147). VEGF 
was key to this process, a rise in EPC found as early as 24 hours after exogenous 
injection although the contribution of other mediators was vague. Granulocyte 
macrophage colony-stimulating factor (GM-CSF) also induced a rise, and enhanced 
vascularisation of CRC cell lines in animal models (191-193). Elevated levels were 
reported after recombinant human erythropoietin for anaemia in renal failure (194). 
 
 
In vivo evidence for EPC activity in cancer 
 
Lyden at al reported that EPCs contributed about 90% to the vascularisation of 
lymphomas in angiogenesis defective mutant mice (195). Transplanting wild-type 
murine bone marrow (BM) reversed tumour regression in mice with poor angiogenic 
potential. EPC incorporation was described in other tumour models, although the 
type of tumour and differences in choice of markers may have contributed in part to 
variations between studies (table 7). Tumours following BM transplantation had a 
small percentage of BM-derived ECs, typically 10-14 days after transplantation. 
Multicolour fluorescent in situ hybridisation (FISH) and fluorescent probes for vWf 
and CD45 levels ranged from 1% in sarcomas to 12% in lymphomas (196). 
Estimates were that EPCs could constitute as much as 38 to 50% of all ECs in 
tumour neovessels (see table 5), but more recent reports showed very low averages 
of 4.9%, similar to normal tissues (151, 196-198). In other solid tumour mice models, 
no EPC incorporation was reported at any time point (172, 199).   
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Recently the HSC origin of EPCs was questioned when in vitro breast cancer stem 
cells had characteristics of ECs (200). Alternatively false positives were from stromal 
stem cells found within  ‘normal’ tissues rather than co-expression from tumour 
associated cells (157). EPCs may intuitively distinguish between well- and poorly- 
differentiated breast cancers (201). Surprisingly robust EPC mobilisation occurred 
after the maximum tolerated dose of chemotherapy was administered but 
consistently fell after anti-angiogenic chemotherapy (166, 202). Gao et al reported 
tumour growth was impaired by blocking EPC mobilisation and postulated roles in 
neovascularisation other than vasculogenesis (166).  
 
The accuracy of conventional histological analyses was also questioned. Recent 3D 
high-resolution multichannel (sequential) confocal scanning of whole mounts blood 
vessels showed BM-derived cells to be perivascular and not in the EC monolayer 
(203). The authors concluded that earlier studies suffered co-localization i.e. false 
positives, from monocytes, lymphocytes and macrophages (tables 5 and 6). 
Purhohen et al suggested that while there was the capacity of adult BM stem cells to 
selectively differentiate into vascular ECs in experimental models, it was not a typical 
in vivo function and therefore an extremely rare event (172).  
 
A number of enumeration techniques were reported over two decades for EPCs in 
cancer (see table 8). The initial methods employed Ficoll-Hypaque density gradient 
centrifugation followed by cell culture (211-213). Significant colony growth was seen 
in breast, liver and non-small lung cancer when compared to healthy controls. Less 
EPCs were found in breast cancer by FC, but the cells were better described as 
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circulating progenitors (CPC) not EPCs (24). Probably the most accurate definition of 
EPCs is (CD45-CD34+KDR+ by Blann et al, though the protocol may not have 
differentiated them from CECs, as numbers of both were very similar (140). 
 
Table 7: EPC incorporation into the vasculature of tumours in animals models 
transplanted with bone marrow (BM) derived cells. 
 
 
LP- Lectin perfusion; IHC- Immunohistochemistry; IF- immunoflourescence; FISH- fluorescence in situ 
hybridization; BM cells- non-selected bone marrow cells; MAPC- multipotent adult progenitor cells; 
GFP- green fluorescent protein. FLK-1- KDR or CD309. Tie-2 is angiopoeitin receptor.  
Reference Tumour Marker 
Detection 
Technique 
Donor Cell 
transplanted 
% 
uptake 
      
(195) Lymphoma vWf IHC Mononuclear cells 90 
(204) Neuroblastoma 
cell 
CD31, 
CD34 
IF Modified BM cells, no 
RBCs 
5 
(205) Uterine 
Carcinoma 
CD31 IHC Mononuclear cells 16 
(206) Breast cancer CD31 IHC BM cells 1.3 
(199) Lung cancer, 
Lymphoma 
CD31 IF BM cells 0 
(196) Various human 
tumours 
vWf FISH na 1 to 12 
(208) Lung Cancer, 
Melanoma, 
Breast cancer 
CD31 IF, FC BM cells <1 
(209) Colon cancer  CD31, vWf FC  na 40 
(210) Lung cancer, 
melanoma, 
breast cancer 
CD31, 
VCAM, 
CD144, LP 
FC, 3D 
microscopy 
BM cells 2 to 20 
(166) Lung cancer, 
breast cancer 
CD31 IF, FC BM cells 12 
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Table 8: EPCs- Techniques of enumeration and relationship with cancer 
 
CFU-EC colony forming unit-endothelial cell; EOC endothelial outgrowth cells; CFr/T controlled freezing & thaw 
procedure; FAb Labelling with flourochromes; LM light microscopy; FC flow cytometry; ICS immunocytostaining; 
Dil-ac-LDL Dil-acetylated low-density lipoprotein; UEA-1  Ulex europaeus agglutinin I;CLL Chronic Lymphocytic 
Leukemia; FHDGC:  Ficoll-Hypaque density gradient centrifugation.  A Percentage of monoculear cells in PB. 
Cancer(s)  Protocol Markers 
EPC levels [median + IQR cells/ml] 
Study Cancer Control P< 0.05 
       
Prostate  
n=31 
FC CD45-CD309+ 
CD34+ 
38 
[15-74] 
32 
[18-82] 
n (140) 
       
       
Breast 
n=160 
FC CD45-CD133+ 
CD34+ 
121 
[81-186] 
169 
[106-241] 
y (24) 
       
       
Non-small cell 
lung cancer   
n=10 
FHDGC,  
IMS- CD34, 
FAb & ICS 
CD34+ 
CD133+ 
1.2%A 
(0.8-1.6) 
0.8% A 
(0.4-1.3) 
y (190) 
CD45- CD34+ 
CD133+ 
90% A 
(57-95) 
42%A 
(6-51) 
y 
CD45- CD34+ 
CD133+ 
VEGFR2+ 
0.18% A 0.01%A y 
       
       
Breast  
n=25 
FHDGC, 
FAb & FC 
CD14+ 
VEGFR2+ 
CD133+ 
↑EPCs with 
cancer stage 
None - (214) 
       
       
Breast 
n=47 
FAb & FC 
 
CD34+ 
VEGFR2+ 
0.4% +/- 0.28A 0.18%+/-
0.13A 
y (215) 
FHDGC, 
EC culture, 
LM & FC 
vWf+  
Dil-ac-LDL+  
CD34+ 
VEGFR2+ 
EOC to confirm EC origin only  
       
 
      
Liver 
n=64 
Culture 
System, 
separation 
& CFU-EC; 
FC 
CD45- CD34+ 
CD133+ 
CFU-EC: 2 times > controls 
 
y (211) 
FC:  0.82%A in cancer  vs 
0.26%  for controls 
y 
       
       
Non-small cell 
lung cancer  
n=53 
FAb & FC 
 
CD34+ 
VEGFR2+  
CD133+ 
1162 345 y (212) 
       
       
Liver 
n=80 
FHDGC, 
Dil-ac-LDL 
& UEA-1 
isolation, 
Culture, 
FAb & FC  
CFU-ECs  
CD133+ 
VEGFR2+  
& CD34+ 
VEGFR2+   
CFU scores 10 fold higher than 
controls & correlated to ↑EPCs 
y (216) 
       
       
Breast (n=19) 
& Gastric 
(n=52) 
FHDGC, 
Culture & 
ICS 
Dil-a-LDL, 
UEA-1, CFU-
ECs 
37.6 per unit 
area 
40.2 per unit 
area 
n (213) 
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1.2.5 Summary of the EC in CRC- why is the endotheliome important? 
 
Our current understanding of EC biology in cancer emerged from studies on factors 
secreted into plasma (e.g. vWf), physiological action on other cells (e.g. NO on VEGF 
production and angiogenesis), and the presence of endothelial cells (CECs, EPCs) 
within the circulation. There is ample evidence of EC perturbation in cancer, e.g. 
increased secretion and release of EC specific markers such as, NO, vWf and 
soluble E-selectin. These reflect activation of the relatively quiescent endothelium. 
Similarly, circulating ECs may result from the loss of endothelial integrity (CECs) and 
increased EPCs to angiogenic or bone marrow stimulators, like VEGF. 
 
While newer methods for assessing vascular biology await translation into clinical 
practice, additional tools are needed to monitor treatments that target the EC (e.g. 
anti-VEGF). However, the various subsets of endothelial form, function, dysfunction 
and its involvement in cancer were often studied in isolation. I therefore propose that 
EC activity incorporating histological, genetic, coagulation, inflammatory or adhesion 
markers in normal homeostasis and cancer warranted evaluation within a unifying 
concept called 'the endotheliome'. However the endotheliome aims to measure more 
than EC expression but also the effects on the cancer microenvironment, staging, 
prognosis and the long-term outcomes of treatment. 
 
It follows therefore that, as a clinical tool, the practical and cost implications of the 
endotheliome are challenging. Furthermore the EC has different properties at various 
anatomical sites (e.g. lung for gas transfer, aorta for cardiac output) and studies often 
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primarily focus on arterial and capillary but less on venous outcomes.  For CRC, a 
key requirement would be to synthesise an array of vascular modifications that occur 
within the EC environment at clinically relevant time points (e.g. before and after 
surgery, with or without chemotherapy) and to understand how those changes 
informed outcomes. The study of the endotheliome is not an attempt at a new field 
but to unify the vast data already in existence on the EC in CRC, to aid future studies 
and developments. Our publication of the concept of the endotheliome with 
‘Thrombosis Research’ (217) is shown in appendix 10. 
 
Given the practical and cost limitations, I hypothesise that the endotheliome in CRC 
is assessable by a combination of three groups of circulating markers: EC-specific 
plasma markers, cellular markers and angiogenic markers. It is therefore a question 
of selecting ‘best’ in each group. Whilst the choice was based on sensitivity and 
specificity, it must also consider patient factors. Ideally, the method must be 
accessible to all cancer patients, transferable to the clinical setting, inform treatment 
strategies, and predict prognosis both of disease progression and survival.  
 
Having discussed EC-specific and circulating cellular markers of the endotheliome, 
the most important role of the EC, that of angiogenesis and the subset of its 
assessment, the angiome, is explored next. 
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1.3 The Angiome 
 
The angiome, a subset of the endotheliome, is defined as the assessment of 
angiogenic activity. It was Judah Folkman’s pioneering premise in 1971 that 
angiogenesis was the crucial step in tumour growth and the basis of vascular biology 
research for almost four decades (13, 219). Angiogenesis is explored next. 
 
 
1.3.1 Angiogenesis 
 
Angiogenesis commences in utero and continues throughout adult life to ensure the 
primary directive of the vasculature is maintained. The macro- and micro- scopic 
tissue and organ structure of vertebrates requires the efficient simultaneous transport 
of gases, liquids, nutrients, signalling-molecules and circulating cells. Anatomically, 
the delivery of blood via the circulation (first described by William Harvey in 1628) 
proceeded from the heart through arteries into smaller arterioles and, finally, into 
extensive networks of capillary beds that allow for exchange of the gases and 
metabolic products (220). To increase transport to growing tissues during 
embryogenesis, arteries and veins expand through circumferential growth and 
remodelling processes, whereas capillaries sprout and branch into larger, more 
complex networks or primary capillary plexi (218). Similar remodelling processes 
were thought to be important for postnatal growth, development and healing, as well 
as tumour growth. While many theories exist, two basic models were widely accepted 
but not mutually exclusive: angiogenesis or the development of new vessels from 
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pre-existing ones, and vasculogenesis in which de novo vessels involve bone 
marrow derived EC and pericyte progenitors (147, 219, 221). However angiogenesis 
often encompassed all processes of blood vessel development. The formation of new 
blood vessels from pre-existing ones involved either sprouting or lumen splitting into 
two conduits by the intussusception of tissue bridges [figure 8] (222). Vasculogenesis 
and the role of EPCs also continued in postnatal life (147). 
 
 
 
 
 
Figure 8: The central role of ECs in angiogenesis  
ECs multiply through sprouting or added to the endothelium by EPCs. Neovessels form by sprouting 
and /or intussception in areas of high angiogenic activity. 
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Ausprunk and Folkman (223) and later modified by Paku and Paweletz  (224) 
described several well-characterised steps of sprouting (223). Angiogenic growth 
factors via receptors on ECs stimulate protease release against the basement 
membrane of the blood vessel. Intact ECs proliferate in parallel to the basal-luminal 
polarity towards the denuded site and surrounding matrix to form a slit like lumen. 
Basement membrane is deposited continuously by ECs except at the tip. Pericytes 
migrate along the basement membrane for complete coverage of the vessel. The 
solid sprouts so formed connect to neighbouring vessels and ECs migrate in tandem 
towards the angiogenic stimulus. The sprouts restructure into loops that developed a 
lumen whilst simultaneously connecting to and infiltrating surrounding blood vessels. 
 
The four phases of intussusception described by Burri et al have been demonstrated 
in both rat and human postnatal lung tissue (225). The opposing capillary walls grew 
into the lumen and established contact. At this zone, the EC junctions reconfigured 
and the bilayer of capillary walls perforated to allow the permeation of vascular 
growth factors. This zone filled with stromal cells, including bone marrow derived 
pericytes and myofibroblasts. These cells produced extracellular matrix (ECM), 
specifically collagen fibres, which organised ECs to form the lumen. Capillaries were 
increased efficiently without a corresponding rise in ECs (222, 225).  
 
To form mature, functional vessels, angiogenesis must be regulated by the 
sequential interplay of a number of ligand–receptor interactions on ECs, pericytes 
and other supportive stromal cells (like monocytes/macrophages). 
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1.3.1.1 The angiogenic switch 
 
The angiogenic switch was cleverly summarised by Hanahan and Folkman (226) as 
the activation of the normally quiescent EC by the balance tipped in favour of its 
activators over endogenous inhibitors (figure 9).  The healthy body controls 
angiogenesis through a balance of on and off switches i.e. pro-angiogenesis factors 
and angiogenesis inhibitors. Broadly, deregulation of these processes in disease may 
cause either excessive new vessel formation, as in cancer, macular degeneration, 
psoriasis and rheumatoid arthritis or insufficient angiogenesis as in coronary artery 
disease, stroke, ulcers, infertility and scleroderma (61). 
 
 
 
Figure 9: The angiogenic switch in which activators ‘outweigh’ inhibitors and 
promote sprouting of ECs. Adapted from Hanahan and Folkman 1996 (226).  
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The most important activator is vascular endothelial growth factor A (VEGFA), a 
member of a large family of potent angiogenic regulators including placental growth 
factor (PIGF), VEGFB, VEGFC and VEGFD (227). It also induces vascular 
permeability and vasodilatation (when injected intravenously), and probably promotes 
a strong survival stimulus on resident ECs. VEGF, on binding to VEGFR-1 and 
VEGFR-2, induced EC proliferation, tightly regulated c-ligand binding to various 
receptors and spliced other subtypes such as the anti-angiogenic b-isoform of 
VEGFA. When bound to the tyrosine kinase receptor VEGFR-2 (KDR or FLK1) it 
promotes differentiation, proliferation and sprouting of ECs. However, VEGFR, a 
weak tyrosine kinase, counteracts this activity by ‘trapping’ VEGF (228, 229).  
 
Sprouting is controlled by a number of pro-angiogenic and inhibitory signals (see 
figure 10). Proteolysis of the ECM increases the bioavailability of VEGF-A (isoform 
121) whereas contact with other ECs and pericytes induces EC quiescence. The tips 
ECs promote capillary growth without compromise to tissue perfusion (230, 231). 
Differential growth of ECs by VEGFA increased the expression of DLL4 in tip cells 
and up regulated notch receptors in neighbouring quiescent ECs. DLL4 suppressed 
VEGFR-2 expression of notch positive neighbouring quiescent ECs, preventing their 
conversion to the tip cell phenotype. The unguided proliferation of ECs is promoted 
by freely diffusible VEGF A isoform 121 in humans whilst the elongating filopodia of 
the tip cell maintains its awareness of direction and polarity by the spatial 
concentration gradient of matrix anchored VEGF (232). 
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Figure 10: Angiogenic factors in sprouting and stalk elongation 
 
The extension of the sprout, which assumes a cone-like morphology, may involve EC 
migration within the stalk (demonstrated in mouse retina) or proliferation within the 
tip. Filopodia formation was observed in some stalk ECs with elevated expression of 
DLL4 and PDGF (233). In order for vessels to connect with each other the tip cells 
must halt their motility when encountering their target, other sprouts or capillaries. 
Adhesive contacts between EC junctions are established when compatible vessels 
meet, whilst repulsive signals prevent abnormal connections like arteriovenous 
shunts. Lumen formation is controlled by EGF-like domain-7 (EGFL7), an ECM-
associated protein, expressed on ECs that suppress matrix adhesion but not EC 
proliferation. The established lumen and improved oxygen delivery stabilises the 
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tubes by suppressing VEGFA expression (234, 235). Pericytes are recruited to 
promote vessel maturation and inhibit angiogenesis resulting in the elimination of 
unwanted connections (or pruning) by EC apoptosis or retraction (232). The vascular 
network may also extend by intussusception (222). Despite strong morphological 
evidence to support this process little was known about its physiological regulation 
and pathological contribution to angiogenesis.  
 
 
1.3.1.2 Vasculogenesis and EPCs 
 
While the majority of vessels grow from the in situ EC, there was much interest in the 
role of embryological mechanisms first proposed by Ashahara et al (147). BM derived 
progenitors contribute to the regenerative and pathological growth of blood vessel in 
postnatal life. EPCs may aid the circumferential enlargement of the vessels and 
incorporate into EC monolayer lining during sprouting and possibly intussusception 
(236). Their contribution was thought to be quite small and further characterisation of 
the steps was needed (172). VEGF mobilises EPCs and non-EC progenitor 
monocytes (called bone-marrow-derived circulating cells [RBCCs]) that express 
chemokine receptor 4 (CXCR4). RBCCs, in response to VEGFA, expressed the 
CXCR4 ligand or stromal-derived factor-1 (SDF1), which aided the cells’ retention in 
the perivascular space (237). Details on EPCs were discussed in section 1.2.4.2. 
 
The next section addresses angiogenesis in cancer. 
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1.3.2 Tumour angiogenesis 
 
The need for tumours to form neovessels was first postulated 65 years ago and later 
developed by Folkman who theorised that anti-angiogenesis was an effective 
strategy for cancer treatment (13). The mechanisms for neovessel formation involve: 
co-option [sprouting from surrounding native vessels] (238), vasculogenic mimicry 
[cancer cells that mimic activities of ECs] (239), mosaicism [cancer cells in the 
luminal surface] (240), and vasculogenesis (165). The angiogenic switch is the 
dominance of stimulators over inhibitors to EC proliferation (226). ECs, stromal cells, 
and ECM also produce many of these promoters along with the cancer cells. Within 
the tumour’s microenvironment promotors signal sprouting and migration of EPCs for 
vasculogenesis; there was no in vivo evidence for intussusception (68). The main 
trigger is the VEGF-A pathway up-regulated mainly by tissue hypoxia and or cell 
death (241). The mechanisms for angiogenesis in the CRC are explored next. 
 
 
Mechanism of angiogenesis in CRC 
 
A variety of cell types promote angiogenesis or the ‘angiogenic switch’ primarily in 
response to tumour growth of a few millimetres, hypoxia and nutritional deprivation 
(221). The heterogeneous vessels carry nutrients irregularly via the tortuous tumour 
vasculature, which continuously remodels to cope with the growing tumour’s demand 
for a ‘better’ blood supply (242). The mechanisms of ECs in angiogenesis and in the 
CRC microenvironment are summarised in figure 11.  
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Figure 11: Angiogenesis and the EC in CRC. 
 
 
 
In summary basal membrane is degraded by MMPs of cancer cells and ECs; the 
exposed membrane attracts platelets, which carry angiogenic and permeability 
factors e.g. PDGF, an activator of ECs and perivascular cells (243). Tumour-
associated fibroblasts deposit ECM and cancer cells release stimulators such as 
VEGF, angiogenin and FGF (244, 245). MMPs cleave ECM fragments, expose 
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hidden epitopes of endogenous inhibitors of angiogenesis e.g. endostatin, but attract 
inflammatory cells that also secrete angiogenic modulators (246). Promoters exceed 
inhibitors for the angiogenic switch (tables 9 and 10). ECs express pro-angiogenic 
receptors, which stimulate intracellular pathways for sprouting and the exposed 
basement membranes attract EPCs (165). The roles of ECs are shown in figure 12. 
 
 
Figure 12: Summary of the roles of ECs in CRC 
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Table 9: Summary of important endogenous activators of angiogenesis in CRC 
 
Activator Function Ref 
   
VEGF -A, -B, -C, -D 
PIGF 
Stimulates EC activity in angiogenesis and 
vasculogenesis. Increases vessel permeability. 
Stimulates leucocyte adhesion, and monocyte/ 
macrophage migration 
(229) 
VEGFR-2 Tyrosine Kinase receptors that integrate angiogenic 
and survival signals mediated by VEGF 
(229) 
Angiopoetins-1, -2 Promote EC sprouting, stabilised neovessels and 
reduced vessel permeability 
(247) 
Platelet derived growth 
factor (PDGF) 
Recruits smooth muscle cells and cells of 
mesenchymal origin 
(248) 
TGF-β1, endoglin and 
other TGF-β receptors 
TGFs stimulated ECM production and vascular 
remodelling; endoglin on ECs activate macrophages 
and smooth muscle cells 
(249) 
FGF, HGF/MET Growth factors that also stimulate angiogenesis  (250, 251) 
Integrins αvβ3, αvβ5, α5β1 Enzymes against and receptors for matrix proteins (252) 
VE-cadherin, PECAM  Endothelial cell junction molecules (101) 
Plasminogen activators, 
MMPs 
Remodels matrix and releases growth factors (54, 82) 
PAI-1 Stabilises nascent blood vessels (67) 
NOS; COX-2 Stimulates angiogenesis and vasodilation (47, 95) 
Cytokines/ Chemokines 
(e.g. IL-6, TNF- α) 
Pleiotropic roles- tumour growth & survival; myeloid 
cell recruitment; T-cell activation. 
(253) 
 
VEGF-vascular endothelial growth factor; VEGFR- vascular endothelial growth factor receptor; HGF- 
hepatocyte growth factor; MET- HGF receptor; PDGF- platelet derived growth factor; TGF- 
transforming growth factor; FGF- fibroblast growth factor; PAI- plasminogen activator inhibitor; NOS- 
nitric oxide synthase; COX- cyclooxygenase. 
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Table 10: Summary of endogenous inhibitors of angiogenesis in CRC 
 
Inhibitor Function Ref 
   
VEGFR-1; NRP-1 A ‘trap’ for angiogenic promoters VEGF-A, VEGF-B, 
and PGIF 
(229) 
Angiopoetin-2 Mixed antagonist to Angiopoetin -1 (247) 
Thrombospondin-1 Inhibits EC migration, growth, adhesion to cells & 
ECM, and survival.  
(254) 
Endostatin (from ECM-
degraded collagen XVIII) 
Inhibits EC proliferation, migration and survival; 
reduces tumour growth 
(255) 
Other ECM degradation-
derived inhibitors 
Arresten, tumstatin and canstatin activity similar to 
endostatin. 
(256) 
Platelet factor 4 Inhibits binding of bFGF and VEGF to receptor (257) 
Tissue inhibitors of 
MMPs 
Chelates MMPs and suppresses pathological 
angiogenesis 
(258) 
Chemokines (CXCL-4, -
9,-10, -11) 
Inhibits EC chemotaxis and proliferation; inhibits 
activities of FGF and VEGF 
(253) 
NO Controversial role as inhibitor to EC sprouting (48) 
   
 
NRP- neuropelin; MMPs- matrix metallopreteinases. 
 
 
 
The basement membrane is cleaved, exposing fragments that alter integrin activity 
and facilitate sequestration of myeloid cells. These cells transform into tumour 
associated macrophages (TAMs) and neutrophils that also promote angiogenesis 
(246). EC surface receptors factors also initiate intracellular pathways to promote 
migration, invasion, survival and proliferation. ECs interact with perivascular cells and 
TAMs to determine their tip or stalk prototype (259).  
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Lyden et al showed that blocking VEGFR1 and VEGFR2 prevented the recruitment 
of EPCs, amongst other BM derived haematopoietic precursors, and eventually 
impaired tumour angiogenesis and growth (195). The pre-clinical studies of 
Kobayashi et al suggest ECs actively attract progenitor cells by ‘angiocrine’ factors 
such as Notch ligands (260). De Palma et al also found that angiopoietin-2 released 
by tumour ECs recruit Tie2-expressing monocytes, and the resultant TAMs signalled 
ECs to release more pro-angiogenic factors, including VEGF (261). 
 
In summary, angiogenesis is an essential requirement of tumour growth and 
metastasis. In this context, measuring its activity may potentially give further insight 
into CRC progression particularly for EC targeted treatment. In the next section, the 
current literature on assessing angiogenesis is discussed including potential 
surrogates for future clinical and research application. 
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1.3.3 Assessing the angiome 
 
Having established angiogenesis as critical to tumour growth and metastasis, it 
follows that its assessment may inform cancer treatment and prognosis. Specifically, 
the angiome may inform the tissue distribution of anticancer drugs and therefore a 
determinant of tumour response. Methods include measuring circulating plasma 
factors, radiological imaging, immunohistochemistry and circulating cellular markers 
such as EPCs. These methods however remain within the realms of laboratory 
research and are yet to be translated to the clinical setting.  These parameters 
provide ‘‘snap-shots’’ that do not necessarily reflect the dynamic status of the 
tumour’s microvasculature or relate to the molecular factors that regulate its growth. 
There is a need for markers of angiogenesis that can be monitored non-invasively in 
vivo at repeated intervals in large number of patients. In the next section I explore the 
various markers that may potentially be used to assess the angiome in CRC. 
 
 
1.3.3.1 Angiogenic growth factors and their receptors 
 
The concentration of circulating angiogenic factors can be measured easily by 
enzyme-linked immunosorbent assay (ELISA). The first meta-analysis on VEGF in 
cancer by Kut et al suggest a prognostic value of its pre-treatment levels in CRC 
patients, specifically VEGF-A (262). A number of other potential biomarkers include 
bFGF, platelet-derived growth factor (PDGF), transforming growth factor-beta (TGFβ) 
and angiogenin (263-267). Their clinical significance is less conclusive as they were 
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also detected in some healthy controls. VEGF continues to spark interest more so for 
its correlation with other emerging biomarkers of CRC (268). 
 
Dirix et al first showed that serum VEGF and bFGF levels were higher in progressive 
(unresponsive) disease when compared to chemo-sensitive metatstatic CRC [mCRC] 
(269). Much of the circulating VEGF is found largely stored in platelets and serum 
levels (which contains more VEGF after platelet release from coagulation) may not 
truly reflect tumour expression (270, 271). However, Peterson et al showed that the 
platelet load of VEGF correlated to disease stage of CRC (272). Clinical trials on anti-
angiogenic (anti-VEGF) therapy measured VEGF to monitor treatment response 
(273). Hyodo et al reported low pre-treatment plasma VEGF levels of mCRC were 
correlated to a significantly better response rate and prognosis with chemotherapy 
(274). However plasma VEGF varied widely, often overlapping with that of healthy 
controls (274, 275).  With no clinical cut off point, translation to bedside application 
remains elusive. The angiogenic effects are dependent on the internalization of 
surface bound VEGF and plasma levels, having no correlation with intracellular 
levels, may not necessarily reflect its activity (276). Soluble serum VEGFR-1 and 
VEGFR-2 were detected in the CRC patients but not healthy individuals (277). The 
ratio of VEGF to VEGFR1 was shown to provide better prognostic value than serum 
VEGF, VEGFR1 or VEGFR2 alone (277, 278). 
 
Proteomics and genomics may offer other surrogates of angiogenic assessment. 
Circulating mRNA and DNA indirectly measure angiogenic factors by quantitative 
PCR and may provide a holistic pattern of gene, protein and metabolite expression 
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(279). Miniaturised ELISA assay (Luminex) quantifies hundreds of proteins in small 
volumes of plasma/serum and offers a promising ‘single-stop’ angiogenic status 
evaluation (280, 281). The key question remains, what do we measure? 
 
 
1.3.3.2 Circulating cellular markers 
 
The roles of EPCs and CECs are discussed in section 1.2.2.  Recently other BM-
derived cells were described in angiogenesis. Inflammatory infiltrates contain CD34+-
, Tie2+- and VEGFR2+- expressing monocytes which may regulate angiogenesis and 
tumour growth by paracrine mechanisms (203). Goede et al cast doubt when Ties2-
expressing monocyte (TEMs) levels in CRC were similar to healthy controls (282). 
DePalma et al suggested that TEMs were a diverse fraction of monocytes that 
require further exploration for cancer staging and prognosis (203, 261).  
 
 
1.3.3.3 Immunohistochemistry 
 
A crude but inconsistent histological measure of angiogenesis is tumour volume. 
Microvessel density (MVD), first described by Weidner et al in 1991 correlated with 
breast cancer survival and/or recurrence (12).  Immunohistochemistry (IHC) with EC 
markers (CD31, CD34, and vWf) stained microvessels, not seen on conventional 
histology, identifies ‘hot spots’ (areas of the highest vascularity) in the tumour section 
on low power (x 40) field. Individual microvessels were counted under a high power 
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(x 200) field in a defined area and the average vessel count in five hot spots was 
taken as the MVD. However ‘vasculogenic mimicry’ (the formation of a well-
structured microcirculation with tumour cells) devoid of ECs and independent of 
angiogenesis, lacked the phenotypes used in IHC analyses (283). A meta-analysis of 
CRC showed a very high MVD correlated with recurrence [RR = 2.84; 95% CI: 1.95-
4.16] and overall survival (OS) [RR=1.65; 95% CI: 1.27-2.14] (284). However, 
inconsistent methods of microvessels selection and restrictions to post-resection 
quantification prevent repeated measures and no better than routine histology. 
 
 
1.3.3.4 Radiological tests 
 
Imaging of tumour angiogenesis or vascularity was not routinely used in CRCs as 
they are expensive, experimental and of unknown clinical value. Tumour growth and 
metastasis is routinely evaluated by several non-invasive modalities: computed 
tomography (CT), magnetic resonance imaging (MRI), positron emission tomography 
(PET-CT), single photon tomography (SPECT), and ultrasound (285). Only MRI of 
the rectum may detect extramural vascular invasion [sensitivity 66%, specificity 88%], 
a poor prognostic indicator of rectal cancers (286). 
 
Potentially CT and/or MRI may image angiogenesis and vascularity by a variety of 
contrast mechanisms e.g. blood flow, microvessel permeability and diameter, water 
diffusion, tissue oxygenation and metabolism. Dynamic MRI of tumour vascularity i.e. 
MRI with contrast media, may identify more aggressive disease (280, 287).  
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1.3.4 Summary of the angiome  
 
In summary the angiome is an important tool for assessing the angiogenic activity of 
a tumour. It requires further development by incorporating plasma, cellular, 
histological and radiological markers in CRC. Studies on the relationship of cellular 
with EC-specific plasma markers in CRC were lacking and therefore worthy of further 
investigation. Our publication of the concept of the angiome with the Journal of 
Clinical Pathology (268) is appended. 
 
Analysing factors of the endothelial-tumour interaction may offer further clinical 
information of tumour activity and/or response to treatment. In the next section I will 
discuss and give justification for the factors that I have chosen for the endotheliome 
and angiome in CRC staging, treatment and prognosis. 
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1.4 The Endotheliome and Angiome in CRC 
 
To recapitulate, various cells in CRC ‘activate’ ECs via the angiogenic switch to 
promote neovascularisation for growth and metastasis. Angiogenesis is a complex 
multistep process: breakdown of the EC basement membrane, digestion of the 
extracellular matrix, proliferation and migration of ECs towards the angiogenic stimuli 
and the formation of functioning capillaries (333). CECs are probably released from 
the vessel wall by invading tumours and EPCs contribute to vasculogenesis. These 
processes are regulated by factors released from tumour cells, stromal cells and ECs 
within the tumour-EC microenvironment (see figure 13). 
 
Figure 13: The proposed endotheliome and angiome in CRC 
 
 
The Endotheliome and Angiome will be determined by measuring (1) angiogenic factors, (2 & 3) 
cellular markers and (4) EC factors of activation/damage. 
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The concept of a multifactorial assessment model of EC activity and angiogenesis is 
not new. Studies of the role of plasma and cellular markers in cancer are shown in 
table 11. Despite their heterogeneity, the results were inconsistent as correlations 
seen in hepatocellular and lung cancers (190, 211) were not demonstrated in 
lymphomas, breast cancers or gastrointestinal stromal tumours (17, 146). Goon et al 
investigated their value in disease stage and concluded that cellular, not plasma 
markers, correlated with the Nottingham Prognostic Index (NPI) in breast cancer (24).  
 
As expected the most quantified factor of angiogenesis is VEGF. It however did not 
correlate to the increased levels of CECs reported. Higher VEGF and its receptor, 
VEGFR-2, were positively correlated to EPCs only in GIST tumours, non-small cell 
carcinomas and hepatocellular cancers (17, 144, 190, 211).  However, this was not 
seen in breast and prostate cancer.  
 
Exactly why correlations of cellular with plasma markers were inconsistent is 
probably multifactorial. They may be from the variations in techniques used to assess 
cellular markers and the lack of consensus on clear definitions of CECs and EPCs. 
Most studies were small; other confounders were less focused study criteria (i.e. the 
inclusion of different cancer), undefined disease stages and/or inclusion of patients 
with concurrent disorders e.g. cardiovascular disease, that may alter these markers. 
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Table 11: The relationship of cellular and plasma markers in cancer 
 
Study Tumour Type(s) 
Cancer vs Controls 
Correlations with Plasma Markers CEC EPC 
     
(140) Prostate Cancer 
n=84 
None None ↑ vWf & ↑ E-selectin. No correlations. 
     
(24) Breast Cancer 
(n=160) 
↑ x 1.3  ↑ x 1.3 ↑ VEGF, ↑ Angiogenin, ↑ vWf. 
No correlations. 
     
(190) Lung cancer 
(n=10) 
NA ↑ x 2.1 ↑ VEGF correlated to ↑ EPC. 
     
(142) CLL (n=20) ↑ x 1.4 NA ↑ FGF-2, ↓TSP-1 and equivocal VEGF 
No correlations. 
     
(144) GIST (n=16) ↑ x 2 NA ↑ VEGF and sVEGFR-2. 
no correlation. 
     
(215)  Breast Cancer 
(n=47) 
NA ↑ x 2.2  ↑VEGF, ↑b-FGF. No correlations.  
     
(334) 
 
Gliomas  (n=39) NA ↑ x 13 ↑ eNOS. No correlation. 
     
(211) Hepatocellular 
cancer (n=64) 
NA ↑ x 2 ↑ VEGF, ↑ PDG-BB.  
No correlations. 
     
(335) Multiple myeloma 
(n=31) 
↑ x 6 Not given ↑ M protein, ↑ β2 microglobulin. 
All Correlated to ↑ CECs. 
     
(139) Breast Cancer  
(n=16) 
↑ x 4.3 ↑ x 2.6 ↑ VCAM-1, ↑ VEGF but normal EPO, 
Ang-2, soluble endoglin levels. 
Correlations not given. 
     
(216) Hepatocellular 
Cancer (n=80) 
NA ↑ x 3.4 ↑VEGF & ↑IL-8 correlated with ↑EPC. 
     
(146) Various Cancersa 
(n=112) 
↑ x 3.3 NA ↑VEGF,↑PIGF,↑SDF-1α,↑SCF 
No correlations. 
     
(213) Breast & Gastric 
cancers (n=71) 
NA ↓ x 0.03 ↑VEGF- no correlation. 
     
(17) Lymphoma & 
Breast (n=76) 
↑ x 5.3 NA ↑ VCAM-1 correlated with ↑ CEC. 
     
 
SDF-1α stromal cell derived factor 1α ; SCF stem cell factor ; EPO erythropoietin; Ang-2 angiopoietin-
2; TSP-1 Thrombospondin 1; FGF-2 Fibroblast Growth Factor 2; eNOS endothelial nitric oxide 
synthetase; GIST- gastrointestinal stromal tumour  a  Breast (n=10), ovarian (n=5), prostate 
(n=25), colon (n=13),head & neck (n=10), renal cell (n=6) cancers. CLL: Chronic lymphocytic leukemia 
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The markers that I have chosen for this study are: 
 
1.  Cellular markers 
 a. CECs   marker of tumour invasion 
 b. EPCs   marker of angiogenesis 
 
2. Plasma Markers 
a. vWf    Marker of EC damage (from vascular invasion and  
displacement from blood vessels in cancer) 
b. E-selectin  Marker of EC activation, tumour invasion and  
angiogenesis.  
c. Angiogenin  Marker of angiogenesis 
d. VEGF   Marker of angiogenesis 
 
 
I next look at the cellular markers chosen for this study in colorectal cancer. 
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1.4.1 Cellular Markers 
 
As outlined already, CECs and EPCs are promising cellular markers of EC activity in 
CRC and may have a role in monitoring chemotherapy. However, what is not clear is 
how these cells vary with cancer stage and surgical treatment. To date no study has 
addressed this specifically in CRC and their prognostic significance. 
 
 
CECs 
 
Circulating endothelial cell analysis has been revolutionised by the use of multiple 
phenotypic markers and flow cytometry. They include CD31, CD34, CD144, CD62E, 
CD105, CD106, CD146 and KDR (see table 3).  
 
Using 4 or more colour-cytometry, researchers have shown that the vast majority of 
mature CECs are CD45-/34+/31+/146+/133- and come from the CD34+ fraction of 
mononuclear cells in blood. To quantify CECs I have used the definition of CD45-
/CD34+/CD146+ i.e. CD45 excludes leukocytes and progenitors, CD146 is heavily 
expressed on mature ECs (not on progenitor cells) and CD34 found on most ECs in 
vivo (17, 184, 197, 336). Non-endothelial CD34+ cells include a small population of 
progenitor and stem cells (both of which also heavily express CD133). CD 31 was 
excluded as its antibodies cross-react with the majority of leukocytes, platelets and 
haematopoietic progenitors (337). Also, in cancer endothelial cell lines a small 
number do not express CD31 and CD105 (338, 339). 
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EPCs 
 
As already described in section 1.2.2.2, EPCs probably represent a heterogeneous 
group of cells. Markers that have been described include CD34, CD105, CD133, 
CD309, CD144, CD 146, and CD45 (dim). Controversially a minority are CD146 
positive, counter to the argument of its expression exclusively on mature ECs (169, 
197, 340). Unfortunately CD133 expression is lost with maturation. It was also found 
on haematopoietic and other progenitors, thus raising the possibility that those 
positive cells were non-EC stem cell derivatives (169, 178).  
 
The most important studies to date showed the growth of CD45+/CD34+ 
progenitor/stem cells into ECs with Weibel-Palade bodies and bearing the mature EC 
phenotype CD45-/CD31+/CD105+/KDR+/CD34+, i.e. a true transformation of 
progenitor into mature ECs (341, 342). Though KDR is co-expressed in other cell 
types, I have taken the more popular definition of the EPC as CD45-/ CD34+ /KDR+ 
since KDR, though initially low in CD45-/CD133+/CD34+ cells, is up-regulated and 
CD133 down-regulated as the cell matures. CD133 positive cells were therefore best 
described as forerunners to the EPC [or circulating progenitor cell, CPC] (343-345). 
 
Table 12 summarised the findings of studies on that measured both CECs and EPCs 
in various cancers against normal controls and phenotypes used to identify the cells.
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Table 12: EPCs & CECs - markers of identification and relationship with Cancer 
Study Cancer 
CEC levels EPC levels 
Markers Cancer Control <0.05 Markers Cancer Control <0.05 
          
(140) Prostate 
Cancer 
CD45− 
CD146+ 
CD34+ 
28 
[11-43] 
cells/ml 
21 
(14-45) 
cells/ml 
n CD45− 
CD309+ 
CD34+ 
32 
[18-82] 
cells/ml 
38 
[15-74] 
cells/ml 
n 
          
(24) Breast 
Cancer 
n=160 
CD45− 
CD146+ 
CD34+ 
14 A 
[8-22] 
cells/ml 
8 A 
[6-10] 
cells/ml 
y CD45− 
CD133+ 
CD34+ 
120 A 
[72-150] 
cells/ml 
169 A 
[106-241] 
cells/ml 
y 
          
(346) 
 
Head & 
Neck 
Cancers  
n=22 
CD45- 
CD146+ 
7AAD- 
CD31+ 
2 A 
[0-5] 
/5x105 
events 
2 A 
[0-7] 
/5x105 
events 
n CD45- 
CD133+ 
CD309+ 
CD3-  
CD19- 
CD33-  
7AAD- 
5 A 
[1-41] 
/5x105 
events 
2 A 
[0-7] 
/5x105 
events 
n 
        
(334) 
 
Gliomas  
n=39 
CD34+ 
CD146+ 
KDR- 
Not given CD34+ 
 KDR+ 
CD133+  
AND 
CD34+  
KDR+ 
CD105+  
0.18% B  
[0-3.6] 
0.013% B   
[0-0.04] 
y 
        
(335) 
 
Myeloma 
n=31 
CD34+ 
CD146+ 
CD105+ 
CD11b- 
6 times higher 
than controls C 
y CFU-ECs 
KDR+ 
CD133+  
Not Stated  
          
(139) 
 
Breast 
Cancer  
n=16 
CD31+ 
CD34+  
CD45- 
CD146+ 
5700 C 1300 C y CD34+ 
CD45low  
KDR+ 
370 C 140 C y 
          
(347) 
 
AML 
 n=48 
CD31+ 
CD34+ 
CD45- 
CD133-  
CD146+ 
 
36,700 C 3200 C y CD45-  
CD133+  
CD31+  
CD34+  
CD146- 
700 C 100 C y 
 
Results presented as median values and interquartile ranges. Sig= significance of p<0.05. A Events by 
flow cytometry. B Percentage of monoculear cells in peripheral blood. C CFU- colony forming units. 
CFU-ECs- colony forming units for endothelial cells. 
 
 
 
CECs and EPCs have been proposed as markers for oncological treatment. 
Changes in their levels, particularly with bevacuximab, have been positively 
correlated to overall survival (OS) and progression free survival (PFS) (see table 13). 
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Table 13: Role of CECs and EPCs in colorectal cancer follow-up and survival. 
      
Study n Marker(s) Method Treatment Findings 
      
      
(348) 24 
mCRC 
CECs 
Apo-CECs 
FC 
(4-colour) 
1st line 
Chemotherapy 
+ 
Bevacuximab 
Longer PFS when both 
markers were high 
after the 6th cycle  
(p=0.002; r=0.83) 
      
(349) 99 
mCRC 
CEC FC 
(4-colour) 
1st line 
Chemotherapy 
+ 
Bevacuximab 
Poor OS (p=0.025) & 
PFS (p=0.002) when 
CECs were high before 
and after 1cycle. 
      
(350) 69 
mCRC 
EPC (CEP) 
CXCR4+ 
CEC 
FC 
(4-colour) 
1st line 
Chemotherapy 
+ 
Bevacuximab 
EPC <0.04% or 
CEC<20% on day 4 of 
treatment: longer PFS 
and OS (p<0.001) 
      
(28) 64 
mCRC 
CEC CellSearch
System™ 
FOLFOX4 
VS 
FOLFOX4 + 
Bevacuximab 
Longer PFS (p=0.003) 
and OS (p=0.027) 
when CECs where <65 
cells/ml before 
Bevacuximab  
      
(201) 40 
mCRC 
EPC (CEP) 
tCEC 
rCEC 
FC 
(MP) 
1st line 
Chemotherapy 
+ 
Bevacuximab 
Longer PFS if tCECs 
were <40 cells/ml. 
EPCs- no correlations 
with survival 
      
(351) 33 
CRC- 
All 
stages 
CD 133 
mRNA 
monocytes 
rt-PCR NA CD133>4.79 correlated 
to higher recurrence 
rates 
OR 14.6 (1.7-126) 
independent of stage. 
      
 
mCRC: metastatic colorectal cancer.  Apo-CEC: apoptotic circulating endothelial cells.  CEP: 
circulating endothelial progenitors.  tCEC: total circulating endothelial cells.  rCEC: resting circulating 
endothelial cells.  FC: flow cytometry.  PFS: progression-free survival. OS: Overall survival.  MP: 
Multiparametric FC.  rt-PCR: Semiquantitative reverse transcriptase real-time PCR. First-line or 
fluorouracil (5-FU)-based therapy. Bevacuximab- Anti-VEGF-A monoclonal antibody. FOLFOX4- 
Folinic Acid + 5- fluorouracil + oxaliplatin 
 
Next I give justification for the plasma markers chosen for my thesis. 
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1.4.2 Plasma Markers 
 
As outlined already various plasma cellular markers of EC activity may have some 
value in disease staging. However, to my knowledge, this has not been evaluated 
alongside CECs and EPCs in the prognosis and treatment of colorectal cancer. 
 
 
Angiogenin 
 
Angiogenin was first isolated in cultured HT-29 human colon adenocarcinoma, is 
encoded on chromosome 14q11 and is a single chain ribonuclease with 123 amino 
acids and weighs 14400 Da. (352, 353). It is similar to bovine pancreatic 
ribonuclease A though 105-106 weaker than human RNase A and, when inhibited, 
blocked angiogenesis in embryonic development (354-357).  
 
Angiogenin may bind to cell surface actin on ECs and the complex that dissociates 
from the cell surfaces trigger tPA generated plasmin from plasminogen. Plasmin 
degrades basement membrane and extracellular matrix to allow ECs to penetrate 
perivascular tissues towards neovascularisation. Angiogenin adheres more rapidly to 
HT-29 human colon cancer cells compared to other ECM proteins. It is postulated to 
therefore aid metastasis by EC attachment prior to trans-vessel migration (358, 359). 
 
There is still a lack of understanding of the mechanisms behind cellular proliferation 
observed in angiogenin treated HUVECs and smooth muscles. It may involve 
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extracellular signal-related kinase phosphorylation of stress-associated proteins (360, 
361). A putative 170-kDa angiogenin receptor has been proposed that triggers 
proliferation of ECs migrated into the perivascular space but down-regulate at a 
critical cell density and with the formation of a capillary network (359, 362). The 
mechanisms of nuclear translocation of angiogenin were unknown but occur rapidly 
in ECs, enhance ribosomal RNA transcription, and may involve the regulation of 
some steps in EC proliferation by other angiogenic factors e.g. b FGF, VEGF (363).  
 
Shimoyama et al showed serum levels of angiogenin were reflected in the distribution 
of angiogenin and its genetic expression in CRC tissues. The mean serum 
angiogenin was significantly higher in cancer patients versus healthy controls and 
significantly higher in mCRC. Though a small study it showed a correlation with high 
sera angiogenin and worse disease-specific survival [p=0.03] (364).  
 
It is therefore my view that there is a paucity of clinical data on angiogenin as a 
biomarker. This probably reflected the difficulties in elucidating its exact role in the 
mechanisms of angiogenesis. Furthermore, there was little related data with other 
endothelial biomarkers and to date; none examined its relationship with circulating 
endothelioid cells in colorectal cancer. 
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VEGF 
 
To recapitulate, VEGF is a heparin-binding peptide and potent angiogenic factor with 
specific mitogenic activity in epithelial cells. It is a key player in tumour angiogenesis 
because it induces EC proliferation, increased vascular permeability, promoted the 
extravasation of proteins from tumour vessels, and mediates the formation of the 
fibrin matrix through which stromal cells invade. The rapid growth of cells, hypoxia 
and apoptosis within the solid tumour stimulates VEGF production, which in turn 
leads to further angiogenesis in areas demanding more nutrients (365, 366). 
 
VEGF is probably the most studied of all biomarkers in cancer. Numerous reports 
consistently showed its expression in the circulation and tumour-tissue interface 
correlated to disease stage and hold prognostic value in CRC. VEGF expression has 
an inverse relationship to prognosis and serum VEGF levels were significantly higher 
when a rapid disease progression occurred (269). The first meta-analysis of the 
VEGF expression in resected colorectal cancer in predicting survival analysed 2050 
patients in 18 independent studies. Trials using circulating VEGF levels were 
excluded to avoid the theoretical contribution from platelets, monocytes, and 
granulocytes in peripheral blood. Higher VEGF expression in tumour tissue indicated 
a shorter relapse-free survival [RR, 2.84; 95% CI, 1.95-4.16; P < .001] and poorer 
overall survival [RR, 1.65; 95% CI, 1.27-2.14; P < .001] (284). However this does not 
negate the consistent findings that circulating VEGF, as a minimally invasive 
biomarker, is of predictive value in disease progression (366). 
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VEGF levels have been shown to correlate with CECs and EPCs in some cancers 
but to date there are no studies of this relationship in CRC stage, surgical treatment 
and survival. However there is emerging support for their role in predicting the 
response of CRC to chemotherapy, specifically in the use of anti-VEGF, though 
results between studies are not consistent (table 13).  
 
It is now well established that VEGF is one of the major player in the angiogenic 
switch in colorectal cancer except in tumours with DNA microsatellite instability. The 
capacity to express high levels of VEGF is acquired in pre-malignant phases of 
colorectal cancer development. The regulation of VEGF expression is under the 
control of p53 as well as ras and src pathways. Serum or tumour VEGF levels may 
have prognostic relevance in specific subgroups of patients, and more likely so when 
combined with other markers of angiogenesis, like KDR receptor, TF, MVD, MMP2. 
 
The demonstration that neutralizing anti-VEGF antibodies are efficacious in 
somewhat prolonging survival in metastatic colon cancer has been the tour de force 
of antiangiogenic drug development. Measurable therapeutic and biological effects 
are also seen in breast, renal and rectal carcinoma. Willett et al. specifically 
demonstrated that following a single infusion of antibody, reductions are seen in 
tumour perfusion, vascular volume, microvascular density, interstitial fluid pressure 
and the number of EPCs, while vessel maturity had increased. 
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E-Selectin 
 
E-selectin (E-Sel) is an adhesion molecule expressed by cytokine activated ECs to 
mediate the migration of neutrophils and monocytes in inflammation. It is often 
considered a marker of activation of the normally quiescent ECs with growing 
evidence that it aids the attachment of malignant cells during metastasis (90, 367, 
368). Small studies of circulating E-Sel suggest a diagnostic and prognostic value in 
CRC but s controversial on the link to life expectancy and site of metastasis (78, 
369). High levels of E-Sel have been linked to VEGF and the coagulation cascade in 
non-CRC tumours (370). Blann et al did not find a correlation with CECs and plasma 
levels of e-selectin despite high levels of both in prostate cancer (140). To date this 
relationship has not been reported CRC in the published literature.  
 
 
vWf 
 
vWf is a multimeric glycoprotein synthesised in ECs and megakaryocytes, stored in 
Weibel-Pallade bodies, released in EC damage and under the effects of inflammatory 
cytokines (27,28). High vWf plasma levels have been seen in CRC patients when 
compared to controls as with many cancers, the highest seen metastatic disease (11, 
16).  Non-significant correlations with CEA levels are reported, but those of tumour 
characteristics such as lymph node spread and venous invasion are inconclusive 
(23). Blood group O has significantly lower plasma levels than other phenotypes, 
though conflicting reports have emerged (371, 372). Additionally many factors such 
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as myocardial infarction, diabetes mellitus, liver disease and acute infections 
influence vWF plasma levels. Schellerer et al concluded that on its own vWf was not 
a useful biomarker in CRC (23, 24). Goon et al and Blann et al found no relationship 
with vWf, CECs and EPCs in breast and prostate cancer respectively (29, 139). 
However, to date this relationship has not been explored in CRC. 
 
In the next section I summarise the introduction, generate questions for the 
endotheliome and angiome in CRC, and propose my study hypotheses. 
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1.5 Summary of the Introduction 
 
Our understanding of endothelial activity and angiogenesis in diseases continues to 
evolve. Given that many questions are yet to be answered from the above 
observations, the vascular infrastructure of CRC, inferred by circulating plasma 
markers, is worthy of further study. Certainly, when compared to healthy individuals, 
various markers of EC activity are disturbed. However, the clinical ramifications of 
these assessors remain unclear and such changes may merely reflect the broad 
disturbance in many physiological systems that may occur in disease in general. 
Furthermore, as newer therapies emerge more accurate assessment tools will be 
required. There are a number of limitations to current assessors most notably a lack 
of standardized methodology. Further studies towards improving the accuracy and 
the assessment of the results of current tests are required before translation to 
clinical application. Therefore, larger disease specific studies with more stringent 
exclusion criteria are necessary.  
 
Most notably, the benefits seen from recent clinical data on the efficacy of anti-VEGF 
therapy for metastatic cancer will continue to drive research into other modulators of 
angiogenesis. The promise lies in more tailored, tumour-specific treatment and will 
probably be determined by the tumour’s genetic make-up including its angiogenic 
potential e.g. kras and p53 status. With the expected rise in clinically validated 
angiogenic modifiers, better surrogate markers, other than the maximum tolerated 
dose, are needed. To date there is no single marker to monitor anti-angiogenesis but 
recent reports support of circulating cellular markers (CECs, EPCs), despite the 
limitations to accurately enumerate them. However, the importance of the multiple 
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assessment strategy of any therapy (involving histological, circulating and imaging 
markers) is its ‘predictive’ potential of the tumour’s response to treatment. 
Furthermore targeting angiogenesis will require more accurate measurements of EC 
activity. In summary the status of the endotheliome and angiome are crucial 
determinants in CRC treatment and prognosis.  
 
The project I describe aims to clarify fundamental questions of EC activity in CRC as 
measure in PB. Building on existing publications and the expertise of my colleagues, 
I have identified the following key facts (1.5.1) and questions for my study (1.5.2): 
 
1.5.1 What was known of the endotheliome and angiome in CRC: 
 
1. Endothelial cells and angiogenesis are fundamentally essential to CRC. 
2. Flow-cytometry defined CECs and EPCs were partially investigated in CRC. 
3. CRC demonstrate a spectrum of EC and angiogenic activity.  
4. Well vascularised CRC are likely to be more advanced but relatively 
chemosensitive versus less advanced and ‘under-vascularised’ ones. 
5. Plasma markers of EC activity and angiogenesis are often high in mCRC. 
6. Surgery, chemotherapy and/or radiotherapy (and/or combined therapy) alter 
levels of circulating plasma markers of EC and angiogenic activity. 
7. Plasma markers of EC and angiogenic activity may predict outcomes before 
and during treatment of CRC.  
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1.5.2 What was NOT known of the endotheliome and angiome in CRC: 
 
1. What are the relative components of the endotheliome and angiome for CRC? 
2. Are the endotheliome and angiome generic or specific to CRC and stage? 
3. How might radiological, histological, circulating cellular and plasma markers 
define the endotheliome and angiome in CRC? 
4. How does the measured endotheliome and angiome alter with intervention(s)? 
5. Does the measured endotheliome and angiome before treatment predict 
outcome and/or response to the treatment? 
6. Does the measured endotheliome and angiome reflect CRC vascular activity 
and could this predict treatment response? 
 
 
From these questions I next formulated the five hypotheses for my study.
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1.5.3 Hypotheses 
 
1. There are altered numbers of CECs and EPCs (and their ratio) in colorectal 
cancer when compared with healthy and non-cancer disease controls. The 
latter will be non-malignant lower gastrointestinal polyps (‘pre-cancerous’ 
disease) and stable coronary artery disease (positive control). A sub-hypothesis 
is that numbers of EPCs and CECs correlate significantly with each other. 
 
2. Numbers/levels of CECs and/or EPCs vary with CRC disease stage. 
 
 
3. Numbers/levels of CECs and/or EPCs correlate positively/negatively with 
plasma markers of the endotheliome and angiome, specifically vWf, angiogenin, 
sE-selectin and VEGF in CRC versus the controls. 
 
4. Altered numbers/levels of CECs, EPCs and/or plasma markers of the 
endotheliome and angiome normalise after treatment by surgery, conventional 
chemotherapy or anti-VEGF antibody therapy. 
 
5. Altered numbers/levels of CECs, EPCs and/or plasma markers predict disease 
progression and recurrence within 2 years. 
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1.5.4 Plan of Investigation 
 
In order to test hypothesis 1, research indices were measured in the blood of patients 
with colorectal cancer and compared to three control groups: benign disease, fully 
healthy, with stable coronary artery disease [SCAD]. The SCAD group was included 
for two reasons: (i) to provide a ‘positive control’ for altered EPCs and CECs (22, 
122) and (ii) to determine whether or not any changes in CRC are of a similar 
magnitude to those in SCAD. Subjects were recruited from patients and there 
relatives attending colorectal, cardiology and oncology clinics. 
 
Hypothesis 2 within the colorectal cancer group, levels of cellular markers and growth 
factors should associate with disease stage as defined by Dukes’ classification 
(and/or AJCC). The disease stage was determined in combination by routine 
radiology (CT scan) assessment and histological examination of the excised tumour.  
 
Hypothesis 3 was tested by the correlation of ELISA-defined plasma markers of the 
endotheliome (vWf and soluble E selectin), and the angiome (VEGF,angiogenin) with 
that of CECs and EPCs from the participants recruited to hypotheses 1. This was 
determined by analysing these plasma markers, against data generated in 
hypothesis 1. 
 
Hypothesis 4 was tested in the blood (for markers as in hypothesis 1 and 2) of 
patients before and on two occasions (3 and 6 months) after surgery for early 
disease with no adjuvant therapy. Similarly blood in subjects with advanced 
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colorectal cancer disease (with or without neoadjuvant therapy) was tested before 
and after standard and/or experimental chemotherapy. 
 
Hypothesis 5 tested the predictive value of hypotheses 2 & 3 on outcomes at 2 years. 
 
 
In the next section I detail the methodology of my study. 
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Chapter 2 
Subjects and Methodology 
 
 
2.1. Subjects 
 
 
2.1.1 Patients with CRC 
 
Participants with colorectal disease were identified from hospital referrals, outpatient 
clinics, endoscopy sessions, emergency presentation and colorectal cancer 
multidisciplinary meetings. They were recruited from colorectal surgery, endoscopy 
and oncology clinics, and acute ward admissions.   
 
 
2.1.2 Controls 
 
The general hypotheses called for several age-matched control groups. 
a. Participants with benign colonic polyps (but free of any inflammatory bowel 
disease) as polyps are recognised ‘pre-cursors’ to colorectal cancer. 
Participants referred for lower gastrointestinal symptoms were approached 
after consultation at colorectal clinic and recommended for colonoscopy. 
Samples were drawn before bowel preparation began and participants were 
only included if found to have one or more tubllovillous adenomas of any size 
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with moderate to high-grade dysplasia. Polyps with high-grade dysplasia and 
uncertain to be cancerous were excluded.  
b. Healthy controls free of any apparent disease were recruited. These 
participants were defined by careful clinical history, routine observations and 
blood tests. They were all relatives of patients attending the colorectal, 
cardiology, rehabilitation and oncology clinics.  
c. Stable cardiovascular disease i.e. patients with known stable coronary artery 
disease for more than 3 months, and had no acute cardiovascular events 
during this time. Stable CAD were categorized on the basis of a history of 
stable angina with or without previous revascularisation procedure(s), left 
ventricular ejection fraction ≥	 45% and evidence of flow-limiting CAD, 
identified by either a positive exercise stress test or on coronary angiography 
(i.e. 70% stenosis in 1 major coronary artery). EC dysfunction is well 
established in CAD; hence this group was used as the positive control. 
All participants gave a 20 ml blood sample, with their medical history and routine 
observations (blood pressure, temperature, heart rate and BMI) fully recorded. 
 
 
2.1.3 Exclusion Criteria: 
 
• Previous chemotherapy, immunotherapy or radiotherapy (for either colorectal 
or non-colorectal cancers) 
• Received any investigational drug or agent/procedure (i.e. participated in a 
treatment trial) within 4 weeks of recruitment.  
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• Moderate or severe renal impairment [creatinine clearance <30ml/min 
calculated according to Cockroft-Gault formula]  
• Any of the following laboratory values (within 2 weeks of recruitment): 
1. Absolute neutrophil count  <1.5 x 109/L 
2. Hb < 10 g/dl 
3. Platelet count < 100 x 109/L  
4. Total bilirubin > 1.5 above the upper limit of normal 
• Patients on anticoagulants, high dose aspirin (>325mg/day), anti-platelet 
drugs or known bleeding diathesis e.g. factor VIII or IX deficiency; low dose 
aspirin was accepted once used in excess of 6 months.  
• Known coagulopathy e.g. deficiencies of proteins C & S, and factor V leiden.  
• Clinically significant cardiovascular disease diagnosed within the last 12 
months i.e. cerebrovascular accident, myocardial infarction, unstable angina, 
congestive heart failure, serious cardiac arrhythmia requiring medication or 
uncontrolled hypertension.  
• Pregnant or lactating women.  
• Concurrent malignancies unless there was a disease free interval of at least 
10 years.  
• Inflammatory bowel disease and/or peptic ulcer, either of which have been 
active or required medication in the last 2 years. 
• History of uncontrolled seizures, central nervous system disorders, dementia 
or psychiatric disability.  
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• Concurrent inflammatory connective tissue disease (e.g. rheumatoid arthritis, 
systemic lupus erythematosis, arteritides) 
• Participants were not recruited whilst on antibiotics and hormone replacement.  
 
2.1.4 Ethical considerations 
 
All participants were fully informed, gave signed consent according to the approved 
local ethics and research protocol in keeping with the Helsinki agreement (Registered 
with Black Country Research & Ethics Committee, Reference 08/H1202/178). 
 
 
2.1.5 Research material 
 
Venous blood was transported in EDTA vacutainers (stored in ice packs) to the 
Haemostasis, Thrombosis and Vascular Biology Unit (HTVBU) at City Hospital for 
preparation and analysis. The excised tumour was analysed by conventional 
histological techniques and reported in accordance with the minimum dataset 
guidelines of the Royal College of Pathologists on CRC [see appendix 2, page] (285, 
373). Radiology reports were also guided by the standards of the Royal College of 
Radiologists, first edition (374). The Stage was obtained from the routine reports of 
the hospital’s histopathology and radiology departments. All results, along with the 
therapeutic strategies were confirmed at the multi-disciplinary meetings.  
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2.2 Assays 
 
 
2.2.1 CEC and EPC Quantification 
 
The major equipments were the Becton Dickinson FACSCalibur™ flow cytometer 
and Bayer Advia Haematology Analyser. The assay development is outlined next 
followed by the detailed flow cytometry standard operating procedure (SOP). 
 
 
Assay Development 
 
This assay was initially developed to simultaneously detect CECs and CPCs 
(circulating progenitor cells expressing CD45-/CD133+/CD34+) in breast cancer (24), 
adapted to detect EPCs in prostate cancer (140), and further developed by myself to 
improve discrimination between CECs and EPCs. The initial work provided details on 
FC settings for 4-colour detection and in accordance with the manufacturer’s 
instructions. The main steps were maintained with no changes to volumes of the 
samples analysed and reagents used: 
 
a. Quantification of WCC  (Bayer Advia Haematology Analyser ™) 
 
b. Quantification of CEC and EPC (by BD FACSCalibur™)  
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The steps for sample preparation were as follows: 
I. Flourochrome Incubation 
II. Lysis/fixation, centrifugation and decanting of supernatant 
III. Re-suspension, centrifugation and decanting of supernatant 
IV. Re-suspension in PBS for FC enumeration.  
 
 
a. Quantification of WCC 
 
From the fresh venous sample a WCC (full blood count) was obtained using the 
Bayer Advia Haematology Analyser ™. Start-up procedures, calibration and general 
maintenance of the Bayer Advia Machine was carried out as per the manufacturer’s 
guidance. Calibrations were performed daily in accordance with the laboratory’s 
protocol and an electronic copy stored on the hard drive of the operating computer. 
 
 
b. Quantification of CEC and EPC 
 
The venous sample was prepared for analysis by flow cytometry. Start-up 
procedures, calibration and general maintenance of the Becton Dickinson 
FACSCalibur™ flow cytometer were carried out as per the manufacturer’s operation 
guide. Calibrations were performed daily in accordance with the laboratory’s protocol 
and an electronic copy stored on the hard drive of the operating computer.  
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I. Flourochrome Incubation 
To 0.2mL of blood 10µL each of the fluorochrome-labelled monoclonal anti-human 
mouse antibodies were added and the solution incubated in the dark at room 
temperature for 20 minutes. These antibodies were FITC-CD45, PE-CD146, PE-Cy 
5-CD34 (Becton Dickinson, Oxford, UK) and VEGF R2 (KDR)-APC (R&D Systems).  
 
 
II. Lysis/fixation, centrifugation and Decanting of supernatant 
This removed red blood cells that may ‘scatter’ the lasers used by the FC machine 
and reduce false positives of the assay. The fixative reduced cell loss from apoptosis 
during storage and incubation. Three millilitres of 1 in 10 diluted FACS lysing/fixing 
solution was then added and the solution incubated for 15 minutes again in the dark 
at room temperature. The solution was centrifuged at 200g for 5 minutes and the 
supernatant containing lysed red blood cells was decanted.  
 
 
III. Re-suspension, centrifugation and Decanting of supernatant 
This wash step aimed to remove residual erythrocyte products. Three millilitres of 
buffer solution (PBS Gibco) was added and vortexed gently to resuspend the pellet.  
The suspension was centrifuged once again at 200g for 5 minutes, the supernatant 
decanted and the cells resuspended in 0.5 ml of PBS solution ready for analysis. 
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IV. FC Protocol Modifications 
 
Each sample was analysed by FC with a 4-colour BD FACSCalibur™ machine 
(Becton Dickinson, Oxford, UK). Events were plotted according to forward scatter 
(FSC) and side scatter (SSC) profile i.e. measures of size and granularity 
respectively. The flow rate was maintained at 1500 or fewer events per second (less 
than 35 µl/min). The CellQuest Pro software on an Apple G4 computer was used to 
determine cell counts. It ran to achieve a target of 1,000,000 events or, if not, until 
the entire volume if the sample was analysed.  
 
The first gating strategy morphologically included only mononuclear events (figure 
14) whilst excluding cell doublets, platelets, dead cells/carcuses, cell debris, 
microparticles and high SSC events  (highly granular dead and/or polynuclear cells).  
 
 
Figure 14: Flow cytometry Inclusion of mononuclear events in R1 (purple). 
 
R1 gates for mononuclear events whilst excluding cell doublets, platelets, dead cells/carcuses, cell 
debris, microparticles, and highly granular dead and/or polynuclear cells. 
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The second gate identified events negative/dim for FITC-CD45 (the pan-leukocyte 
marker). A ‘dump’ channel also excluded all CD45 positive events (including CD45dim 
ones) and low to medium side scatter events including singlets (figure 15). From 
these events a third gate identified CD34 (PE-Cy 5) events in R3. Only high intensity 
doubly fluorescent events for CD146 and CD34 were defined as CECs; similarly 
EPCs were CD34 and KDR positive.  
 
 
Figure 15: FC: events negative for CD45 (R2, outlined in purple) and positive 
for CD34 (R3, magenta rectangle). 
 
   
 
 
To improve assay discrimination between both cells, HUVECs (angiogenesis 
activated expressing VEGR-2 from Cell Applications Inc.) were used. This was 
diluted to obtain one EPC per 10 µL of BD buffer solution (total of 20 events). 
Similarly, CECs were derived from cultured mature ECs (Cell Applications Inc.) and 
diluted to 1 in 20 µL of buffer. Both were added to make up a 200 µL suspension for 
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FC analysis. A flourochrome minus one (FMO) control assay was applied to optimise 
the gate settings and detect all CD146+ and KDR+ events (figure 16). 
 
Figure 16: Assay improvement: flourochrome minus 1 with HUVECs and ECs. 
 
 
 
	
Using a flourochrome minus 1 technique:  
A. All flourochromes minus CD146 detected all EPCs (R4 red circles) only, not CECs (R5) 
B. All flourochromes discriminated between all EPCs (R4) and all CECs (R5).  
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When applied to a patient with metastatic CRC the following results were obtained 
with better discrimination between both cells (red box for EPCs and CECs in grey).  
 
 
Figure 17: CECs & EPCs from CD34 positive events (gating not shown). 
 
   
The assay improved the discrimination between EPCs and CECs in the protocol used for detecting the 
cells in breast cancer. Prior to this change, the 10 events in the CEC box (grey) would have been 
counted as EPC events (red box). 
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Determining EPC and CEC counts 
 
The following calculation determined the CEC and EPC counts: 
 
CEC counts (cells/mL) =  Number of EPC events   x White Blood Cell Count x  106 
      Number of white cell events 
 
EPC counts (cells/mL) =  Number of EPC events   x White Blood Cell Count x  106 
      Number of white cell events 
 
The number of EPC events, number of CEC events and number of white cell (WBC) 
events were determined by flow cytometry and the White Cell Count  (WCC) from the 
Bayer Advia® full blood count output.  
 
 
 
 
Interpretation with example (figure 18) 
 
1. The WCC count by Bayer Advia® was determined e.g. 4.71 x106/mL. 
2. The plot showed the FSC/SSC plot (in green), which gated nearly all cells, gate 
statistics out of 753078 total WBC events on FC.  
3. The SSC to CD34 plot with the R3 box detected highly positive CD34 events. 
e.g. n=176 in the gate statistics out of 753078 total WBC events on FC. 
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Figure 18: Flow Cytometry example of results from a CRC participant.  
 
 
 
 
Results: R1=753078, R3=127, R4=8 & R5=4 events. 
 
4. The non-WCC events was confirmed in the R3 box of SSC/CD45 by collecting 
‘CD34+ve cells’, i.e. n=127. Hence 127/753078 = 1.686 x 10-4 WBCs were CD34 
positive. As a fraction of the WCC of the Bayer Advia® i.e. 4.71 x 106 cells/ml, 
there were 794 CD34+ve cells/ml in the venous blood. These cells will be 
referred to CD34+CD45- cells, which include EPCs (8 events), CECs (4 events) 
and other cells/events of unknown classification that also express these 
phenotypes (782 events). 
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5. On the plot of KDR PE vs CD45 PerCP the CD34+ve events were scanned for 
KDR and CD45. The events, e.g. 8, in the upper left quadrant (R4) were KDR+ve 
but CD45-ve and therefore were EPCs. Thus 8/127 of the CD34+ve events were 
EPCs, so the EPC count was 8/127th of 794 = 50 EPCs/mL. 
 
6. Similarly, on the plot of CD146FITC vs CD45PerCP, CECs were low for CD45 
and high for CD146 (R5), i.e. 4 events. Since all the cells in this analysis were 
CD34+ve, and there were 99 CD34+ events, 4/127 of the CD34+ve cells were 
CECs. That is 4/127th of 794 CD34+ cells/mL, or 25 CECs/mL. 
 
Appendix 3 contains the details of the Standard Operating Procedure to enumerate 
CECs and EPCs, along with the gating strategy.   
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2.2.2 ELISA for vWf Assay 
 
The method was modified from Short et al using commercial antisera from the 
Danish company, Dako, and recognised worldwide by most major Journals (60, 375-
377). The full SOP is detailed in appendix 4.  
 
Brief Method 
	
1. The microtitre plate was coated with 100 µl of diluted primary antiserum (30 µl in 
20.5 ml coating buffer pH 9.6) at room temperature for >60 minutes or overnight 
at 40C. 
2. The plate was washed 3 times in PBS/tween, 100 µl of 1/40 serum or plasma in 
pbs/tween was added along with the standards and incubated for >60 minutes at 
room temperature. 
3. The wash was repeated 3 times and 100 µl secondary antiserum was added i.e. 
the peroxidase-labelled conjugate (30 µl in 20.5 ml PBS/tween), and incubated for 
>45 minutes at room temperature. 
4. The plate was washed and 100 µl substrate (OPD, hydrogen peroxide, pH 5 
citrate buffer) was added. The colour developed almost immediately. 
5. This was stopped with 50 µl acid, read at 492 nm 
6. Plot against standard curve. 
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Expected values:  in citrated normal plasma are in the region of a mean of 100 with a 
standard deviation 30 IU/dL. Typical values in stable atherosclerosis are 130 IU/dL 
and acute coronary syndromes often 150 IU/dL. The data is normally distributed.                   
 
 
Figure 19: Curve of the standards for vWf versus optical absorption. 
	
 
This curve was generated from the standards of an ELISA performed in this study. 
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2.2.3 ELISA for soluble E-Selectin 
 
This was the standard ELISA for measurement of soluble E-Selectin\CD62E (sE-Sel) 
using the duoset from R&D. My colleagues in cardiovascular disease and breast 
cancer studies have used it extensively (24, 116). 
The brief method is described below and the full SOP is detailed in appendix 5. 
 
Brief method 
1. The microtitre plates were coated with 112ul of capture primary antibody in PBS 
buffer and incubated in the fridge (4oC) overnight or 1.5 hours at room 
temperature. 
2. The plates were washed, 100 ul serum/plasma (diluted 1/5 i.e. 20 plasma plus 80 
blue or pbs-tween buffer) with standards (top ‘prepared’ at 50 ng/mL) were added 
and incubated for 1.5 hours at room temperature. The ‘Universal’ plasma was 
also prepared. 
3. The plates were washed again, 112 ul detection antibody (one vial in 20 mls 1% 
BSA PBS for two plates) was added and incubated for 1.5 hours at room 
temperature 
4. Again the plates were washed, 100 ul Streptavidin-HRP conjugate (diluted 1/200 
in PBS, i.e. 100 ul plus 20 mls) was added and incubated for a minimum of 20 
minutes at room temperature in the dark. 
5. The plate was washed again and 100ul of substrate (made up from equal 
volumes of reagents A and B) was added. This went blue after 3 – 5 minutes. 
The key definition was a clear gradation of blue colour from the top to the blank. 
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6. The reaction was stopped with 75ul Acid (a yellow reaction) and the optical 
density was read at 450 nm. A curve of standards was generated and used to 
determine the concentrations.  
 
Expected values: Between 20-40ng/mL and the Universal around 40 ng/mL. 
 
 
Figure 20: Curve of the standards for sE-sel ELISA vs optical absorption. 
 
 
  
This curve was generated from the standards of an ELISA performed during this study. 
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2.2.4 ELISA for VEGF 
 
This ELISA used commercial antibodies from R&D and was performed by my 
colleagues in previous studies of cardiovascular disease and cancer (24, 91). The 
brief method is outlined below and the full SOP is detailed in appendix 6. 
 
Brief Method: 
	
1. Microtitre plates were coated with 100µl of primary antisera (40µl of 40µg/ml in 
10ml coating buffer for 1 plate) and stored overnight in the fridge. 
2. Plates were washed and blocked with 100µl /well of 5% Marvel (1g in 20mls PBS-
T for 2 plates) for 1 hour at room temperature. 
3. Plates were washed, 100µl of neat plasma and recombinant standards added and 
incubated for 2 hours at room temperature.. Standards were diluted tenfold with 
fresh tips for each sample. 
4. Plates were washed; 100µl of 500ng/ml of biotinylated anti-human VEGF antibody 
(100µl of 5 µg/ml in 10ml PBS) was added and incubated for 2 hours at room 
temperature. 
5. Plates were washed; extravidin peroxidase (100µl/well) was added and incubated 
for 45 minutes at room temperature. 
6. tes were washed; 100µl substrate (Solutions A and B) was added and incubated 
for 30 minutes at room temperature. The blue colour developed. 
7. Reaction was stopped with 50µl/well acid and read at 450 nm.  
2.2.4 VEGF Assay 
96 
	
Expected values: Data was usually non-parametrically distributed. Controls generally 
had median values of about 30-50pg/ml (but wide IQRs, at times exceeding 
200pg/ml). Patients’ median values generally were between100 to 200 pg/ml. 
 
 
Figure 21: Curve of standards for the VEGF ELISA vs optical absorption. 
 
 
This curve was generated from the standards of an ELISA performed during this study. 
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2.2.5 ELISA for angiogenin 
 
This ELISA uses commercial antibodies from R&D systems and performed by my 
colleagues in previous studies of breast cancer and cardiovascular disease (24, 378). 
The brief method is outlined below and the full SOP is detailed in appendix 7. 
 
Brief Method: 
	
1. Microtitre plate wells were coated with 100µl of primary antiserum at room 
temperature for 90 minutes or at 4oC overnight. 
2. Plates were washed, plasma added and recombinant standards diluted in 
PBS/tween for 90 minutes at room temperature. 
3. Plates were washed again, 100µl of biotinylated anti-human angiogenin antibody 
added to each well for 90 minutes at room temperature. 
4. Plates were washed again; 100µl/well of streptavidin-HRP (50µl strep-HRP in 
10mls of PBS-T for 1 plate) was added and incubated for at least 20 minutes at 
room temperature avoiding direct light. 
5. Plates were washed again, 100µl warm substrate solution (5mls A + 5mls B for 1 
plate) were added. The colour developed in less than 5 minutes. 
6. The reaction was stopped with 50µl/well of acid and read at 450 nm. 
 
Expected values:  parametric data was obtained and the controls generally had 
median values of about 5 pg/ml. 
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Figure 22: Curve of standards for Angiogenin ELISA vs absorption. 
 
 
 
This curve was generated from the standards of an ELISA performed during this study. 
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2.2.6 Assay Variability 
 
The coefficients of variation (CV) of the assays are shown below. They were 
determined from processing samples of 7 healthy volunteers on 5 and 3 different 
occasions for the FC protocol and ELISAs respectively. The angiogenin ELISA was 
re-performed another 3 ocassions as, of all the protocols, stopping the very swift 
colour change required additional practice. The CV was calculated as follows: 
 
CV=    Standard Deviation  x  100% 
     Mean 
 
 
Assay Inter-observer CV (%) Intra-observer CV (%) 
CEC 39 (24-60) 24 (13-47) 
EPC 28 (16-40) 17 (11-24) 
vWf 9 (6-9) 4 (4-5) 
E-Sel 6 (5-9) 4 (4-5) 
VEGF 8 (8-10) 5 (4-5) 
Angiogenin 9 (7-10) 5 (4-5) 
 
CV: cumulative variability. Values expressed as means and ranges. 
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2.3 Statistics and power calculation 
 
As the Department had experience in measuring CECs in breast cancer, rheumatoid 
disease, and in cardiovascular disease (24, 91, 379), the indexed results were used 
as the test statistic for power calculations.  
 
 
2.3.1 Cross-sectional Studies 
 
Hypothesis 1 
 
I predicted that CECs will be raised in colorectal cancer (CRC) compared to both 
healthy controls (HC) and patients with benign colorectal disease (BD), and that 
levels in CRC will be comparable to those with stable coronary artery disease 
(SCAD). A model in statistical package Minitab 16 was developed of a median 
(interquartile range) count of 3 (1.5-5.0) CECs/mL in CRC and SCAD compared to 1 
(0-3) cells/mL on HCs and BD [CECs were known to have a non-normal distribution]. 
For p<0.05 between CRC and SCAD versus the other two groups, and p<0.01 
overall (Kruskall-Wallis test), 25 subjects were required in each of the four groups.  
 
I regarded n=20 as an absolute minimum and aimed to recruit an excess to provide 
improved confidence. A sample size of n=20 provided the two-sided p value of <0.05 
and the 1-beta power of 0.8 for a correlation coefficient (r) of 0.55. My co-
investigators generated published data comparing CECs (median 8, IQR 4-12) and 
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EPCs (median 78, IQR 42-128) in 19 women with breast cancer and no correlation 
was found (Spearman r= -0.086, p=0.726). 
 
 
Hypothesis 2 
 
Cellular markers were predicted to associate with CRC stage as defined by Dukes’ 
classification. This is effectively the same sample size estimation as in hypothesis 1 
with four distinct groups i.e. Dukes stages A, B, C and D.  Therefore I recruited n=25 
in each staging group giving 100 patients overall. However, a participant’s tumour 
stage could not be pre-determined and accordingly, I aimed to recruit to excess, i.e. 
to circa 150, and ultimately towards correct staging ratios.  Hence, far more CRC 
patients in hypothesis 1 were recruited, giving more power and confidence. It 
followed that with n=150, I would have the power to detect a correlation coefficient of 
0.25, at 2p<0.05 and 1-beta = 0.8. By definition, the disease stage progressed in a 
linear manner i.e. from good to bad. This therefore allowed further analysis by 
Altman’s test of linear trend of ordered groups. 
 
 
Hypothesis 3 
 
This is a correlation matrix to determine the relationship of the plasma makers with 
CECs and EPCs of  hypotheses 1 and 2 above.  
 
2.4 Statistics & Power Calculation 
102 
	
Cross-sectional Analyses 
 
Results were expressed as numbers and percentages, mean and standard deviation 
(SD) or median and interquartile range (IQR). Analyses between groups were 
performed using ANOVA, Kruskal Wallis, Mann-Whitney, t-test and Chi Square as 
appropriate. Correlations were by derived by Spearman’s rank method or stepwise 
multiple regression. Analysis of variance (ANOVA) was inappropriate for changes 
with CRC stages as each were dependent on the previous in moving from one stage 
to the next. Altman’s test of linear trend of ordered groups was applicable (380). A 
two-tailed p value < 0.05 was considered significant. Data was analysed by IBM 
SPSS Statistics software (2014) and figures drawn using Prism 6 package (2013). 
 
 
2.3.2 Longitudinal Studies 
 
 
Hypothesis 4 
 
I predicted that treatments would reduce the CEC and EPC counts by a third. That is 
from a median (IQR) of 3 (1.5 – 5.0) cells/mL to 2 (0.5 – 3.5) cells/ml after treatment. 
If numbers of CECs fell in 21 patients, but rose in 4 patients (25 participants in total), 
then the calculated paired t test would give p=0.003 (verified by my supervisor, Dr 
Blann, a statistician with the University of Birmingham). 
  
2.4 Statistics & Power Calculation 
103 
	
Hypothesis 5 
 
To predict disease progression (death and/or recurrence and/or increase in disease 
size) all markers measured in the 150 CRC participants would have the power to 
detect a correlation coefficient of 0.25, at 2p<0.05 and 1-beta = 0.8. 
 
Data on outcomes was prospectively collected over the 2-year period after surgery. 
Details were obtained from hospital notes, clinic reviews, radiology reports, 
multidisciplinary outcomes and the Somerset Cancer Database. Follow-up was 
determined by local hospital policy and based on the guidelines of the ACPGBI 
(2007) (285). All patients were routinely discussed at the MDT meeting. Follow-up 
and further treatment were determined by histological prognostic factors and/or 
radiological evidence of disease spread (section 1.4). It was offered to all patients 
with primary CRC undergoing treatment with or without curative intent. 
 
Follow-up after curative surgery typically began at 4–6 weeks after discharge from 
their operation. Patients undertook regular surveillance with (1) a minimum of two 
CTs of the chest, abdomen, and pelvis in the first 3 years, (2) regular serum 
carcinoembryonic antigen (CEA) tests at least 6 monthly in the first 3 years, and (3) 
surveillance colonoscopy was performed at 1 year after initial treatment. 
Investigations were restarted if there were clinical (e.g. weight loss, bowel obstruction 
masses, lymphadenopathy or hepatomegaly) or biochemical (rise in CEA) suspicion 
of recurrence. Contrast enhanced CT scan of the chest, abdomen and pelvis 
achieved confirmation of disease recurrence and/or metastases, if any. Indeterminate 
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lesions were further characterised by ultrasound +/- MRI +/- PET scans where 
appropriate. Biopsies were not routinely performed unless features on radiology were 
atypical or suspicious of primary tumours in other organs. 
 
In considering the need for adjuvant treatment after potentially curative resection (i.e. 
no evidence of metastases), all patients were discussed at MDT. A follow-up 
enhanced CT scan was routinely performed 2-4 weeks after completing therapy. CT 
scans were performed during treatment if there was clinical or biological suspicion of 
disease progression, as described above. 
 
After potentially curative surgery, indeterminate lesions on radiology i.e. of the 
abdomen (lymph nodes), liver or lungs on CT or MRI were typically less than 10 mm 
on size criteria. Patients were routinely followed-up at 3 months with further radiology 
(CT scan +/- MRI for liver or rectum) unless requested earlier by the MDT. Patients 
may or may not have received adjuvant therapy during this time. PET scans were not 
routinely performed unless the MDT decided further characterisation was necessary. 
For this study, lesions reported as indeterminate on repeat imaging (unchanged or 
absent) were not classed as ‘recurrent or metastatic’ disease. 
 
For bowel resection (curative) and potentially resectable metastases to the liver +/- 
lung, and palliative surgery with non-resectable metastases, there was no set 
protocol for follow-up. They typically underwent chemotherapy (+/-radiotherapy), 
unless they declined and were followed-up at the discretion of the Oncologist. 
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Patients were monitored for disease progression/regression with regular clinic visits 
and definitively by contrast enhanced CT of chest, abdomen and pelvis. 
 
Progression for this study was defined according to the widely accepted criteria of 
Eisenhauer et al (381, 382). It used ‘measurable’ evidence (X-rays, USS, CT, MRI, 
PET-CT or biopsy) of one of the following: 
• Local recurrence or metastases after surgery with curative intent and/or 
• For Dukes’ D, increasing tumour size of involved organs and/or new metastases, 
specifically of at least a 20% increase in the sum of the diameters of all lesions. 
 
The temporal relationship with disease progression and survival was further 
analysed. The definitions accepted internationally on reporting outcome measures in 
cancer treatment (383-385) were: 
Time to Progression (TTP) Patients with evidence of disease spread to other 
organs and/or local recurrence (also known as 
disease free survival, DFS). 
Progression Free Survival (PFS) Patients that either had disease spread to other 
organs and/or local recurrence and/or or died. 
Overall Survival (OS)  All cause mortality during or after treatment. 
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Longitudinal Analyses 
 
Results were expressed as numbers and percentages, mean and standard deviation 
or median and interquartile range. Analyses between groups were performed using 
ANOVA, Kruskal-Wallis, Mann-Whitney, t-test and Chi-squared as appropriate. For 
hypothesis 4, data over time was analysed by repeated measures (two-way) analysis 
of variance (for parametric data) or by Friedman’s method (for non-parametric data). 
For hypothesis 5, data was analysed by binary regression and Cox proportional 
hazards were estimated, and outcomes over time presented as Kaplan-Meier plots. 
All analyses were performed on IBM SPSS Software (2014) and figures produced by 
Prism 6 package (2013). A p<0.05 was taken to assume statistical significance. 
 
 
 
 
Recapitulation 
 
The introduction has set the scene and justified the project. The materials and 
methods have outlined the tools and plan of investigation. The section that follows 
will show the results and discussion of each of the study hypotheses. 
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Chapter 3 
Clinical Studies 
 
3.1 Cross-sectional Studies 
 
3.1.1 Cellular markers in CRC versus controls 
 
Abstract 
Background: CECs and EPCs were elevated in metastatic CRC and other disorders, 
including cardiovascular disease. Both markers were hypothesised to be higher in 
CRC at all stages than in participants with benign colonic polyps (BD), stable 
coronary artery disease (SCAD) and healthy controls (HC). 
Methods: Prospective study of 154 CRC participants, were compared with 26 BD, 33 
SCAD, and 29 healthy age-matched controls. CECs (CD45-CD146+CD34+) and 
EPCs (CD45-CD34+KDR+) were enumerated by an improved 4-colour flow 
cytometry protocol. 
Findings: The CEC and white cell counts (WCC) were higher in CRC versus BD and 
HC groups (p<0.001) but comparable to those with SCAD. EPCs (p<0.001) were 
elevated in CRC only and correlated to CECs (Spearman’s r=0.646, p<0.001). On 
multivariate regression analysis only BMI influenced EPC levels in CRC (p=0.03). 
EPCs were higher in and hence predictive (p<0.001) of CRC compared to the 
controls, while CD34+CD45- cells were highest in SCAD (p<0.0001). 
Conclusion: EPCs and CECs were important to the vascular biology of CRC. EPCs 
and CD34+CD45- cells, for unrecognised coronary artery disease, may be useful 
markers for clinical decisions in CRC management. 
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Background 
 
CECs and EPCs were proposed as biomarkers to monitor response to treatment of 
metastatic CRC (28, 146, 201, 351). They were also altered in many diseases 
including cardiovascular disorders and other cancers (22, 92, 140, 386). For CRC, 
their value across all stages, performance against cardiovascular disease and 
differences with pre-cancerous disease, i.e. colonic polyps, were unknown. I 
hypothesised that levels were higher in CRC than healthy (HC) and benign polyp 
(BD) controls, but comparable to those with stable coronary artery disease (SCAD). 
The later was also used as a positive disease control. 
 
 
Method 
 
Participants were recruited as detailed in section 2.1 (page 94) and after applying the 
exclusion criteria of section 2.1.3 (page 94). CECs and EPCs were measured in 
peripheral blood by an improved 4-colour flow cytometry protocol (section 2.2.1, page 
98). Pre-treatment levels were quantified in those with CRC (n=150) and compared 
to the 25 BD, 25 HC and 25 SCAD control groups.  
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Statistics 
 
Results were expressed as numbers and percentages, mean and standard deviation 
(SD) or median and interquartile range (IQR). Analyses between groups were 
performed using ANOVA, Kruskal Wallis, Mann-Whitney, t-test and Chi Square as 
appropriate. Correlations were obtained by Spearman’s rank method, and for the 
clinical variables, by stepwise multiple regression analyses. A two-tailed p value of 
<0.05 was considered statistically significant. 
 
During the study period there were 335 patients diagnosed with CRC of which 10 
declined to participate and 181 did not meet the inclusion/exclusion criteria. To 
ensure a target of 20 for each of the 4 Dukes’ stages, I recruited 154 participants. 
Fewer were recruited for stage A (19) as compared to stages B, C and D (54, 49, 32 
respectively). To obtain the 20 with stage A (equivalent to 1 in every 8 cancer 
recruited), at least 16 more participants were needed (as only 1 in 2.1 met the 
criteria) and therefore not achievable within the study’s timeframe. For the controls, 
109 candidates were approached, 5 declined and 16 did not meet the 
inclusion/exclusion criteria (12 of which were in the SCAD group). Furthermore, to 
ensure they were age-matched, I recruited 26 to benign disease, 29 to healthy and 
33 to the SCAD control groups, exceeding the intended targets outlined above. 
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Results 
 
The demographics of all participants are listed in Table 14, and unsurprisingly there 
were differences of the co-morbidities between groups. However altogether, they 
were matched for sex, age, blood pressure, family history and BMI.  
 
Numbers of white blood cells, EPCs, CECs and the EPC/CEC ratio are shown in 
Table 15. CEC and EPC data was not normally distributed; hence non-parametric 
statistical tests (Kruskal-Wallis) were used to calculate the differences in median 
values. Other cell indices were normal distributed. Participants with CRC and SCAD 
had a higher white blood cell count (WCC) than other groups.  
 
Patients with CRC and SCAD had comparable CEC counts though both were higher 
than in the other two groups. However, there were more EPCS in CRC than all other 
groups. It follows mathematically that the ratio of EPCs to CECs was highest in CRC. 
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Table 14: Demographics of patients with CRC versus control groups 
 
 
Colorectal  
Cancer  
[CRC] 
Healthy  
Controls 
[HC] 
Benign  
Controls*  
[BD] 
Coronary 
Disease‡ 
 [SCAD] 
p 
Number  154 29 26 33 - 
Age  (years) 73 (10) 70 (6) 70 (6) 71 (6) 0.683 
Male (%)  
Female (%) 
86 (56) 
78 (44) 
15 (52) 
14 (48) 
13 (50) 
13 (50) 
18 (55) 
15 (45) 
0.616 
BMI  (Kg/m2) 27.4 (7) 25.9 (2) 25.8 (2) 27.1 (6) 0.434 
Systolic BP (mmHg) 135 (16) 133 (9) 131 (9) 138 (11) 0.286 
Diastolic BP (mmHg) 75 (10) 73 (8) 71 (7) 80 (9) 0.086 
Family History (%) 26 (17) 3 (11) 2 (7) 5 (15) 0.145 
Smokers (n (%)) 49 (32) 5 (19) 7 (24) 0 (0) <0.001† 
Hypertension 83 (54) 0 (0) 0 (0) 16 (84) <0.001 
Previous MI/IHD 30 (19) 0 (0) 0 (0) 33 (100) <0.001 
Previous CVA 19 (12) 0 (0) 0 (0) 3 (9) <0.001c 
Hyperlipidemia 47 (31) 0 (0) 0 (0) 17 (52) <0.05 
Diabetes Mellitus 24 (16) 0 (0) 0 (0) 7 (21) <0.001d 
Heart Failure 10 (6) 0 (0) 0 (0) 2 (6) 0.006h 
 
BP - Blood Pressure; BMI- Body Mass Index; CVA- cerebrovascular accident. MI- Myocardial Infarct; 
IHD- Ischaemic Heart Disease. * Benign controls: non-cancerous colonic polyps.  ‡ Stable Coronary 
Artery Disease [SCAD]. Results were expressed as numbers and percentages, mean (SD) or median 
and interquartile range. ANOVA, Kruskal Wallis, Mann-Whitney and Chi Square were used as 
appropriate. † CRC vs HC p=0.208; CRC vs BD p=0.035 and SCAD vs all other groups p<0.001d CRC 
vs SCAD p=0.363. h CRC vs SCAD p=1.00. c CRC vs SCAD p=0.489. 
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Table 15: CECs, EPCs and their ratio in CRC versus controls 
 
 Colorectal 
Cancer 
[CRC] 
Healthy 
Controls 
[HC] 
Benign 
Controls 
[BD] 
Stable 
Coronary 
Artery 
Disease 
[SCAD] 
p 
      
Number (n) 154 29 26 33  
CECs 
(cells/ml) 
12 
(0-22) 
7 
(0-10) 
0 
(0-8) 
8 
(0-25) 
<0.001a 
EPCs 
(cells/ml) 
21 
(10-44) 
7 
(0-14) 
7 
(0-12) 
10 
(0-27) 
<0.001b 
EPC : CEC 
Ratio 
1.4 
(1.0-5.1) 
1.0 
(1.0-1.0) 
1.0 
(1.0-1.0) 
1.0 
(1.0-2.1) 
0.015b 
CD34+CD45- 
(x103 cells/ml) 
0.80 
(0.49-1.15) 
0.95 
(0.60-1.42) 
1.05 
(0.69-1.44) 
1.56 
(1.26-2.24) 
<0.001C 
WCC 
(x106 /ml) 
7.17 
(2) 
5.73 
(2) 
5.76 
(1) 
6.38 
(2) 
<0.001a 
 
Results were expressed as mean (SD) or median (interquartile range). Data was analysed by 
Kruskal-Wallis test, then log transformed for ANOVA and Tukey’s post hoc test. a p<0.05 
higher in CRC and SCAD than the other two groups, no difference between CRC and SCAD 
and no difference healthy controls to benign disease controls. b  p<0.05 higher in CRC than 
all other groups, no difference between levels in the three other groups. C All CD34 positive 
monocytes were higher (p<0.001) in SCAD only. 
 
 
Thus in testing hypothesis 1 there were: 
• raised CECs and WCC in CRC similar to levels in SCAD (figures 23 & 24) 
• raised EPCs only in CRC (figure 23) 
• EPC to CEC ratio was highest in CRC only (mathematically predictable) 
• raised CD34+CD45- cells in SCAD only (figure 24). 
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Figure 23: Box (median with IQR) and whisker [2.5 to 97.5 percentile] plots of 
CECs (grey) and EPCs (red) in CRC versus controls  
 
 
 
 
 
 
 
For both plots outliers are shown as red dots. CECs were higher in CRC and SCAD than 
the other two groups (p<0.05), with no differences of CRC with SCAD and BD with HC. 
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Figure 24: Box (median with IQR) and whisker [2.5 to 97.5 percentile] plot of 
CD34+CD45- cells (yellow) and mean WCC with 95% CI in CRC versus controls 
 
 
 
 
  
Mean is shown as red box with 95% interval bar; box and whisker plots show outliers as red dots. For 
WCC p<0.05 in CRC and SCAD (but no difference between them) than the other two control groups. 
CPC was higher in SCAD only. 
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Correlations between cellular indices 
 
While there was a correlation between CEC and EPC in SCAD (r=0.621, p<0.001), 
only the CRC group is reported as the low numbers in the other three groups gave 
considerable scope for type 1 and 2 statistical error, particularly with so many zero 
values. The sample size of n=154 gave the 1-beta power of 0.85 to detect at 2p<0.05 
a correlation coefficient of 0.25 (387). 
 
As EPC and CEC data were non-parametrically distributed, they were ranked by 
Spearman’s method: 
 
• EPC:CEC   r=0.646, p<0.001  
• CEC:WCC   r=0.197, p=0.014 
• EPC:WCC   r=0.141, p=0.080 
 
The EPC:CEC analysis was within power limits and therefore highly reliable (figure 
25). However, CEC:WCC and EPC:WCC relationships had were correlated (r<0.25). 
The CD34+CD45- cells were strongly correlated to WCC (r=0.317, p<0.001, see 
figure 26), but not to EPCs (r=0.200, p=0.013) or CECs (0.152, p=0.062). 
 
The study was powered to determine if clinical and demographic factors influenced 
the cell levels. A stepwise multivariate linear regression analysis was performed for 
CECs and EPCs versus the factors listed in Table 14 and are shown in Table 16.  
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Figure 25: Scatterplot showing the relationship between CECs and EPCs (log 
scales) for all CRC participants.  
 
 
 
 
 
 
Figure 26: Scatterplot showing the relationship between WCC and CD34+CD45- 
cells for all CRC participants.  
 
 
 
  
The mean is shown by 
the black line with 95% 
SE by grey dotted lines. 
Spearman’s correlation 
was r=0.646, p<0.001. 
	
The mean is shown by 
the black line with 95% 
SE by grey dotted lines. 
Spearman’s correlation 
was r=0.317, p<0.001. 
. 
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Table 16: Multiple regression analysis of the effect of clinical and demographic 
factors on CECs, EPCs, CD34+CD45- cells and WCC. 
 
 p values * 
Predictor CEC EPC CD34+45- WCC 
Overall p value 0.293 0.482 0.790 0.241 
Sex 0.482 0.405 0.510 0.334 
Age 0.685 0.706 0.652 0.605 
BMI 0.483 0.030a 0.580 0.770 
Systolic BP 0.252 0.421 0.521 0.545 
Diastolic BP 0.110 0.562 0.631 0.754 
1st degree relative with CRC 0.127 0.213 0.541 0.324 
Smoker 0.916 0.744 0.991 0.991 
Hypertension 0.767 0.747 0.245 0.519 
Ischaemic Heart Disease 0.326 0.365 0.278 0.018b 
Previous TIA/stroke 0.287 0.307 0.340 0.104 
Hyperlipidaemia 0.899 0.905 0.744 0.874 
Diabetes Mellitus 0.767 0.676 0.335 0.422 
 
* Analysis performed by stepwise multivariate linear regression. The Odds Ratio (95% CI) for BMIa 
was 1.8 (-0.4 to 2.5) and for IHDb 0.1 (-0.9 to 0.6). 
 
 
Regression analysis showed no effects of age, sex, smoking, blood pressure or heart 
rate on either CEC or EPCs. Ischemic heart disease may have contributed to higher 
WCC (OR 0.1 with 95% CI -0.9 to 0.6, p=0.018), similar to the relatively higher levels 
seen in the SCAD group (table 19). No factors were identified as major influences on 
CECs (overall p= 0.293) or CD34+45- cells (overall p=0.790). 
 
However, with the same analysis on EPCs in CRC, the participants’ BMI (OR 1.8, 
95% CI of -0.4 to 2.5, p=0.030) may have influenced the levels but overall not across 
the four groups (p=0.431). Once again, the relationship for the control groups could 
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not be examined, as they were not reliably powered (<35 per group). Next I examine 
the use of cellular markers as a test for CRC when compared to controls.  
 
 
Cellular Markers as a test for CRC 
 
All cellular markers reached significance on ROC analysis of above median levels in 
CRC when compared to that of the control groups (see table 17 & 18).  
 
Table 17: ROC analysis of all cellular indices in CRC versus controls 
 
 CRC vs ALL Controls CRC vs SCAD only A 
 ROC area p value ROC area p value 
     
CEC 0.649 
(0.579-0.719) 
0.0001 0.551 
(0.441-0.669) 
0.362 
EPC 0.708 
(0.641-0.775) 
<0.0001 0.646 
(0.543-0.749) 
0.009 
CD34+45- cells 0.665 
(0.594-0.737) 
<0.0001 0.802* 
(0.720-0.884) 
<0.0001 
WCC 0.612 
(0.504-0.719) 
0.044 0.560 
(0.441-0.679) 
0.309 
 
ROC area is shown as fraction with 95% Confidence Interval. A Comparisons were made with 
SCAD as a positive control group. * CD34+CD45- cells were more predictive of SCAD. 
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Table 18: Cellular indices in detecting CRC versus controls. 
 
Marker Level* 
Sensitivity 
% 
Specificity 
% 
Likelihood 
Ratio 
 
       
   
 Cellular Markers in CRC versus ALL Controls  
 CEC >12 cells/ml 61.3 79.6 2.51  
 EPC >21 cells/ml 53.2 72.7 2.05  
 CD34+CD45-  <0.80x103 cells/ml 26.4 50.0 1.50  
 WCC >7.17x106 cells/ml 46.1 81.8 2.54  
       
   
 Cellular Markers in CRC versus SCAD only  
 CEC >12 cells/ml 44.1 63.6 1.41  
 EPC >21 cells/ml 53.5 60.6 1.35  
 CD34+CD45-  <0.80x103 cells/ml 50.0 6.4 8.25  
 WCC >7.17x106 cells/ml 46.1 69.7 1.46  
       
* Above or below median (CEC, EPC, CD34+CD45-) and mean (WCC) levels.  
 
Though the median EPC was higher in and therefore more predictive of CRC (ROC 
area 0.649, 95% CI of 0.641-0.775, p<0.001 in figure 27) than the controls it was not 
sensitive for the disease (for median value of >21 cells/ml, sensitivity and specificity 
were 53.3% and 72.4% respectively; see table 18). Remarkably CD34+CD45- cells 
were less in CRC (median 0.80, IQR 0.49-1.15 x103 cells) and a good predictor of 
SCAD (median 1.6, IQR 1.3-2.4 x103 cells) on ROC analysis (area 0.802, p<0.0001) 
with a sensitivity of 50% and specificity of 93.4% for ≥0.80x103 cells/ml. 
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Figure 27:  ROC Curve of EPCs in CRC versus all controls (in red) and 
CD34+CD45- cells in SCAD only (yellow). 
 
 
 
 
 
  
EPCs in CRC 
versus ALL Controls 
 
ROC Area=0.708 
p<0.0001 
 
 
 
 
For EPCs > 21 cells/ml: 
 
Sensitivity= 53.2% 
Specificity= 92.7% 
LR= 2.05 
	
CD34+CD45- cells in SCAD 
versus CRC 
 
ROC Area=0.802 
p<0.0001 
 
 
 
 
For cells > 0.8 x 103/mL: 
 
Sensitivity= 50.0% 
Specificity= 93.4% 
LR= 8.25 
[Good discriminator of SCAD] 
3.1.1 Cellular Markers: CRC vs Controls  
121 
	
Discussion 
 
Validation of the FC Protocol 
 
The preferred technique of 4-colour flow cytometry was used for multi-parametric 
detection of CECs and EPCs in the monocyte fraction of PB. While most agree to this 
approach, there was no consensus on definitions for CECs or EPCs. There were also 
agreements that, while CECs reported over the years may reflect a diverse 
population of cells given the variations in phenotypes, most express CD45-, CD34+, 
CD31+, CD146+, and CD133- (19, 388, 389). They were found in the CD34+ gated 
fraction on FC. For this study CECs were defined by the expression CD45-, CD34+ 
and CD146+. That is, CD45 negativity excluded leukocytes and progenitors, CD146 
was heavily expressed on mature ECs (rarely on mature progenitor cells) and CD34 
was found on most ECs in vivo (17, 139, 197, 390).  There were no reports that 
detecting the presence or absence of more than 3 phenotypes improved the assays 
ability to detect these rare cells and differentiate them from other non-EC monocytes.  
Identification by FC with the chosen antigens with was validated by my colleague 
(21) against immunomagnetic separation (IMS), the previously preferred but 
laborious technique of quantification.  
 
Having filled three channels (CD45-, CD34+ and CD146+), the fourth was labelled for 
VEGFR-2 (CD309, also known as KDR) events and hence simultaneously detected 
EPCs (CD45-/CD34+/CD309+, see below). This approach excluded non-EC CD34+ 
cells such as small population of progenitor and stem cells (both of which also 
heavily express CD133).  CD 31 was excluded as its immuno-fluorescent antibody 
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bound to the majority of leukocytes, platelets and haematopoietic progenitors (391). 
Also, a small number of in vitro cancer EC lines do not express CD31 or CD105 (339, 
392). The protocol detected similarly accepted levels of CECs in healthy participants 
(median 7, IQR 0-10) and those with SCAD (median 8, IQR 0-25) (24, 91). This 
contrasted with the results of Mariucci et al (393) of more than 100 CECs per ml in 
healthy subjects by a similar protocol and higher than levels detected by IMS. They 
did not report on the assay variability or attempts to avoid false positives from large 
platelets proposed by Strijbos et al (394). 
 
EPCs probably represent a heterogeneous group of cells. Popular markers, as 
outlined in section 1.2, included CD34, CD105, CD133, CD309, CD144, CD 146, and 
CD45 (dim). While the ideal phenotype may appear questionable, the choice was 
reasonably straightforward. Firstly a minority express CD146, counter to the 
argument of its exclusivity to mature ECs (20, 197). Secondly, CD133 expression 
was lost with maturation and most importantly its function was largely unknown. It 
was also found on haematopoietic and other progenitors, thus raising the possibility 
that non-EC stem cells were detected in error by other authors (20, 395, 396). 
Therefore EPC was defined as CD45-/ CD34+ /KDR+ since KDR, though initially low 
in CD45-/CD133+/CD34+ cells, is up-regulated and CD133 down-regulated as the cell 
matures. I would agree with other authors that CD133 positive cells were best 
described as forerunners to the EPC or circulating progenitor cell, [CPC] (24, 336, 
343). The CD105 marker was not chosen as it was up-regulated by angiogenic ECs 
and may therefore be found on CECs released from the rapid vascular turnover of 
tumours (397).  That is, with 3 channels already occupied for CEC detection (CD45-, 
CD34+ and CD146+) by FC the fourth identified KDR expression for EPC 
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quantification. My colleagues used a similar strategy to detect CECs and EPCs in 
prostate cancer and from this I developed my assay (140). Though there were no 
significant differences with healthy controls, curiously they reported much higher than 
expected levels of both cells (median [IQR] of 28 [11-43] and 32 [18-82] respectively) 
compared to other published studies (17, 24). Having examined this protocol in detail 
I suspected the gating strategy did not differentiate entirely between the two cell 
populations or ‘double-counted’ i.e. some EPCs were counted as CECs, hence the 
higher than expected levels reported. 
 
To improve the assay’s ability to differentiate between CECs and EPCs pro-
angiogenic HUVECs (expressing CD34 and KDR but not CD146 and CD45) was 
used with an antibody minus 1 protocol to reduce the false positive events of the 
gating strategy. The preparation protocol was maintained and tested on blood from 7 
participants with Dukes’ D stage not undergoing chemotherapy, assuming that both 
CECs and EPCs would be high.  That is, processing a 0.2 ml sample of EDTA blood 
within 2 hours of collection by the following 5 sequential steps: 
 
1. Incubation with flourochromes,  
2. Incubation with lysing/fixative solution, 
3. Centrifugation and decanting of supernatant, 
4. Re-suspension with PBS, centrifugation and decanting of supernatant, 
5. Re-suspension in PBS ready for FC.  
 
This ‘reduced’ the median [IQR] levels of CECs and EPCs of healthy participants 
from 28 [11-43] and 32 [18-82] respectively to 0 [0-8] and 7 [0-12] respectively in my 
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study. The CEC levels were in keeping with quantification results by IMS. It was 
difficult to establish a ‘true’ level of EPCs in healthy controls as numerous cellular 
definitions existed and hence varying numbers were reported.   
 
I was not able to reproduce the inter- and intra-assay variability of below 17 % of 
Widemann et al and my colleagues (24, 140, 398). I believe the protocol to be robust 
and the high coefficients of variability of 17 to 39% to reflect the difficulties in 
detecting extremely rare events. Comparisons with other studies were generally 
inconclusive as results were expressed as means with standard deviation (though 
the data was typically non-parametric) or events only, rather than cells per ml, the 
units chosen for my study. Other studies, including Mancuso et al, expressed their 
results in cells or events per µl, which translated to less than 1 cell per millilitre even 
when expected to be well above this in cancer (399).  
 
There may be other potential causes for the differences in numbers reported: 
1. Quantity of blood analysed: that is the more blood analysed the more likely rare 
events were detected. Mancuso et al and Furstenberger et al analysed more 
than 2 mls of blood and reported observer variability under 16%. My colleagues, 
who also analysed 0.2 ml of blood, also had lower variability, which probably 
resulted from the higher than expected levels detected (140), as already 
discussed above. Simply, the more cells to be found the smaller the inter- and 
intra- observer variability. I therefore determined the effect of volume and found 
no differences after analysing 0.2, 0.4, 0.6 or 1.0 ml of blood from healthy 
participants. It certainly took longer to analyse a larger sample volume 
(approximately 5.6 minutes for every 0.1ml) by FC. Furthermore, I found no 
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significant difference between the volume of the sample analysed and a 
detection limit of 1 million total events.  
2. Sampling error, as proven by Goon et al, specifically traumatic blood letting, may 
displace ECs from veins and into the sample collected (21). To avoid this one 
observer drew all samples and all traumatic ones (which occurred on 5 occasions 
only) were discarded and repeated 24 hours after initial sampling. 
3. Mancuso et al suggested that the blood-lysis step with or without fixative might 
destroy other circulating ECs, though they reported much lower than expected 
levels in healthy participants after omitting this step (399). I was unaware of any 
other study on CECs and EPCs to support this argument. Blood lysis is an 
important step to reduce the scattering of the laser light by haemoglobin 
molecules during FC. Recently, questions were raised on the reagent FACS 
Lyse, as used in my study (400). The report concluded that, when compared to 
other agents, it significantly reduced the number of CD45+ CD34+ blast cells 
detected by standard FC protocol. The reasons for this were unclear. 
4. Wash procedures may dispense with rare cells, but once again to my knowledge 
had never been demonstrated in CEC and EPC enumeration. To reduce 
variability all samples were analysed within 4 hours, blood was drawn from no 
more than 5 participants at any given time (maximum number that could be 
processed without breaching the 4 hour target) and strict adherence to the 
protocol was maintained to minimise the potential errors above.  
 
In summary the multi-parameter FC protocol, through careful assay reproduction, 
had acceptable intra-assay variability (all specimens processed by one user only) 
and was therefore robust at identifying and discriminating between EPCs and CECs. 
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CECs and EPCs in CRC versus control groups 
 
I found higher levels of both EPCs and CECs in CRC compared to control groups 
except CEC, which alongside the WCC, was comparable to the SCAD group. As 
discussed in section 1.2 disturbances in CEC and EPC levels in PB were well known 
in SCAD (91, 401) but less so in CRC, isolated typically to metastatic disease only 
(197, 402). The data of Boos et al on acute coronary syndrome and endothelial 
dysfunction showed similar CEC levels by the immune-magnetic separation (CD146 
beads) technique in both healthy and SCAD participants, the latter used specifically 
as a disease control (91). Having applied similar criteria for recruitment I found 
slightly more CECs in my SCAD group (p<0.05) than that of Boos et al. The result 
probably reflected the higher accuracy of enumeration by FC against the IMS method 
of counting beads under microscopy and extrapolating to a wider field. Notably the 
participants in my study were on average older by 10 years but there was no 
published data to support a theory that CEC levels, unlike EPCs, increased with age. 
Alternatively, patients with on-going EC damage were unintentionally included.  
 
Comparing levels of EPC in SCAD was less straightforward. Typically EPCs were 
elevated in the presence of acute vascular injury e.g. acute coronary syndrome or 
unstable angina (403, 404). In SCAD levels were usually at baseline similar to that of 
healthy patients (386). This was certainly the case in my study. Pellicia et al recently 
challenged the limited role of EPCs postulated by Werner and proved that higher 
tertiles of EPCs were predictive of further cardiovascular events (401). Their study, 
using my chosen definition for EPC by FC detection, expressed levels as 
percentages of the mononuclear fraction and therefore comparisons with my study 
3.1.1 Cellular Markers: CRC vs Controls  
127 
	
(units of cells/ml) were limited. Arguably there were more exclusion criteria to my 
study, but a number of factors may affect EPC levels in both studies including aging, 
smoking, dyslipidemia, hypertension and end stage renal failure (405-409).  
 
Rowand et al, in validating an automated IMS CD146 technique, and Beerepoot et al 
respectively found 5 and 3 times as many CECs in progressive tumours (mCRC 
included) compared with healthy participants (143, 146). Much attention has been 
given to the value of the changes in CEC and EPC levels in monitoring the response 
to, progression with and survival from chemotherapy for mCRC (410). However, at 
the time of submitting this thesis there were no studies on their role in predicting the 
stage, progression and survival of CRC before treatment. Furthermore, after a 
thorough literature search, this was the first to compare their levels in CRC 
(regardless of stage) with that of SCAD. They both share some risk factors (e.g. 
smoking, diabetes mellitus), which may contribute to the disturbances of both cellular 
markers though, as discussed later, were not significant after stepwise linear 
regression. While both conditions and their risk factors may occur concurrently in 
some patients, there were no risk associations between them and when compared to 
the general population (411). Disturbances of the markers were known in both 
diseases of similar age groups. However, I found fifty percent more CECs and twice 
as many EPCs (p<0.001 for both) in CRC, and hence both, though not diagnostic, 
were potentially valuable markers for CRC prognostication. 
 
Another first was the analysis of these markers in benign colonic adenomas (BD), or 
the ‘pre-cancerous’ group as per the adenoma-carcinoma sequence hypothesis 
(412). The question asked by its inclusion and comparison with CRC was whether 
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circulating factors of EC activity were altered before malignant transformation. As 
predicted and on the basis that adenomas (identified histologically by incomplete 
cellular differentiation) were slow-growing benign neoplasias with low angiogenesis 
activity (413), levels were similar to that of the HC group (median [IQR] CECs of 7 [0-
10] and EPCs of 7 [0-14] cells/ml). This difference supported the theory by Goon et al 
that tumour invasion alongside angiogenesis increased CECs (92). The adenoma to 
carcinoma transformation is a slow process found in polyps more than 1cm in size 
(only 10% versus 1% of those less than 1 cm) with substantial villous changes (>25% 
of the architecture) and highly dysplastic changes; typically this was less than 10% of 
all polyps (414). Ideally adenomas with high-grade dysplasia without invasion (the 
feature that distinguished them from cancer) should be considered truly ‘pre-
cancerous’ i.e. the step before malignant transformation. However such polyps were 
rare. In fact there were only three potential recruits with highly dysplastic polyps 
during the 18-month study period; as is often the case, the invasion status was 
uncertain, probably detected in ‘malignant transformation’ but not truly malignant by 
histological characteristics and were therefore excluded. To collect a well powered 
group would require at least a 5 to 10-year study, and as there was no published 
data of circulating markers of EC activity in this group (probably reflecting the 
difficulties with recruitment), levels were likely to be similar to the BD or HC group.  
 
The WCC in CRC and SCAD, though within normal limits and of similar levels, was 
higher than that of HC and BD participants (p<0.001).  Elevated inflammatory 
markers such as WCC, monocytes and neutrophil-lymphocyte ratios have long been 
described in both conditions, but their predictive value in disease progression and 
mortality remained inconclusive (415, 416). There were no other reports of WCC in 
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SCAD exceeding that of healthy controls. In a Japanese cohort by Takeda et al of 
SCAD versus acute coronary syndrome, WCC were comparable to the levels found 
in this study but not dissimilar to their healthy age-matched controls (417). This may 
reflect population differences of WCC, variations to the definition and/or inclusion 
criteria for this group and/or the inclusion in my study of participants with 
unrecognised unstable coronary artery disease with EC dysfunction. 
 
Differences in the levels of all CD34+ cells were also found but their role in both 
health and disease was uncertain. Asahara first reported that progenitors expressing 
CD34 and KDR (CD309) differentiated into ECs and from which the theory of 
postnatal vasculogenesis was hypothesised (147). However there may be others 
roles of progenitors in angiogenesis than simply ‘adding’ to the endothelial layer. 
Yoder et al examined by clonal analysis the proliferation and differentiation outcomes 
of monocytes from peripheral blood and found not all subsets of EC-antigen 
expressing cells formed vessels (418). These were dubbed endothelial colony 
forming cells (ECFC), which did not mature into ECs and appeared to promote 
maturation of other similar monocytes (called colony-forming units of EC type or 
CFU-EC) into ECs. A recent well-conducted study by Bellows et al suggested that 
such cells expressing CD34 but not CD45 and CD31 were elevated in CRC; the 
authors called these mesenchymal stromal cells [MSC] (419). In brief MSCs are cells 
derived from the embryonic mesoderm with high capacity for cloning and, when 
cultured in the laboratory, can differentiate into muscle, cartilage, adipose and 
fibroblast cells (420). This versatility is currently being exploited extensively for tissue 
regeneration towards autologous organ replacement (421). The flaw with the 
assumption of Bellows et al was that MSCs, for which there is no single marker of 
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identification, arguably do not express CD34. Asahara et al referred to Yoder’s ECFC 
as non-haematopoietic EPCs, and although not examined for CD34 expression, were 
not derived from HSCs and were therefore from an alternative source (147). 
Nevertheless, I support the theory of Bellows et al of a substantive role of CD34 
expressing cells in tumour angiogenesis, but suggest a similar function to ECFCs (if 
not the same subtype) of promoting differentiation of EPCs into ECs. 
 
In a comprehensive review by Sydney et al (120) a compelling argument for the 
expression of CD34 expression on all progenitors, including those of MSC origin, was 
given. They cited Ferraro’s work on highly proliferative colonies of MSCs expressing 
CD34 that eventually matured into fibroblasts at which stage CD34 was no longer 
expressed (422). Apart from ECs, CD34 was commonly used for haematopoietic 
stem cell identification but was also co-expressed by other normal cells (e.g. dermal 
dendrocytes, fibroblasts, interstitial cells of Cajal) and numerous tumours e.g. acute 
lymphoblastic leukemia, blood vessel tumour, thymoma (120, 423-425). The marker 
was linked to a number of normal cellular activities mainly modulating adhesion, 
proliferation and differentiation (426-428). On this basis I propose that progenitor 
mononuclear cells in PB that express CD34, have other non-EC mature endpoints in 
tumours, but further clarification on the diversity of this population by co-expression 
of other mesenchymal markers required a more in-depth study.  
 
Cohen et al reported the clinical and genetic features of CD34+ cells (which they 
called progenitor cells) in the large community-based healthy population of the 
Framingham Heart Study (429). While they may have included all positive events, 
e.g. CD34+ microparticles and therefore did not specifically identify CD34+CD45- 
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mononuclear cells (as CD45 flourochromes were not used), an inverse relationship to 
older age, smoking and female sex was reported. A positive association was seen 
with weight, cholesterol levels and the use of statins. Risk factors alone may account 
the significantly higher levels of CD34+CD45- cells in SCAD than in all other groups 
in my study as all patients had hypercholesterolemia, though historically were well 
controlled at the time of sampling their blood. 
 
While some CD34+CD45- circulating progenitors eventually become EPCs (i.e. some 
were ‘immature’ EPCs) there numbers were quite considerable in all groups of my 
study (1-2 x 10-3 per ml) and their eventual identity and function at maturity cannot be 
clearly ascertained by the published literature. Yoder et al suggested only 2 possible 
outcomes (CFU-EC and ECFC) but to date there was no assay to separate CD45- 
cells from the CD34 fraction of monocytes. Nevertheless, in my study there were 
higher numbers of CD34+CD45- cells (p<0.005) in SCAD but less so in CRC (p>0.05) 
compared to other groups, including healthy controls. Bellows et al found much 
higher levels in CRC than healthy patients, though they compared a smaller cohort of 
45 participants of an average age of 54 years (versus 154 with average age of 72 
years in my study) to 26 younger participants and were therefore not matched for 
age. Cangiano et al reported much higher levels of these cells over several days 
after acute myocardial ischemia, necrosis and revascularisation with angioplasty 
(430). Once again, as with many other studies, a comparison with my study was 
difficult as they reported proportions of MCs and not numbers relative to blood 
volume measured (cells/ml). However, there were no differences of these cells in 
their control group of SCAD (by definition similar to my group) to that of their healthy 
participants. This raised the question once again as to whether patients in my SCAD 
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group where truly ‘stable’ i.e. some may have on-going ischemia. The smaller size of 
the HC and BD groups may account for the slightly higher levels but the IQRs were 
quite similar to the CRC group and therefore adequately powered. Assuming I have 
not unknowingly committed a type 1 error, I theorised differing roles of these cells, 
mainly regeneration of the ‘dysfunctional’ vasculature in SCAD versus modulation 
(mainly promotion) of neo-angiogenesis and/or cellular proliferation in cancer.  
 
My study was the first to report a correlation of CD34+CD45- cells with the WCC 
(r=0.314, p<0.001), and therefore a potential role in tumour growth as well as 
angiogenesis, rather than purely a mathematical relationship. Neoplastic proliferation 
is dependent on inflammatory cytokines by immune cells e.g. monocyte derived 
macrophages or dendritic cells, NK cells from lymphocytes and mast cells from 
eosinophils (431). Though not within the remit of this thesis, the correlation 
suggested immune cells in CRC may stimulate (by cytokines) the increase in 
CD34+CD45- cells which, as proposed by Bellows et al, may well be MSCs that 
eventually become mesenchymal cells e.g. fibroblasts, within the tumour. However 
further in vitro clarification is required. 
 
Correlations between levels of CEC and EPC, as found in my study (r=0.646, 
p<0.001), have also been reported in breast and prostate cancer (24, 140). The 
authors inferred that the rise of CECs from tumour invading into blood vessel created 
a void subsequently replaced by EPCs. In its simplest form it would account for the 
correlations but a more complex mechanism driven by the need for angiogenesis 
within a hypoxic tumour environment may offer a better explanation. This is 
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discussed in more detail in sections 2.5.2 and 2.5.3 on the relationships with disease 
stage and other plasma markers respectively. 
 
A number of patient co-morbidities, mainly linked to vascular insult/injury were shown 
to alter levels of both EPCs and CECs. They include unstable angina, MI, rheumatoid 
arthritis, uncontrolled hypertension, and smoking (104, 161, 162, 432, 433). However 
in my study, after multivariate stepwise and univariate linear regression analysis, only 
BMI was linked to levels of EPCs in CRC. This was the first result of its kind and no 
plausible reason was found, as reports generally on obesity and EPCs were 
conflicting. Müller-Ehmse et al suggested reduced numbers and function of these 
cells predisposed to cardiovascular disease (434). Graziani et al however found that 
morbidly obese patients with higher EPCs (as defined in my study) and without 
insulin resistance were protected against atherosclerosis (435). It was possible that 
within my study there was more diversity to the CD34+CD45-KDR+ cell fraction in 
CRC patients with a BMI greater than 29. Bellows et al found that patients with a BMI 
greater than thirty had significantly higher levels of circulating cells expressing 
CD34+CD45-CD31- (MSCs) but not cells of CD34+CD45-CD31+ (CECs) and 
CD34+CD45dimCD31dim (CPCs, which they called ‘EPCs’) phenotypes (419). 
 
As a study extracting endothelioid phenotypes from CD34+ circulating cells, there 
were two significant findings, which to my knowledge were not previously reported. 
Firstly, of all the cellular markers measured in all groups, EPCs were higher in and 
therefore more predictive (p<0.001 on ROC analysis) of CRC compared to the 
controls, including SCAD, the positive control. This suggested that EPCs might have 
roles in repair and angiogenesis other than remodelling the architecture of the inner 
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layer of blood vessels. While there may be limited clinical application, measuring their 
levels may offer a laboratory method of discriminating EC activity between the two 
conditions in experimental models of vascular biology. More importantly there may be 
a clinical role for CD34+CD45- cells to detect the presence of un-recognised 
coronary disease in CRC patients. That is, levels of these cells may help to risk 
stratify CRC patients with concurrent but unrecognised cardiovascular disease 
whose extensive treatment may include potentially harmful general anaesthesia (i.e. 
bowel resection) and /or cardiotoxic chemotherapy (e.g. oxiloplatin and 
Bevacuximab). However, further characterisation of this risk was beyond this thesis. 
 
In summary, significantly higher levels of CECs and EPCs were found in CRC 
compared with controls except CECs, which, alongside WCC were comparable to the 
SCAD group. Higher EPCs, in discriminating between CRC and SCAD, may have 
practical applications in experimental models. Higher CD34+CD45- cells may be 
useful in identifying CRC patients with unrecognised coronary artery disease. 
 
 
The relationship of the cellular markers and the CRC stage is explored next. 
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3.1.2 Cellular markers in staging CRC 
 
 
Abstract 
 
Background: CECs and EPCs were suggested as biomarkers for monitoring 
treatment of metastatic CRC but little was known of their changes with each stage. 
Levels were hypothesized to be associated with the CRC stage. 
Methods: CECs (CD45-CD146+CD34+) and EPCs (CD45-CD34+KDR+) were 
prospectively enumerated by 4-colour flow cytometry in 154 CRC participants. The 
stage was determined from the reports of the hospital’s histopathology and radiology 
departments, and confirmed at multidisciplinary team meetings. Reports were 
generated as per the guidelines of the Royal College of Pathologists (second edition) 
and Royal College of Radiologists (first edition). 
Findings: Both CECs and EPCs independently increased in a linear trend with Dukes’ 
stage (P<0.05) and a modified AJCC, but were not significant when adjusted for each 
other. There was also a linear trend (p<0.05) of EPCs with tumour differentiation. 
Conclusion: EPCs and CECs were important to the vascular biology of CRC and its 
stage. This may have implications for predicting disease outcomes. 
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Background 
 
CECs and EPCs were proposed as biomarkers to monitor response to treatment of 
metastatic CRC (28, 146, 201, 351) but little is known of their clinical value in staging. 
I hypothesized that levels of these cellular markers were associated with, and 
therefore, informative of the cancer’s stage before surgery.  
 
 
Methods 
 
The subjects and methodology were similar to that described for testing hypothesis 1 
in section 3.1.1. Colorectal cancer (n=154) participants were recruited (as detailed in 
section 2.1, page 94) and pre-treatment cellular markers were measured in 
peripheral blood by FC (section 2.2.2, page 98). Histology was reported in 
accordance with the minimum dataset guidelines of the Royal College of Pathologists 
on reporting CRC [see appendix 2, page 252] (285, 373). Radiology was guided by 
the standards of the Royal College of Radiologists, first edition (374). Stage was 
obtained from the reports of the hospital’s relevant departments, and confirmed at the 
multi-disciplinary meetings.  
 
 
Statistics 
 
This was effectively the same sample size estimation as for hypothesis 1 with four 
distinct groups i.e. Dukes stages A, B, C and D.  Therefore 25 participants for each 
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stage were recruited for total of 100. However, tumour stage could not be pre-
determined without resection. Accordingly, I aimed to recruit to excess, i.e. to circa 
150, and ultimately towards correct staging ratios.  Hence, far more CRC patients in 
hypothesis 1 were recruited, giving more power and confidence. It followed that with 
n=150, the study was powered to detect a correlation coefficient of 0.25, at 2p<0.05 
and 1-beta = 0.8. By definition, the disease stage progressed in a stepwise manner 
i.e. from good to bad. Analysis of variance (ANOVA) was inappropriate as the groups 
were not independent and Altman’s test of linear trend of ordered groups was 
applicable (380). That is, the Dukes’ system is of an ordered linear trend: stage B is 
worse than stage A, C is worse than B and D is worse than C. 
 
 
Results 
 
There was a statistically significant upward trend for CECs and EPCs with advancing 
Dukes’ stage (see table 19, Figures 28). Despite the clear rise in WCC with Dukes’ 
stage, this was not significant. The better marker of advanced stage was determined 
by ordinal regression analysis (see Table 20). Although both CECs and EPCs 
independently increased with CRC stage, neither was significant when adjusted for 
each other. However given the close mathematical relationship between CECs and 
EPCs i.e. r=0.646, p<0.001, one may not perform better than other (see figure 25). 
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Table 19: CEC and EPC counts and Dukes’ Stage 
 
  
Dukes’ A 
 
Dukes’ B 
 
Dukes’ C 
 
Dukes’ D 
 
 
P 
(trend) 
Number (n) 19 54 49 32  
Age (years) 73 (11) 74(10) 72 (9) 71 (9) n.a. 
Male (n,%) 
Female (n,%) 
11 (58) 
8 (42) 
26 (50) 
26 (50) 
23 (49) 
24 (51) 
22 (71) 
9 (29) 
0.170* 
CECs (cells/ml) 
 
10 
(0-18) 
12 
(2-23) 
11 
(0-22) 
20 
(10-29) <0.05 
EPCs (cells/ml) 20 
(0-26) 
20 
(11-37) 
21 
(10-44) 
30 
(20-93) 
<0.01 
WCCs (106/ml)  6.79 
(1.59) 
6.93 
(2.06) 
7.41 
(1.85) 
7.44 
(2.33) 
<0.1 
CEC: EPC 
Ratio 
0.9 
(0.8-1.1) 
1.0 
(0.8-1.0) 
1.0 
(0-2.8) 
0.9 
(0.9-1.0) 
n.a. 
 
CD 34+CD45-
cells* 
0.9 
(0.7-1.2) 
0.7 
(0.4-1.0) 
0.8 
(0.5-0.8) 
0.8 
(0.4-1.4) 
n.a. 
 
Results are expressed as numbers and percentages, mean (SD) or median (interquartile range). 
P (trend) values from Altman’s linear trend of ordered groups. n.a. = not appropriate as no clear linear 
trend, so analysis not attempted. *Chi Squared test. * CD34+CD45- cells x 103/ml. 
 
 
The linear trends of CECs and EPCs are illustrated in figure 28 below. 
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Figures 28: Linear trend of CECs, EPCs and Dukes’ stage (p<0.05) 
 
 
 
For both figures data points are shown as red dots, mean as block bars and 95% CI interval bars. 
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Table 20: Ordinal regression – Which marker(s) related better to Dukes’ stage? 
 
Factor Odds Ratio P value 
CEC 1.01 0.275 
EPC 1.00 0.368 
CD34+CD45- cells 1.00 0.233 
WCC 1.34 0.093 
Model fit: Chi-Square=5.286, p=0.259; Pearson’s Goodness-of-fit p=0.420 
 
 
 
Next I determined if other classifications, with modification, showed any correlations. 
 
 
Modified Dukes’ classification  
 
I examined other models that may offer better discriminators of disease severity 
and/or prognosis. Using the same principles above, I tested the hypothesis that 
CECs and EPCs performed better when the Dukes’ stages were modified into 3 
groups: bowel wall involvement (Dukes’ A+B), spread to lymph nodes (Dukes’ C) and 
spread to distant organs  (Dukes’ D). Unlike Dukes’ stage, this reclassification did not 
reveal any significant ordinal or linear trend (table 21). 
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Table 21: CEC and EPC counts according to lymphatic and metastatic spread. 
 
 
Localised 
disease & no 
spread to 
lymph nodes 
Dukes’ A+B 
Localised 
disease with 
spread to 
lymph nodes 
Dukes’ C 
Metastasis to 
other distant 
organs 
Dukes’ D 
P of 
linear 
trend 
     
Number (n) 73 49 32 - 
Age (years) 73 
(10) 
72 
(9) 
71 
(10) 
n.a 
Male (%) 
Female (%) 
38 (52) 
35 (48) 
29 (58) 
23 (42) 
15 (68) 
7 (32) 
0.410* 
 
CEC /mL 11.5 
(0-21) 
14 
(0-22.5) 
11 
(0-23) 
n.a. 
EPC /mL 20 
(9-43) 
21 
(11-40) 
28.5 
(12-47) 
>0.2 
WCC x106 
cells/mL 
7.0 
(2.1) 
7.3 
(1.8) 
7.3 
(2.0) 
n.a. 
EPC:CEC 
ratio 
1.1 
(0.5 – 5.9) 
1.14 
(0.7 – 4.0) 
1.75 
(0.6 – 5.5) 
>0.1 
CD 34+CD46-
cellsA 
0.8 
(0.5-1.1) 
0.9 
(0.7-1.2) 
0.8 
(0.4-1.4)  
 
Results are expressed as numbers, percentages, mean (SD) or median (interquartile range). 
P values from Altman’s linear trend of ordered groups. n.a. = not appropriate as no clear linear trend. 
*Chi Squared test.  A CD34+ cells x 103/ml.. No differences on ordinal regression analysis (not shown). 
 
 
Localised disease with of lymph node spread (Dukes’ A,B&C) was examined against 
metastatic disease (Dukes’ D). Once again there were no differences by either 
comparative analysis or ordinal regression. That is, the cellular indices were not good 
discriminators of distant spread (see table 22 below).  
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Table 22: Cellular markers in localised versus distant organ spread in CRC. 
 
 
Localised 
disease 
Dukes’ A+B+C 
Metastasis  
Dukes’ D p-value 
Ordinal 
Regression 
     
Number (n) 122 32 - - 
Age (years) 72 
(10) 
71 
(10) 
0.920 0.480 
Male (%) 
Female (%) 
67 (52) 
58(48) 
15 (68) 
7 (32) 
0.410 0.130 
CEC /mL 12 
(0-21) 
11 
(0-23) 
0.392 0.148 
EPC /mL 20 
(9-43) 
29 
(12-47) 
0.966 0.440 
EPC:CEC 
ratio 
1.13 
(0.5 – 5.7) 
1.75 
(0.6 – 5.5) 
0.774 0.236 
CD 34+ CD45- 
cells/ml 
0.50 
(0.79-1.11) 
0.80 
(0.39-1.38) 
0.529 0.925 
WCC x106 
cells/mL 
7.11 
(1.95) 
7.43 
(2.23) 
0.405 0.450 
 
Results are expressed as numbers, percentages, mean (SD) or median (interquartile range). 
P values from Chi Squared or t-test; ordinal regression model fit was acceptable at p=0.608 with 
Pearson’s Goodness-of-Fit of p=0.243. 
 
The AJCC system was also modified; otherwise ten sub-stages would under power 
the analyses. Therefore tumours with poorer prognoses i.e. less than 50% 5-year 
survival were pooled together (see table 13). That is, sub-stage T4 N2 M0 of stage 
IIIC (27-47% 5-year survival) was pooled with stage IV (8% 5-year survival). This 
gave the following groups n= 19 (AJCC I), 54 (AJCC IIA, IIB), 45 (AJCC IIIC) and 36 
(AJCC IIIC & IV). The results of the markers are outlined in table 23 below. 
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Table 23: CEC and EPC counts according to modified AJCC Classification 
 Modified AJCC Stages & expected 5-year survival   
 I 97% 
IIA+IIB 
72-88% 
IIIA+IIIB+IIIC‡ 
69-88% 
IIIC* + IV 
8-47% 
p 
(trend) 
      
Number (n) 19 54 45 36  
Age (years) 72 (11) 73 (10) 72 (9) 73 (9) n.a. 
Male n (%) 
Female n (%) 
12 (63) 
7 (37) 
26 (53) 
23 (47) 
21 (45) 
26 (55) 
27 (69) 
12 (31) 0.123^ 
CECs (cells/ml) 10 (0-19) 
10 
(0-22) 
11 
(0-22) 
19 
(9-23) 
 
<0.05 
EPCs (cells/ml) 18 (0-38) 
21 
(9-38) 
21 
(11-44) 
28 
(13-75) <0.05 
WCC (106/ml)  6.7 (2.2) 
6.9 
(1.9) 
7.3 
(1.8) 
7.6 
(2.2) <0.05 
EPC: CEC Ratio 1.5 (1-1.8) 
1.1 
(1-6.9) 
1.5 
(1-4.8) 
1.5 
(1-6.2) n.a. 
CD 34+CD45- 
cells 
0.9 
(0.7-1.2) 
0.7 
(0.4-1.0) 
0.8 
(0.5-0.8) 
0.8 
(0.4-1.4) n.a. 
      
Results are expressed as numbers, percentages, mean (SD) or median (interquartile range). P values 
are of Altman’s linear trend of ordered groups. n.a. = not appropriate as no clear linear trend and 
hence analysis was not attempted. ^Chi Squared test. No differences on were found on ordinal 
regression (not shown). ‡ IIIC - T3 N1 M0 + T3 N2 M0 + T4 N1 M0. * IIIC- T4 N2 M0. 
 
As with Dukes’ Stage, a significant upward trend of CECs and ECPs was found. Next 
other histological determinants of prognosis were examined. 
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The table 24 below shows additional tumour characteristics.  Differentiation, tumour 
type and vascular invasion, are associated with poorer prognoses (285). Only 4 
patients of the 127 who underwent surgery had incomplete or indeterminate 
resection margins (another poor prognostic marker) and were therefore excluded. 
 
Table 24: Details of the tumour characteristics other than Disease Stage 
 
Features 
All Cancer Patients 
n %  
    
Number 154 100  
    
Diagnosis    
Screening 12 8  
Symptomatic 142 92  
    
Family history of colorectal cancer 40 35  
    
Anatomical position    
Right (caecum +ascending) 53 34  
Transverse & descending 19 12  
Sigmoid 25 16  
Rectum 55 36  
Unknown 2 1  
    
Histological Grade* 122 100  
Well differentiated  19 4  
Well/Moderate 39 44  
Moderate 56 45  
Poor 8 7  
    
Tumour Type*    
Adenocarcinoma 122 82  
Mucinous adenocarcinoma 5 16  
Unknown 27 2  
    
Vascular Invasion*    
Yes 25 19  
No 85 62  
Unknown 12 19  
    
Metastatic* 32 20  
    
 
*Histology was available for the 148 patients that underwent surgical excision; biopsy results were not 
included. Five patients of the 32 with metastatic disease underwent palliative resections. 
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The histological features that did influence the levels of the cellular markers (not 
shown) were: size, site, depth of invasion relative to the serosa, relationship with 
peritoneal reflection (for rectal cancers), number of nodes excised and number of 
nodes involved.  However more CECs and EPCs were found with poorly 
differentiated tumours though not significantly (table 25). An Altman’s linear trend 
(p<0.05) was seen with EPCs and progression of tumour differentiation. The smaller 
power in the poorly differentiated group may increase the likelihood of type 1 and 2 
statistical errors. Remarkably both markers were non-significantly higher in the 
unreported vascular invasion group, and probably resulted from observer error. 
 
Table 25: Cellular markers, tumour differentiation and vascular invasion. 
 
            
  Differentiation   Vascular Invasion  
  
Well 
Well to 
Moderate Moderate Poor 
  
No Yes ? 
 
            
 n 19 39 56 8   85 25 13  
            
 CECs 12 
(0-22) 
10 
(0-19) 
12 
(0-19) 
19 
(0-30) 
  10 
(0-21) 
11 
(0-22) 
22 
(8-30) 
 
            
 EPCs 15 
(11-24) 
20 
(9-36) 
22 
(9-44) 
54* 
(17-97) 
  21 
(10-40) 
12 
(7-40) 
22 
(13-44) 
 
            
 WCC 7.8 
(2.5) 
7.3 
(2.3) 
6.9 
(1.8) 
7.3 
(1.1) 
  7.2 
(1.9) 
7.2 
(2.3) 
7.2 
(2.3) 
 
            
 CD34+ 
CD45- 
1.1 
(0.4-1.6) 
0.8 
(0.4-1.2) 
0.8 
(0.4-1.2) 
0.9 
(0.7-1.2) 
  0.8 
(0.4-1.2) 
0.7 
(0.5-1.1) 
0.8 
(0.4-1.2) 
 
            
            
 
Levels displayed as medians with IQR cells/ml, WCC as mean with sd x 106 cells/ml and CD34+CD45- 
cells as median with IQR x 103 cells/ml. P values were by Kruskall Wallis and  * Positive linear trend of 
ordered groups, p<0.05. The histologists in 13 patients did not report on vascular invasion. 
 
 
The significant results of multivariate and univariate analysis of CECs and EPC s for 
both patient and tumour variables are shown in table 26 below.   
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Table 26: Regression analysis of CECs and EPCs showing only the significant 
correlations when all variables were analysed. 
 
            
   CEC   EPC  
   r2 
(p) 
OR (CI) 
p 
  r2 
(p) 
OR (CI) 
p 
 
           
 BMI  - -   0.156 
(0.041) 
126 (0-108) 
0.112 
 
            
 No. of 
nodes* 
 -0.09 
(0.092) 
0.1 (0-1.2) 
0.048 
  - -  
            
 CEC  - -   0.417 
(0.001) 
4.1 (2.1-8.0) 
<0.001 
 
            
 EPC  0.394 
(0.001) 
1.1 (1.1-1.2) 
0.001 
  - -  
            
 WCC  0.205 
(0.011) 
8.7 (0.8-98) 
0.505 
  - -  
            
 
r2=Pearson correlation by multiple regression; Univariate regression analysis for odds ratio [OR] with 
confidence interval; significance was p<0.05. Factors without correlations were indicated by (-). The 
model fit for both CECs and EPCs was: r2 = 0.276, p=0.004. Other non-significant factors (not shown) 
were: age, sex, smoking, blood pressure, temperature, SCAD, hypertension, DM, screening, family 
history of CRC, tumour site, vascular invasion, tumour differentiation, number of involved lymph 
nodes, CD34+CD45-cells, Dukes’ and mAJCC stage. * Number of lymph nodes with CRC spread 
 
 
Both EPCs and CECs correlated with each other after multivariate and univariate 
analyses. As already shown in section 3.2, BMI correlated with EPCs while the 
proposed model fit for univariate analysis showed higher CECs with more lymph 
node involvement. The later must be interpreted with caution, as nodal yield was 
inconsistent from variations in patient anatomy, ‘incomplete’ excision at surgery or 
under-sampling by the pathologist. Similarly regression analysis for Dukes’ stage 
showed only a correlation with CEC (OR 1.0, CI 1.0-1.0, p=0.032), which did not 
remain with regression against the modified AJCC (not shown). 
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Discussion 
 
To date Dukes’ and AJCC-TMN staging of CRC are the best determinants of 
prognosis and are therefore used to inform the need for further oncological treatment 
where suitable. Both depend on surgical resection (stage I-III or Dukes’ A, B & C 
disease) with CT staging or invasive biopsies (radiology-guided or endoscopic) for 
confirmation of metastatic CRC detected by CT, as surgical resection may be 
inappropriate (285). Diagnostic and prognostic tests of CRC that were minimally 
invasive with high specificity and sensitivity were certainly elusive. I therefore 
theorised that CECs and EPCs, though altered in various other diseases, may a 
clinical role in prognostication. Some authors suggested changes during 
chemotherapy for metastatic CRC were predictive of treatment outcomes, though 
results of ‘success’ (e.g. improved PFT versus OS) varied. What had not been 
studied previously, and the basis of this hypothesis, was that pre-treatment levels 
may change with advancing disease and was therefore predictive of CRC stage. 
 
On first glance there appeared to be increasing levels of CECs and EPCs with 
advancing stage (the highest observed in Dukes’ D), but there were no significant 
differences by ordinal regression. However the suspicion was verified by Altman’s 
linear trend of ordered groups (p<0.05), and confirmed the hypothesis that markers 
increased with tumour progression from one stage to the next. This was further 
explored in section 5.2.4 on plasma and cellular markers with CRC stage. 
 
Modifying stages did not reproduce this trend. Comparisons included analysis by 
oridinal regression of CRC as three groups: disease confined to the bowel wall 
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(Dukes’ A plus B), lymph node spread (Duke’s C) and metastases. Similarly there 
were no differences between localised disease (Dukes’ A+B+C) and metastatic 
disease. Pooling T4N2M0 from stage III with stage IV disease of the AJCC-TMN 
classification (which I called the mAJCC) produced a more distinct upward trend of 
CECs and EPCs (p<0.05). Stage III disease, as with Dukes’ C, was characterised by 
nodal involvement and the sub-category above was associated with a poorer 5-year 
survival rate similar to metastatic disease (AJCC stage IV). Another first was the 
finding that CECs and EPCs increased in a linear trend (p<0.05 by Altman’s method 
for ordered groups) with tumour differentiation regardless of tumour stage. Poorly 
differentiated status was a predictor of disease recurrence after resection (285). 
 
Only CECs correlated to Dukes’ stage on multivariate and univariate regression, 
which did not remain after analysing the mAJCC stages (i.e. pooling T4N2M0 from 
stage 3 (or Dukes’ C) to stage 4 (Dukes’ D) disease. However a nearly significant 
(p=0.049) link between BMI and mAJCC (OR 0.9, CI 0.9-1.1) was found i.e. patients 
with more advance disease had lower BMIs. Although data on weight changes were 
collected, for most it was not reliably quantifiable and therefore excluded from the 
analysis. Otherwise, there were no significant findings when all measured cellular 
indices were analysed against tumour characteristics such as method of detection 
(screening versus symptomatic), site of origin, size of tumour, vascular invasion or 
tumour grade. I postulated higher EC activity was reflected histologically by the 
presence of tumour cells within blood vessels, or vascular invasion. That is, 
displaced ECs by invasion or translocation of tumour into blood vessels increased 
CEC levels and ‘mobilised’ more EPCs to repair the damage. However, there were 
less EPCs with vascular invasion, though non-significantly (median 12 [IQR 7-40] 
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cells/ml versus 21 [10-40] with no invasion; p=0.113). Although the status was 
unknown in 19% of the specimens examined, the finding, which was not previously 
reported, suggested that the presence of tumour within the blood vessels might 
suppress EPC mobilisation from the bone marrow and/or transformation into the EPC 
phenotype. Neither theory could be supported by the data, even less so for the later, 
as numbers of CD34+CD45- cells (assuming they were circulating precursors to the 
EPC phenotype) were not elevated by vascular invasion. Therefore further in vitro 
studies were required and other possible explanations are suggested in section 5.2.4 
when plasma and cellular markers are discussed together. 
 
Goon et al reported the first successful attempt at utilising pre-treatment levels of 
circulating endothelioid cells as predictors of disease stage in breast cancer (Goon 
2009).  CECs and CPCs (circulating progenitor cells with phenotype CD45-
CD34+CD133+, which the authors described as the forerunner to EPCs) increased 
and decreased respectively with advancing stage as assessed by both the 
Nottingham Prognostic Index (3 stages) and the AJCC-TNM (4 stages) criteria. 
Unlike my study, they also reported correlations of the CEC with NPI, tumour size, 
histological grade, vascular invasion and screen-detected cancers.  They mainly 
inferred that CEC was related to tumour bulk. This was not as evident in my study 
given that tumour size did not correlate with the cellular markers, but rather indirectly 
by the positive Altmans’ linear trend with Dukes’ stage. That is the findings supported 
my suspicion that both EPCs and CECs were influenced more by angiogenic activity 
or the angiome, than increasing tumour load by advancing stage. 
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There were certainly more CECs and EPCs with metastasis to distant organs, while 
spread to lymph nodes had little effect on levels when compared to disease localised 
to the bowel wall. This suggested that a critical volume of endothelial and angiogenic 
activity must be reached before the circulating median levels doubled at progression 
to Dukes’ D stage. It was possible that this volume was achieved at Dukes’ C stage 
when levels were similar to Dukes’ B stage. That is increased angiogenesis 
‘consumed’ more EPCs and hence did not produce the further rise anticipated in 
moving to Dukes’ C disease. Alternatively, there was shift to metastasis rather than 
angiogenesis, as blood vessel growth was less of a priority for the tumour after it 
achieved its critical mass (436). Similarly CECs from vascular invasion did not rise 
significantly as metastasis favoured the lymphatic rather than haematogenous route.  
 
As all patients in my study with Dukes’ D stage had at least liver metastases, the 
organ involved rather than disease load and neovessel demand were linked to the 
increase in CECs and EPCs found. However, I support the view that the priority once 
again shifted to angiogenesis, having achieved spread, to aid the growth of new 
seedlings (436, 437). With ‘chaotic’ neoangiogenesis in tumours sited at other 
organs, immature vessels added more CECs to the circulation while more EPCs 
were mobilised to repair the damage (339). Other tumour changes with liver 
metastasis may further contribute to the rise in CEC and EPC levels. Hanrahan et al 
established variable angiogenic activity when levels of VEGF and VEGFR subtypes 
were measured in the adenoma-carcinoma sequence and site of metastasis (438). 
Localised and lymph node disease expressed higher levels of VEGF-A mRNA, 
VEGFR-1 and VEGF-R2. With metastatic disease, mainly to the liver, there was a 
‘shift’ in expression to VEGF-C mRNA and the VEGFR-2 receptor. Generally VEGF-
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C promoted angiogenesis via VEGFR-2 and was comparatively higher in lymphatic 
spread than liver metastases (439, 440).  
 
In summary although there were linear positive trends of CECs and EPCs with 
advancing Dukes’ stage and tumour differentiation, they did not inform on the 
disease stage itself. Nevertheless, the trends had implications for the vascular 
biology of CRC as EC activity varied with each stage and may therefore be important 
determinants of its prognosis (as examined in section 5.2.6). 
 
 
All pre-treatment plasma and cellular indices in CRC are analysed next.  
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3.1.3 Plasma & cellular markers in CRC 
 
 
Abstract 
 
Background: Markers of endothelial activity were altered in cancer and other 
diseases. In CRC the relationship between factors of the endotheliome (vWf, sE-
selectin) and angiome (VEGF, angiogenin) with EPCs and CECs were unknown. All 
indices were hypothesized to be higher than controls and correlations of plasma with 
cellular markers to be associated with the CRC stage. 
Methods: Prospective study of 154 CRC participants compared to 26 participants 
with benign colonic polyps (BD), 33 with stable coronary artery disease (SCAD) and 
29 healthy (HC) age-matched controls. CECs (CD45-CD146+CD34+) and EPCs 
(CD45-CD34+KDR+) were enumerated by 4-colour flow cytometry. All plasma 
markers were measured by ELISA assays. The CRC stage was determined by the 
hospital’s histopathology and radiology departments, and confirmed at 
multidisciplinary team meetings.  
Findings: All indices were higher in CRC versus the controls except vWf and sE-
selectin, which were comparable to the SCAD group. VEGF correlated with CECs 
(r=0.407, p<0.001) and EPCs (r=0.530, p<0.001). Angiogenin, VEGF and EPCs (all 
p<0.001), were more predictive of CRC. Except for Dukes’ A (stage 1), only 
angiogenin and VEGF were higher in all Dukes’ & mAJCC stages (p<0.001) when 
compared to SCAD. Like EPCs and CECs, angiogenin rose in a linear order with 
advancing stage. This relationship remained on ordinal regression analysis after 
3.1.3 Plasma & Cellular Markers in CRC 
153 
	
adjusting for all other indices (p=0.001). EPCs and WCC were higher only in stages 
C and D (p<0.05). CD34+CD45- cells and sE-sel remained unchanged at all stages. 
Conclusion: There were disturbances of all measured indices of the endotheliome 
and angiome in CRC. However, only angiogenin may be a potential biomarker of 
diagnosis. Along with CECs and EPCs, it progressed with disease stage and may 
therefore be important for the risk stratification of CRC. 
 
 
Background 
 
CECs and EPCs were proposed to monitor response to treatment of metastatic CRC 
(28, 146, 201, 351). Angiogenin (267), VEGF (284, 366), vWf (11, 23) and sE-
selectin (78, 369) were also suggested to be of diagnostic and prognostic value. As 
with most biomarkers of EC activity, they were also altered in many diseases 
including cardiovascular disorders and other cancers (22, 92, 140, 386). For CRC, 
their value across all stages, performance against cardiovascular disease and 
differences with pre-cancerous disease, i.e. colonic polyps, were unknown. I 
hypothesised that levels were higher in CRC than healthy (HC) and benign polyp 
(BD) controls, but comparable to those with stable coronary artery disease (SCAD). 
The later was also used as a positive disease control. The markers and their 
correlations with each other were hypothesised to be associated with, and therefore, 
informative of the cancer’s stage before surgery. 
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Method 
 
Participants were recruited as detailed in section 2.1. CECs and EPCs were 
measured in peripheral blood by 4-colour flow cytometry (section 2.3.1) and all 
plasma markers (vWf, sE-sel, VEGF & angiogenin) by ELISA assays as summarized 
in sections 2.3.3 to 2.3.6. Pre-treatment levels were quantified in CRC (n=154) and 
compared to the 26 BD, 29 HC and 33 SCAD control groups. As detailed in the 
methods of section 3.1.2, the stage was obtained from the reports of the hospital’s 
relevant departments, and confirmed at the multi-disciplinary meetings. 
 
 
Statistics 
 
The power calculation was the same as section 2.3.1 (page 117) for testing 
hypothesis 1. That is, I determined the correlations of plasma markers of the 
endotheliome (vWf and sE-sel), and the angiome (VEGF, angiogenin) with CECs and 
EPCs from the participants recruited to hypothesis 1. Results were expressed as 
numbers and percentages, mean and standard deviation (SD) or median and 
interquartile range (IQR). Analyses between groups were performed using ANOVA, 
Kruskal Wallis, Mann-Whitney, t-test and Chi Square as appropriate. Correlations 
were obtained by Spearman’s rank method, and for the clinical variables, by stepwise 
multiple regression. Analysis of variance (ANOVA) was inappropriate for changes 
with CRC stages as each were dependent on the previous in moving from one stage 
to the next. Altman’s test of linear trend of ordered groups was applicable (380). A 
two-tailed p value < 0.05 was considered statistically significant.  
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Results 
 
All indices were higher in CRC versus the controls except for vWf and sE-sel in 
SCAD (Table 27 below). The variables were then tested by ROC analysis for their 
diagnostic accuracy of CRC The ROC curves showed that, like EPCs, there were 
less false positives for angiogenin and VEGF (figure 29).  
 
 
Table 27: Plasma markers in CRC versus Control Groups 
 
Colorectal 
Cancer 
[CRC] 
Healthy 
Controls 
[HC] 
Benign 
Controls 
[BD] 
Coronary 
Disease 
[SCAD] p 
Number 154 29 26 33  
vWf  [IU/dL] 119 
(26)a 
 
97 
(17) 
 
110 
(31) 
 
128 
(48)b 
 
<0.001 
 
sEsel 
[ng/mL] 
27 
(18-34)a 
 
20 
(16-28) 
 
18 
(16-26) 
 
31 
(28-41)b 
 
<0.001 
 
VEGF 
[pg/mL] 
195 
(30-703)a 
 
30 
(0-65) 
 
32 
(0-82) 
 
90 
(23-110) 
 
<0.001 
 
Angiogenin 
[ng/mL] 
312 
(248-367)c 
140 
(55-176) 
143 
(107-175) 
137 
(78-160) 
<0.001 
 
 
Data presented as mean (standard deviation) or median (interquartile range), overall p value by 
ANOVA or Kruskall-Wallis. Post-hoc Tukey’s test found a higher levels in CRC than controls except b 
SCAD; c higher in CRC compared to the other three groups, p<0.05. 
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Figure 29: ROC curves for Angiogenin & VEGF in CRC versus controls 
 
 
	  
		
 
 
That is, higher VEGF and angiogenin were predictive of CRC. The next analysis 
determined the relationships with CECs, EPCs, WCC and CD34+CD45- cells by 
correlation (table 28). As in hypothesis 1, only the CRC group was assessed, as the 
low numbers in the controls were likely to result in types 1 and 2 statistical errors. 
Angiogenin 
Area under curve: 0.938 
P value:  <0.001 
 
For Angiogenin > 312 ng/ml: 
Sensitivity:         98 % 
Specificity:       50 % 
Likelihood Ratio: 1.9 (0.9-2.2) 
 
VEGF 
Area under curve: 0.732 
P value:  0.001 
 
 
For VEGF > 195 pg/mL  
Sensitivity:        93 % 
Specificity:        49 % 
Likelihood Ratio: 1.8 (1.0-2.1) 
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Though results were similar when all groups were included, the correlations with 
VEGF were within power limits and therefore highly reliable in CRC.  
 
Table 28: Correlation matrix of plasma and cellular markers in CRC. 
 
 
CECs 
 
EPCs WCC CD34+CD45- 
     
vWf 
 
r = 0.050 
p = 0.542 
r = 0.153 
p = 0.059 
r = 0.062 
p = 0.445 
r = 0.085 
p = 0.293 
eSelectin 
 
r = -0.010 
p = 0.945 
r = 0.000 
p = 0.995 
r = 0.059 
p = 0.464 
r = 0.013 
p = 0.871 
VEGF 
 
r = 0.407 
p < 0.001 
r = 0.530 
p < 0.001 
r = 0.141 
p = 0.081  
r = 0.169 
p = 0.035  
Angiogenin 
 
r = 0.049 
p = 0.546 
r = 0.144 
p = 0.075 
r = 0.134 
p = 0.097 
r = -0.067 
p = 0.409 
     
 
r= Spearman’s correlation coefficient. 
 
 
 
 
VEGF therefore was an important determinant of CECs, EPCs and CD34+CD45- 
cells. Scatterplots of the relationships between CECs to VEGF, and EPCs to VEGF, 
are shown in Figures 30 and 31. Logarithm (base 10) of the raw data was performed 
as the data had a strong non-parametric distribution. The EPC/VEGF plot (r=0.530) 
and hence correlation was more convincing than the CEC/VEGF results  (r = 0.407). 
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Figure 30: Relationship between CECs and VEGF in CRC. By Spearman’s test 
r=0.407, p<0.001, with mean (solid) and 95 % SE (dashed) lines shown. 
 
 
 
 
 
Figure 31: Relationship between EPCs and VEGF in CRC by Spearman’s test 
r=0.53, p<0.001, with mean (solid) and 95 % SE (dashed) lines shown. 
 
 
 
 
 
The relationships between the plasma markers and Dukes’ stage are shown in Table 
29. As for EPC and CEC, ANOVA was inappropriate as groups were not independent 
and hence Altman’s linear trend of ordered groups was used instead. Only 
angiogenin rose in a linear order with Dukes’ stage (figure 32 below). 
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Table 29: Plasma markers and Dukes’ Stage 
 A B C D P (trend) 
Number (n) 19 54 49 32  
vWf  [IU/dL] 115 (23) 
117 
(22) 
115 
(26) 
129 
(34) < 0.1 
sE-sel [ng/mL] 28 (22-32) 
29 
(20-37) 
24 
(11-32) 
25 
(7-34) > 0.2 
VEGF [pg/mL] 120 (10-560) 
188 
(5-610) 
220 
(10-885) 
265 
(5-742) 
> 0.2 
 
Ang [ng/mL] 254 (190-290) 
319 
(242-353) 
322 
(264-374) 
356 
(293-396) < 0.01 
 
Results expressed mean and standard deviation or median and interquartile range. 
Approximate p value of Altman’s linear trend of ordered groups’. Table B4 in Altman (1991). 
 
 
 
 
 
Figure 32: Relationship between Angiogenin and Dukes’ stage p (trend) <0.01, 
mean (red dot) with 95% CI (error bars). 
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As in hypothesis 2, I compared the indices in those with localised disease (confined 
to the bowel wall), involvement of lymph nodes and spread to other organs (table 30).  
  
 
Table 30: Plasma markers in local, node and metastatic disease 
 
 Localised 
disease  
 
Dukes’ A+B 
Lymph nodes 
involved 
 
Dukes’ C 
Metastasis to 
other organ 
 
Dukes’ D 
 
 
 
P 
Number (n) 77 53 24 - 
vWf  
[IU/dL] 
117 
(22) 
115 
(26) 
129 
(34) 
>0.1 
sE-sel 
[ng/mL] 
 
29 
(21-36) 
24 
(11-32) 
25 
(7-34) 
n.a. 
VEGF 
[pg/mL] 
180 
(30-559) 
220 
(10-885) 
265 
(5-742) 
>0.2 
Ang 
[ng/mL] 
291 
(91) 
322 
(264-374) 
356 
(293-396) 
<0.01 
 
Results are mean (SD) or median (interquartile range). P values are from Altman’s linear trend of 
ordered groups. n.a. = not appropriate as no clear linear trend, so analysis was not attempted.  
 
 
 
Once again only angiogenin showed a significant trend with disease progression. 
 
For the AJCC-TMN classification, as with hypothesis 2, I pooled the poorer 
prognostic tumours from stage IIIC (T4N2M0) with stage IV (5-year survival of less 
than 50%). Again only angiogenin showed a linear trend  (table 31, figure 33). 
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Table 31: Plasma markers versus modified AJCC stage 
 I IIA+IIB IIIA+IIIB+IIIC‡ IIIC*+ IV p (trend) 
Number (n) 19 54 42 39  
vWf  [IU/dL] 115 (23) 
117 
(22) 
114 
(24) 
128 
(23) n.a. 
sEsel [ng/mL] 28 (22-32) 
29 
(20-37) 
24 
(18-34) 
25 
(16-30) n.a. 
VEGF [pg/mL] 120 (10-560) 
188 
(5-610) 
363 
(80-1200) 
190 
(23-750) n.a. 
 
Ang [ng/mL] 
 
254 
(190-290) 
319 
(242-353) 
325 
(102) 
332 
(100) <0.01 
 
Results are mean (SD) or median (interquartile range). P values are from Altman’s linear 
trend of ordered groups. n.a. = not appropriate as no clear linear trend, so analysis not 
attempted. Abbreviations are as per table 27. ‡ IIIC are stages T3 N1 M0 + T3 N2 M0 + T4 
N1 M0.  * IIIC is T4 N2 M0. 
 
 
Figure 33: Relationship between modified AJCC score and angiogenin 
(mean in red dot with 95% CI error bars). 
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Only vWf showed ordinal regression when localized disease, inclusive of lymph node 
spread, was compared with metastatic disease (see table 32 below). 
 
Table 32: All indices in localized versus metastatic CRC 
 
Localised 
disease 
Dukes’ A+B+C 
Metastasis  
Dukes’ D p-value 
Ordinal 
Regression 
     
Number (n) 122 32 - - 
Age (years) 72 
(10) 
71 
(10) 
0.920 0.323 
Male (%) 
Female (%) 
67 (52) 
58(48) 
15 (68) 
7 (32) 
0.410 0.130 
CEC /mL 11.5 
(0-21) 
11 
(0-23) 
0.392 0.159 
EPC /mL 20 
(9-43) 
29 
(12-47) 
0.966 0.509 
EPC:CEC 
ratio 
1.13 
(0.5 – 5.7) 
1.75 
(0.6 – 5.5) 
0.774 0.285 
CD 34+ CD45- 
cells/ml 
0.50 
(0.79-1.11) 
0.80 
(0.39-1.38) 
0.529 0.787 
WCC x106 
cells/mL 
7.11 
(1.95) 
7.43 
(2.23) 
0.405 0.537 
vWf  [IU/dL] 118 
(22) 
127 
(29) 
 
0.009 0.045 
sEsel [ng/mL] 27 
(21-36) 
24.5 
(16-32) 
0.153 .0199 
VEGF [pg/mL] 225 
(30-833) 
177 
(21-699) 
0.911 0.674 
Ang [ng/mL] 
 
314 
(98) 
310 
(101) 
0.014 0.186 
 
P-values were by Mann-Whitney test or t-test. For ordinal regression model fit p=0.161; Pearson’s 
Goodness-of-fit p=0.080. 
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Although vWf was significantly higher in Dukes’ D compared to all other stages, it did 
not perform as a good discriminator of metastatic CRC (for vWf > 118 IU/dl sensitivity 
was 41%, specificity 78%, ROC area=0.602 [p=0.075, LR=1.6]; see figure 34). 
 
 
Figure 34: ROC curve for vWf in Dukes’ D versus ALL other stages. 
 
 
 
I then compared the stages with the positive control (SCAD) to determine if there was 
a difference that was more significant in CRC for all the measured indices (table 33). 
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Table 33: Differences between measured indices of Dukes’ Stage and SCAD. 
 Dukes’ Stage versus SCAD (p values) 1 
  A B C D 
n  19 54 49 32 
Age (years)  73 (11) 74 (10) 72 (9) 71 (9) 
CEC cells/ml 
 
0.752 0.796 0.249 0.217 
EPC cells/ml 
 
0.156 0.129 0.007 0.004 
WCC 106/ml  
 
0.444 0.213 0.021 0.046 
CEC:EPC 
 
0.617 0.763 0.436 0.248 
CD34+CD45-* 
 
0.002 <0.001 <0.001 <0.001 
vWf  [IU/dL] 
 
0.252 0.151 0.096 0.914 
sEsel 
[ng/mL] 
 
0.009 0.062 <0.001 <0.001 
VEGF 
[pg/mL] 
 
0.074 0.018 <0.001 <0.001 
Ang [ng/mL]  <0.001 <0.001 <0.001 <0.001 
 
Results were p values [significance <0.05]. SCAD: Stable coronary artery disease. * There were less 
CD34+CD45- cells in CRC than SCAD. 
 
 
Only angiogenin was higher in all CRC stages while EPCs, WCC, and VEGF were 
higher only in stages C and D when compared to the positive SCAD control. 
Conversely CD34 cells and sEsel were lower regardless of stage. The results were 
similar with the modified AJCC classification (not shown). 
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Summary of the cross-sectional analyses 
 
There were raised CECs in CRC (that are comparable with levels in SCAD), raised 
EPCs only in CRC and the EPC/CEC ratio was high only in CRC. EPCs strongly 
correlated to CEC levels and body mass index. While CECs, EPCs and the WCC all 
increased across Dukes’ stage, none of the measured markers correlated to the 
disease on multivariate or univariate regression analysis.  
 
As expected, all four plasma markers (vWf. sE-sel, VEGF, angiogenin) were raised in 
CRC compared to HCs, and some were comparable to those in SCAD. However, 
only VEGF correlated to both CECs and EPCs, while angiogenin progressively 
increased with progression of Dukes’ stages and the modified AJCC. Results of 
ordinal regression analysis of angiogenin, VEGF, CECs, EPCs, and Dukes’ stage is 
shown table 34. This unequivocally found that the relationship between angiogenin 
and Dukes’ stage remained after adjustment for the other indices (p=0.001).  
 
 
Table 34: Ordinal Logistic Regression of Dukes’ Stage and measured factors. 
 
Predictor Z P 
CECs -0.81 0.419 
EPCs -0.44 0.66 
VEGF -0.04 0.969 
Angiogenin -3.18 0.001 
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Discussion 
	
Angiogenesis is essential to CRC growth and metastasis, hence its measurement 
and that of EC activity may inform on disease stage and prognosis (267, 441, 442).  
This thesis was the first practical approach on the correlation of plasma with cellular 
markers of the endotheliome and angiome.  It compared levels in participants with 
CRC, SCAD, benign polyps and those who were otherwise healthy (recruited to 
hypothesis 1). In CRC and SCAD (positive control) I hypothesized that the 
mobilisation of EPCs was linked to angiogenesis as determined by plasma VEGF 
and angiogenin levels (i.e. the angiome). Also expected were abnormal levels of 
sectin and vWf, measures of EC activity or the endotheliome. Perturbation of CEC 
levels was also expected to correlate with all measured plasma indices. That is, 
tumour growth by vascular invasion (aided by sE-selectin) displaced ECs from 
vessels (from which effete ECs released vWf) and/or with high angiogenic activity 
(high VEGF and angiogenin levels) produced immature blood vessels that easily 
shed CECs (92, 235) With the exception of VEGF on EPCs, no correlations between 
my chosen cellular and plasma markers were previously studied in CRC (20, 147). 
 
All plasma marker, as with CECs and EPCs, were significantly higher in CRC than 
the controls, except vWf and sE-selectin which were similar to the SCAD group. For 
the later, levels were also more or less the same as those from studies on acute 
coronary syndrome in which SCAD was the disease control (22, 443). Both factors 
were described by the authors as indicators of EC dysfunction or damage and were 
markedly increased with acute coronary occlusion. Nevertheless, vWf on its own, as 
described by Schellerer et al and now confirmed in this study, was not a useful 
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biomarker of CRC (23). It also disproved the diagnostic value of sE-selectin 
suggested by Uner et al (78). Only VEGF and, more so, angiogenin were good 
discriminators of CRC from all the other groups studied (that is, for a VEGF > 195 
pg/mL sensitivity = 49%, specificity = 93%, ROC area of 0.732, p=0.001; for 
angiogenin >312 ng/mL sensitivity = 75%, specificity = 98%, ROC area of 0.938, 
p<0.001). This raised the possibility of angiogenin as a good diagnostic tool for CRC, 
but, like VEGF, was also elevated in other cancers e.g. breast cancer (24). 
 
Correlations were calculated in the CRC group only, since the numbers were within 
power limits. The findings in the smaller sized controls were more likely to result in 
types 1 and 2 statistical errors. Significant results were found with VEGF only; that is, 
there were correlations to CECs (r=0.407, p<0.001), CD34+CD45- cells (r=0.169, 
p=0.035) and more so, EPCs (r=0.530,p<0.001). Asahara et al first reported that 
EPCs were partially mobilized from the bone marrow by VEGF while, for cancer, 
correlations were reported in lung and hepatocellular carcinomas only (147, 190, 
216).  As for metastatic CRC, neither CECs nor EPCs were linked to VEGF levels but 
these findings of Beereport et al included other solid organ tumours (146).  
 
Based on the study of Asahara et al (147), I hypothesized a relationship of VEGF 
with EPCs but not CECs; however, I found correlations with both. This probably 
resulted from the inclusion of all disease stages or was ‘mathematical’ from the 
correlation that existed between CECs and EPCs described in section 5.2.2. Since 
this was not reported in other cancers [breast and prostate (24, 140)], alterations in 
CECs were more likely the result of angiogenesis in CRC given VEGF was the ‘gold 
standard’ test of the angiome. It would also support the hypothesis that CEC levels 
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increased as they were displaced from invasion into vessels by the growing tumour. 
As tumour growth demanded blood supply (probably by hypoxic factors) more 
angiogenic factors, like VEGF, were released, which gave rise to immature vessels 
with ‘loose’ basement membranes that shed ECs, further increasing CEC levels. 
 
The positive correlation of VEGF with CD34+CD45- cells, not examined previously by 
other authors, probably resulted from the presence of EPCs within this fraction. 
Alternatively VEGF may mobilize (from the bone marrow or otherwise) CD34+ 
‘precursors’ of other non-endothelial cells (CD34+CD45-KDR-) important to CRC 
growth e.g. fibroblasts (419). However, the fate and phenotype(s) of this fraction of 
cells could not be determined from my study or the published data. 
 
 
vWf 
 
The lack of a correlation with CEC to the ‘gold standard’ of EC damage, vWf, was 
unexpected and did not fit with the model of the endotheliome I proposed (89, 122). 
That is, I expected tumour invasion into blood vessels to release and/or damage 
ECs. CECs were mature cells shed from the vasculature, which on apoptosis should 
increase levels of vWf. This non-correlation was not unique to CRC, as it was also 
not found in prostate and breast cancer (24, 140). A criticism of my study was that 
ABO blood group, a major determinant of vWf levels (444), were not collected. 
However, I anticipated that vWf, as recently suggested by Schellerer et al (though 
their findings were not yet published when I formulated this hypothesis), should be 
high from increased EC activity in cancer regardless of blood type (23). To detect 
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influences of ABO blood type in CRC would require a much larger cohort than my 
study. Also, it was possible that vWf was cleared significantly within the portal 
circulation to discern any detectable differences in the peripheral circulation (445). 
Although vWf was significantly higher in Dukes’ D stage, ROC analysis proved it was 
only a fair discriminator of metastatic disease. 
 
 
sE-selectin 
 
The results of Ito et al of a trend of sE-selectin with disease stage, the highest levels 
in Dukes’ D (n=11), may have overestimated the effect from under-powering with 
only 54 participants recruited as this result was not reproduced in my study (369). 
Soluble E-selectin (also known as CD-62E, ELAM-1 or LECAM2) is a 
transmembrane adhesion protein activated on ECs by cytokines and bind to 
glycolipids and glycoproteins of leukocytes during inflammation (446). Attachment to 
sialyl Lewis carbohydrate-ligands (specifically x) on tumour cells was shown in CRC 
lines to facilitate haematogenous metastasis (447). The expression on ECs and the 
subsequent increase in plasma levels were highly inducible by cancer-derived 
cytokines e.g. TNF- and interleukins, and VEGF (448, 449). On these findings alone, 
the hypothesised correlations with VEGF, and CEC, the latter I proposed as a marker 
of vascular invasion and metastasis, were rejected. As the highest levels were found 
in SCAD not CRC, vascular dysfunction in atherosclerosis with a greater 
inflammatory effect, may be a more potent stimulator of sE-selectin expression (22, 
377). Alternatively, apoptosis of CECs was less frequent than in SCAD (22). As no 
marker of apoptosis (e.g. sFas or sFasL) was measured in my study, I was unable to 
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conclude that CEC death resulted in either increased vWf or sE-Sel but the absence 
of correlations suggested more viable cells remained in the circulation than SCAD. 
This may have been less so in metastatic disease as vWf, but not sE-Sel, levels were 
similar to that of SCAD. There may be a role for vWf in identifying Dukes’ D stage 
where conventional methods (CT, PET-CT or MRI) failed and therefore better inform 
therapeutic strategies but further conclusions were beyond the remit of this thesis. 
 
 
Angiogenin 
 
The trend of increasing levels of CECs and EPCs with Dukes’ and mAJCC-TMN 
stage described in section 5.2.3 was also hypothesised to occur with the measured 
plasma markers. However, only angiogenin displayed this quality and remarkably 
more so (p<0.01) than with either circulating cell (p<0.05). Shimoyama in a smaller 
study (34 CRC patients) similarly described changes in serum and tissue levels that 
varied with disease stage, with the highest concentrations found in Dukes’ B 
participants (267). My study was adequately powered to support this trend but was 
measured in the participant’s plasma. There were no reports in the literature, unlike 
VEGF, of differences between serum or plasma levels, or the contribution, if any, of 
intra-cellular angiogenin e.g. from leukocytes or platelets. The mechanisms of 
angiogenin in angiogenesis were unclear. This 14kDa tumour-derived ribonuclease 
protein was first isolated from the supernatant of a CRC cell line (352, 450). It 
interacted with the endothelium and smooth muscles of blood vessels to induce a 
range of EC responses including migration, invasion, proliferation and formation of 
vascular ‘tubes’. It primarily stimulated tPA release when bound to surface actin on 
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ECs. Plasmin, from the enzymatic breakdown of plasminogen by tPA, then degraded 
basement membrane and extracellular matrix to allow ECs to penetrate perivascular 
tissues and facilitate neovascularisation. Angiogenin adhered more rapidly to HT-29 
human CRC cells compared to other ECM proteins, hence a role in metastasis by 
aiding EC attachment prior to cancer migration across the vessel wall was postulated 
by Hu et al (358, 359, 362). Tumour cell proliferation was also shown in this cell line 
to involve tyrosine kinase pathway and increased RNA activity with angiogenin 
translocation (endocytosis) into the nucleus.  Its physiological substrates were largely 
unknown but interactions with the intracellular cytoskeleton and the ECM protein 
fibulin-1 supported the theory of aiding cell adhesion towards metastasis (451, 452). 
 
 
VEGF 
 
VEGF expression was highlighted by a Ferrara et al (229) as the ‘best’ biomarker to 
guide treatment as, was often assumed but only recently proven by Jin et al 
(specifically VEGF-C), levels reflected tumour size in CRC (453). There was sufficient 
evidence that VEGF on its own had limited clinical application but its inclusion, as a 
marker of the angiome, was to determine its clinical relationship with markers of EC 
activity (the endotheliome) and specifically with CECs and EPCs. The relationship 
had not been examined with the cellular definitions proposed, which I considered the 
‘best’ fit based on the evidence to date. On initial inspection, median VEGF (-A) 
levels in my study appeared to increase with disease stage, though not significantly, 
and were similar to other reports of the last three decades (454-456). However, 
unlike angiogenin, levels tended to be higher in serum than in paired plasma, and 
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presumed to arise from stores within platelets released during clotting (270, 284, 
457). Hence, anti-coagulated plasma may more accurately reflect ‘true’ circulating 
levels, rather than serum contaminated by ‘accumulated’ stores from platelets, and 
therefore VEGF was indeed independent of Dukes’ stage. Platelets, which can be 
higher in advanced disease, were recognised depots for and hence transporters of 
angiogenic and growth factors via the peripheral circulation to cancer cells (458, 
459). Like plasma, there were also inconsistencies of the serum levels reported 
between studies and therefore the differences were not necessarily from platelet 
contamination. Rudge et al proposed that the accuracy of assays may improve by 
chemical traps to stop its rapid breakdown during blood storage as VEGF otherwise 
had a half-life of only minutes (460). I proposed that a ‘trap’ already existed within 
platelets themselves, and this quantity, if measurable, was the best reflection of 
VEGF secreted by tumours. A few studies on the quasi-differential content measured 
plasma (free VEGF) versus serum (containing free and stored VEGF) levels (461, 
462). Otherwise, I could not find published assays to test this hypothesis. 
 
In summary levels of CECs, EPCs, angiogenin and VEGF were good measures of 
angiogenic activity (the angiome) and therefore were important to the understanding 
of the vascular biology of CRC. However, angiogenin alone was the best 
discriminator of the disease and its stage. Hence, angiogenin may be a useful 
biomarker of CRC detection and risk stratification. Of the other measures of the 
endotheliome, only vWf was significantly higher in Dukes’ D stage which may also be 
useful in identifying metastatic disease and hence inform treatment strategies.  
 
The longitudinal studies are next, starting with the serial changes of markers in CRC. 
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3.2 Longitudinal Studies 
 
 
3.2.1 Serial changes of cellular and plasma markers in CRC  
 
Abstract 
 
Background: Serial changes to CECs, EPCs and VEGF were proposed to predict 
outcomes after CRC treatment. However the overall value of these changes, along 
with that of other markers of the endotheliome (vWf, sE-selectin) and the angiome 
(angiogenin) were unknown. I hypothesized that all markers fell after surgery and the 
changes with treatment strategies were important determinants of outcomes.    
Methods: Sixty-eight participants treated for CRC were recruited and three 
subgroups were compared: surgery only (n=16), surgery followed by standard 
chemotherapy (n=32), and surgery followed by standard chemotherapy plus anti-
VEGF therapy (Bevacizumab, n=20). Peripheral blood was taken before surgery and 
again at 3 and 6 months. CECs (CD34+CD45-CD146+) and EPCs (CD34+CD45-
KDR+) were measured by 4-colour flow cytometry and the plasma makers by ELISA. 
Findings: All markers fell after surgery at 3 months (p<0.05). CECs and EPCs fell by 
3 months but returned to pre-surgery levels at 6 months (p<0.05). VEGF remained 
lower throughout except after anti-VEGF, increasing to pre-surgery levels. After 
standard chemotherapy, sE-sel was higher than baseline. 
Conclusions: The changes with CECs and EPCs regardless of treatment strategy 
after surgery, VEGF with anti-angiogenic therapy, and sE-selectin and angiogenin 
with standard chemotherapy may have clinical and pathophysiological implications. 
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Background 
 
Studies on the serial changes of CECs and EPCs were isolated to metastatic CRC 
and reported as good predictors of outcomes (28, 143, 201, 463). A fall in EPCs 
during treatment was associated with improved progression-free survival (28, 147, 
201) while Ronzoni et al proposed the pre-treatment levels, not the fold changes, as 
better surrogates (201). Low VEGF was reported by Hyodo et al as predictive of non-
responders to chemotherapy (274), but later refuted by Berglund et al (464). The 
value of the changes in vWf, sE-sel and angiogenin after surgery were unknown.  
 
Having described the changes of markers of the angiome and endotheliome in CRC 
stage (sections 3.1.2 & 3.1.3), their changes over time after surgery, with or without 
adjuvant therapy were analyzed. All markers were predicted to fall after surgery. 
Participants receiving adjuvant treatment (that is, they had histological predictors of 
recurrence as stated section 1.4.2, page 72) were hypothesised to have fewer 
changes than those treated with surgery only (as most had favourable histology), 
though not planned in my original hypothesis. 
 
 
Methods 
 
Participants treated for CRC and monitored thereafter, were recruited. Peripheral 
blood was taken before surgery and again at 3 and 6 months. CECs (CD34+CD45-
CD146+) and EPCs (CD34+CD45-KDR+) were measured by 4-colour flow cytometry 
and the plasma makers by ELISA assays as for the cross-sectional studies 
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(described in section 2.2, SOPs detailed in appendices 3 to 7). The exclusion criteria 
of section 2.1.3 (page 95) were also applied to the repeat measurements. 
 
The options for those needing adjuvant chemotherapy were diverse but nearly all 
received the modified de Gromant regime (folinic acid and 5-fluorouracil [5-FU] or its 
oral equivalent, capecitibine), while only 4 with Dukes’ C had FOLFOX  (5-FU, folinic 
acid and oxaloplatin).  These two regimes were evidence-based, and protocolled by 
the oncology departments; they were therefore referred to as ‘Standard 
Chemotherapy’ (see section 1.4.3 and appendix 8, page 291). Another group 
received anti-VEGF therapy, predominantly as part of the QUASAR 2 trial, and for 
metastatic disease (Dukes’ D). The trial period overlapped with my study and 
fortunately the hospital from which most of my participants were drawn, was one of 
the top 3 recruitment centers in the UK. It allowed the effects on the markers to be 
measured with the addition of the anti-VEGF agent Bevacuximab to standard 
chemotherapy. Therefore three categories were analysed (see figure 29): 
 
1. Surgery alone i.e. no adjuvant treatment was needed 
2. Surgery plus adjuvant therapy with standard chemotherapy (intravenous 5-
fluorouracil [5-FU]) or Capecitabine (oral 5-FU equivalent) 
3. Surgery plus adjuvant therapy with anti-VEGF (Bevacuximab, Avastin®). 
 
After adjuvant treatment, markers were typically measured 2 to 4 weeks after 
completion but excluded those with significant biochemical or haematological 
abnormalities (see ‘exclusion criteria, section 2.1.3, page 95). For Dukes’ D disease 
treatment continued beyond 6 months where applicable, and therefore, levels were 
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measured while on a break at six months and 2 to 4 weeks after the last cycle. Of the 
154 patients recruited, 114 were approached to participate. Those on adjuvant 
treatment unable to complete their course were excluded. After applying the 
exclusion criteria (section 2.1.3 page 95), and receiving consent, 68 were recruited. 
Subgroups were as follows (see figure 29): 1). n=16 for surgery only,  2). n=32 for 
surgery followed by standard chemotherapy, and 3). n=20 for surgery followed by 
standard chemotherapy plus anti-VEGF therapy (Bevacizumab, Avastin®). Changes 
of the indices from pre-surgery to 3 months (range 2.6 – 3.8 months, before starting 
adjuvant treatment, if given) and then to 6 months (range 5.5 – 8.7 months, and 
where applicable, 2-3 weeks after completing chemotherapy) were analysed. 
 
 
Statistics 
 
For the power calculation, surgery was predicted to reduce the CEC and EPC counts 
by a third, as found in by Goon et al in breast cancer (24). That is from a median 
(IQR) of 3 (1.5 – 5.0) cells/mL CEC levels were expected to fall to 2 (0.5 – 3.5) 
cells/ml after treatment. If numbers fell in 21 patients, but rose in 4 patients (25 
participants in total), then the calculated paired t-test would be significant at p=0.003.  
Results were expressed as numbers and percentages, mean and standard deviation 
or median and interquartile range. Analyses between groups were performed using 
ANOVA, Kruskal-Wallis, Mann-Whitney, t-test and Chi-squared as appropriate. Data 
over time was analysed by repeated measures (two-way) analysis of variance (for 
parametric data) or by Friedman’s method (for non-parametric data). 
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Figure 35: Study outline of numbers recruited to the serial groups. 
 
 
 
 
 
Results 
 
Clinical and demographic data are shown in table 34. The ‘serial’ group was 
effectively matched to the ‘non-serial’ group, except in sex, CECs and sE-sel levels 
(see table 34 and 35). The unmatched factors were not influenced by Dukes’ stages 
(p=0.630). The differences were probably from multiple testing and therefore not 
knowingly a selected subgroup unrepresentative of CRC. 
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Table 35: Tumour characteristics of the serial versus the non-serial groups 
 
 
All 
Cancers 
Non-serial 
Group 
Serial 
Group P value 
Number  154 86 (56%) 68 (44%)  
Age (SD) years 73 (9) 73 (10) 70 (8) 0.064 
M:F ratio 86:78 37:31 49:37 <0.001 
Diagnosis 
Screening 
Symptomatic 
 
12 
142 
 
7 
79 
 
5 
63 
 
1.00 
Family history of 
CRC* 40 28 12 0.313 
Histological Grade 
Well 
differentiated  
Well/Moderate 
Moderate 
Poor 
 
7 
67 
70 
10 
 
3 
39 
38 
6 
 
4 
28 
32 
4 
 
 
0.857 
Tumour Type 
Adenocarcinoma 
Mucinous     
Unknown 
 
126 
24 
4 
 
79 
13 
4 
 
57 
11 
0 
0.219 
Vascular Invasion 
Yes 
No 
Unknown 
 
29 
96 
29 
 
18 
48 
20 
 
11 
48 
9 
 
0.149 
Dukes’ 
A 
B 
C 
D 
 
19 
54 
49 
32 
 
8 
31 
29 
18 
 
12 
23 
20 
13 
 
0.630 
 
Values were expressed as number of cases and p values by Chi-Squared test. 
* First degree relatives with CRC. SD-standard deviation 
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Table 36: Differences of measured indices of the endotheliome and angiome 
between the serial and non-serial groups before treatment. 
 
 Non-serial Group 
n=86 
Serial Group 
n=68 
P value 
 
    
CEC cells/ml 12 
(0-30) 
10 
(0-20) 
0.295 
EPC cells/ml 24 
(12-45) 
17 
(2-40) 
0.090 
CD34+CD45- x 103 
cells/ml 
0.80 
(0.44-1.18) 
0.79 
(0.55-1.15) 
0.602 
WCC (106/ml) 7.09 
(2.06) 
7.28 
(1.93) 
0.476 
EPC:CEC ratio 1.5 
(1.0-4.8) 
1.1 
(1.0-9.7) 
0.809 
vWf  [IU/dL] 117 
(24) 
121 
(30) 
0.810 
sE-sel [ng/mL] 23 
(16-32) 
30 
(24-37) 
0.003 
VEGF [pg/mL] 180 
(30-610) 
310 
(30-771) 
0.333 
Ang [ng/mL] 321 
(122-376) 
305 
(262-352) 
0.404 
Data presented as mean (standard deviation) or median (interquartile range), p value by t-
test or Mann-Whitney’s with significance <0.05. 
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The results after surgery in the 68 patients are shown in table 36. As hypothesised, 
all measured markers were significantly reduced except sE-selectin (p=0.067 at 3 
months, p=0.973 at 6 months), vWf (p=0.113 at 6 months) and WCC (p=0.176 at 6 
months). This reduction was consistent with the hypothesised effect from ‘debulking’ 
of the cancer. The unchanged indices of EC activation (vWf) were still higher 
(p<0.01) than those of the HC group (table 27).  
 
Table 37: Changes in the measured indices of the endotheliome and angiome 
in all 68 patients before and (3 and 6 months) after treatment. 
 
     
 Pre-treatment 3 months 6 months 
Overall 
P value 
     
     
CEC 
cells/ml 
10 
(0-20) 
0 A* 
(0-10) 
9 B*, C 
(0-11) 
<0.001 
EPC 
cells/ml 
17 
(2 - 40) 
0 
(0-9) 
10 B*, C 
(2-19) 
0.003 
WCC x 106 
cells/ml 
7.29 
(1.93) 
5.39 A* 
(1.47) 
5.76 C* 
(1.67) 
<0.001 
EPC:CEC 
 ratio 
1.1 
(1.0-9.7) 
1.0 A 
(1.0-1.0) 
1.0 B 
(1.0-7.7) 
0.016 
CD 34+ CD45-  
x 103 cells/ml 
0.81 
(0.62-1.24) 
0.83 
(0.62-1.31) 
0.64 
(0.32-0.94) 
0.081 
vWf 
 [IU/dL] 
121 
(30) 
110 A 
(25) 
120 B 
(25) 
0.033 
sEsel 
[ng/mL] 
30 
(24-36) 
28 
(16-32) 
25 C 
(19-32) 
0.567 
VEGF 
[pg/mL] 
310 
(30-771) 
23 A* 
(12-51) 
40 B*, C 
(20-534) 
<0.001 
Ang 
[ng/mL] 
305 
(261-352) 
242 A* 
(179-294) 
323 B* 
(249-396) 
<0.001 
 
Data is presented as mean (standard deviation) or median (interquartile range) and p values 
between time points by ANOVA of repeated measures. P values of < 0.05 were A, B (from 3 
to 6 months) and C (from pre-treatment to 6 months). P values of <0.001 were A*, B* (from 3 to 
6 months) and C* (from pre-treatment to 6 months).  
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Participants who required adjuvant therapy had tumours with local organ invasion, 
perforation, lymph node spread, vascular invasion or distant metastases (285). 
Hence as a group with poor prognostic factors and as hypothesized, significantly 
more perturbed indices were found except of CD34+CD45- cells (table 37).  
 
 
Table 38: Preoperative characteristics of participants after surgery receiving no 
further treatment versus those receiving adjuvant therapy. 
 
 Surgery only 
 
n=16 
Surgery + 
Adjuvant 
treatment 
n=52 P value 
Vascular Invasion 
Yes 
No 
Unknown 
 
0 
16 
0 
 
34 
11 
7 
 
<0.001 
 
Dukes’ 
A 
B 
C 
D 
 
10 
6 
- 
- 
 
2 
17 
20 
13 
 
0.003 
 
CEC cells/ml 4 (0-19) 12 (0-20) 0.002 
EPC cells/ml 14 (0-39) 19 (10-42) <0.001 
CD34+CD45- cells/ml 0.92 (0.64-1.22) 0.83 (0.53-1.22) 0.395 
WCC (106/ml) 6.68 (1.57) 7.47 (2.04) <0.001 
EPC : CEC ratio 1.08 (0.82-18.65) 1.13 (1.00-5.63) <0.001 
vWf  [IU/dL] 115 (22) 123 (31) <0.001 
sEsel [ng/mL] 30 (24-35) 30 (23-37) <0.001 
VEGF [pg/mL] 120 (10-494) 374 (33-1128) <0.001 
Ang [ng/mL] 295 (267-350) 306 (253-357) <0.001 
 
Data presented as mean (standard deviation) or median (interquartile range), overall p value 
by t-test, Mann-Whitney, or Chi-Squared test; significance of p<0.05. 
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For patients undergoing surgical follow-up only (table 38), all indices fell after 3 
months except WCC, sE-sel and vWf. CECs rose after 6 months (p=0.045).  
 
 
Table 39: Research indices in 16 patients in Group 1 (Surgery only) 
 
 Baseline 3 months 6 months P value 
     
CECs (cells/mL) 4 
(0-19) 
0 
(0-9) 
8 
(0-10) 
0.045 
EPCs (cells/mL) 13 
(0-39) 
0 
(0-9) 
8 
(0-10) 
0.036a 
vWf (IU/dL) 115 
(22) 
106 
(19) 
118 
(30) 
0.441 
sE-selectin (ng/mL) 31 
(9) 
26 
(9) 
29 
(11) 
0.302 
VEGF (pg/mL) 120              
(10-494) 
23                  
(6-23) 
16                   
(5-82) 
0.024b 
Angiogenin (ng/mL) 308 
(75) 
235 
(97) 
300 
(96) 
0.061 
CD34+CD45- cells 
(cells/mL) 
0.9             
(0.6-1.2) 
1.1 
(0.7-1.6) 
0.9             
(0.5-1.3) 
0.395 
WCC (x106/mL) 6.7 
(1.6) 
5.7 
(1.7) 
6.2 
(1.3) 
0.175 
 
Data are mean (standard deviation) or median (interquartile range). P value by ANOVA, 
general linear model or Tukey’s post-hoc test. a p<0.05 baseline to 3 month. b p<0.05 
baseline to 3 month and 6 month. 
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There were no significant changes in vWf, sE-sel, angiogenin, CD34+CD45- cells or 
WCC. CECs fell significantly overall, except between 3 and 6 months (figure 36).  
 
 
Figure 36. Serial Changes in CECs: Surgery only. 
 
 
  
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
 a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months 
respectively. Boxes= median, Interval bars= Interquartile ranges. 
 
 
 
 
EPCs and VEGF fell from baseline to 3 months (both p<0.05). At 6 months, VEGF 
remained low (p<0.05), but the EPC was similar to baseline (see figure 37). 
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Figure 37: Serial changes in EPCs & VEGF for Surgical Treatment only. 
 
  
 
 
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
 a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months respectively. 
Boxes= median, Interval bars= Interquartile ranges. 
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The picture was quite different when the indices were examined for those undergoing 
standard chemotherapy after surgery (table 39).  
 
Table 40: Research indices Group 2  (Surgery + chemotherapy), n=32. 
 
 Baseline 3 months 6 months P value 
     
CECs (cells/ml) 12 
(0-19) 
3 
(0-11) 
10 
(0-12) 
0.019a 
EPCs (cells/ml) 16 
(9-44) 
0 
(0-11) 
10 
(8-15) 
<0.001b 
vWf (IU/dl) 123 
(33) 
106 
(25) 
119 
(28) 
0.08 
sE-sel (ng/ml) 34 
(12) 
38 
(9) 
24 
(10) 
0.007c 
VEGF (pg/ml) 320                
(30-1200) 
30                
(20-287) 
30                
(21-310) 
0.001d 
Angiogenin (ng/ml) 282 
(97) 
231 
(93) 
346 
(109) 
<0.001e 
CD34+CD45- cells 
(x 103 cells/ml) 
0.81            
(0.40-1.31) 
0.83              
(0.62-1.21) 
0.74           
(0.44-1.12) 
0.304 
WCC (x106/ml) 7.93 
(2.22) 
5.44 
(1.31) 
5.82 
(2.00) 
<0.001d 
 
Data are mean (standard deviation) or median (interquartile range). P value by ANOVA/general linear 
model/Tukey’s post-hoc test.  ap<0.05 baseline to 3 month point. bp<0.01 baseline to 3 months, p<0.05 
3 months to 6 months. cp<0.05 3 moths to 6 months. dp<0.01 Baseline to 3 months and to 6 months. 
ep<0.05 Baseline to 6 months, p<0.01 3 months to 6 months. 
 
CECs were lower at 3 months (p<0.05), but no different to baseline at 6 months. 
EPCs fell at 3 months (p<0.01) but returned to near baseline at 6 months (p<0.05). 
VEGF were lower at 3 and 6 months (both p<0.01, see figure 39) and sE-sel was 
lower at 6 months versus baseline and 3 months (p<0.05). Angiogenin and WCC fell 
from baseline to 3 months and increased at 6 months (figure 40). 
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Figures 38: Serial changes in CECs and EPCs for 
Surgery + Standard Chemotherapy (n=32). 
 
 
 
 
 
  
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
 a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months respectively. 
Boxes= median, Interval bars= Interquartile ranges.  
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Figures 39: Serial changes in eSel and VEGF for 
Surgery + Standard Chemotherapy (n=32). 
 
 
 
 
  
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
 a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months respectively. 
Boxes= median, Interval bars= Interquartile ranges.  
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Figure 40: Serial changes in Angiogenin and WCC for 
 Surgery + Standard Chemotherapy (n=32). 
 
 
 
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months respectively. 
Boxes= median or mean, Interval bars= Interquartile ranges or standard deviation. 
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Bevacuximab added to the chemotherapy regime is examined in table 40. CECs 
numbers fell to 3 months (p<0.01), then increased to 6 months (p<0.05). EPC and 
VEGF levels fell at 3 months and then increased at 6 months (all p<0.01). There 
were no changes in vWf or angiogenin. The CD34+CD45- cells were lower at 6 
months than at baseline, and the WCC fell at 3 months (figures 41 – 43).  
 
 
Table 41: Research indices in 20 patients: surgery followed by standard 
chemotherapy and anti-angiogenic therapy 
 
 Baseline 3 months 6 months P value 
     
CECs (cells/mL) 21 
(7-60) 
0 
(0-13) 
11 
(7-48) 
0.005a 
EPCs (cells/mL) 21 
(10-39) 
0 
(0-0) 
12 
(7-32) 
<0.001b 
vWf (IU/dL) 121 
(30) 
122 
(26) 
122 
(15) 
0.943 
sE-selectin (ng/mL) 26 
(8) 
22 
(15) 
29 
(12) 
0.195 
VEGF (pg/mL) 500              
(40-1000) 
30                 
(23-55) 
770             
(630-1900) 
<0.001b 
Angiogenin (ng/mL) 319 
(97) 
255 
(117) 
317 
(87) 
0.074 
CD34+CD45- cells 
(cells/mL) 
0.8            
(0.6-1.1) 
0.6            
(0.4-1.1) 
0.3             
(0.2-0.5) 
0.003c 
WCC (x106/mL) 6.7 
(1.5) 
5.1 
(1.7) 
5.3 
(1.4) 
0.003 
 
Data are mean (SD) or median (IQR). P value by ANOVA/general linear model/Tukey’s post-hoc 
test  a p<0.01 Baseline to 3 months, p<0.05 3 to 6 months. b p<0.01 Baseline to 3 months and baseline 
to 6 months. c p<0.01 Baseline to 6 months. 
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Figure 41: Serial changes in CECs and EPCs for 
 Surgery + Standard Chemotherapy + Bevacizumab (n=20). 
 
 
 
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months 
respectively. Boxes= median, interval bars= IQR. 
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Figure 42: Serial changes in VEGF and WCC for 
 Surgery + Standard Chemotherapy + Bevacizumab (n=20). 
 
 
 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months 
respectively. Boxes= median or mean, Interval bars= IQR or S.D. 
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Figure 43: Serial changes in CD34+CD45- cells for 
Surgery + Standard chemotherapy + Bevacizumab (n=20). 
 
 
* Overall p value by value by ANOVA/general linear model/Tukey’s post-hoc test. 
a b c p values by Wilcoxon test between 0 to 3 months, 3 to 6 months and 0 to 6 months 
respectively. Boxes= mean, Interval bars= S.D. 
 
 
 
Relationships were examined between indices regardless of treatment modality. At 
baseline, significant Spearman correlations were of EPCs with CECs (r=0.70, 
p<0.001), VEGF with CECs (r=0.55, p<0.001) and VEGF with EPCs (r=0.69, 
p<0.001). These relationships were still present at 3 months, though less so, at r= 
0.52 (p=0.001), r=0.28 (p=0.019) and r=0.25 (p=0.037) respectively. The latter two 
may be false negatives as they were only powered for r>0.4. At 6 months only CEC 
with EPC (r=0.45, p=0.001) and VEGF with EPCs (r=0.25, p=0.037) were significant. 
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Discussion 
 
At submission, this thesis was the first comprehensive study of a panel of cellular and 
plasma markers of EC activity with CRC treatment. Having found elevated EPCs, 
CECs, angiogenin, VEGF and to a lesser extent vWf in mCRC, the effect of surgery, 
with or without adjuvant treatment, was analysed. This tested the hypothesis that 
levels fell to that of healthy controls at 3 months after surgery and remained low at 6 
months. Debulking of CRC certainly reduced all measured indices at 3 months, 
similarly reported by Goon et al, in breast (24, 140). From the literature, the changes 
of these markers regardless of CRC stage and with adjuvant therapy, was reported 
only for VEGF (456) and vWf (14), though their relevance was inconclusive.  
 
CEC and EPC measurements were isolated to studies on metastatic disease only but 
changes with treatment informed outcome, probably as they reflected Dukes’ Stage 
(28, 143, 201, 463). Cross-comparisons between studies were hindered by the lack 
of consensus on the definitions with the ‘best fit’ of CD markers (217, 268, 399, 465). 
Nevertheless, EPCs, given their partial mobilisation by VEGF, may be good 
surrogates of anti-VEGF treatment, with Matsusaka et al reporting better outcomes 
when levels (CD45-CD31+CD34+CD133+ cells) fell below 0.04% at day 4 of 
treatment (28, 147, 201). Ronzoni measured changes at baseline before 
chemotherapy and then again at the third and sixth cycles, with baseline levels of 
CEC < 40 /ml associated with better outcomes (201). Variable and random time 
points were chosen by other studies on anti-VEGF treatment, probably based on the 
convenience of sampling with each cycle. Nevertheless, most reported pre-treatment 
or baseline levels were better indicators of response (441, 466). The choice of time 
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points in my study was deliberate to avoid the possible effects of chemotherapy on 
EC activity during treatment. Therefore, they were measured before and after 
treatment, except in Dukes’ D disease when treatment continued, hence levels were 
measured while on a break at six months and 2 weeks after the last cycle. 
 
Strikingly, after surgery with or without adjuvant standard chemotherapy and 
regardless of the addition of Bevacizumab, both CECs and EPCs increased nearly to 
that of baseline median levels. This was unexpected given the correlation of both 
markers to VEGF, which, as shown in this study, fell with tumour debulking. The 
correlation with VEGF also continued up to 6 months and more so with EPCs (albeit 
measured in smaller groups). The effect in participants who underwent surgery 
without adjuvant therapy may reflect angiogenesis for physiological repair rather than 
residual tumour (only 1 participant with recurrence at 2 years). This may also 
occurred with the addition of adjuvant therapy or the result of drug-related injury to 
and subsequent repair of the endothelium. Nevertheless, chemotherapy, once 
completed, did not appear to hinder angiogenesis in physiological repair required 
after surgery, as reflected by a rise in EPC levels. 
 
While the WCC generally fell after surgery and remained low regardless of treatment, 
CD34+CD45- cells fell only when anti-VEGF therapy was included with standard 
chemotherapy. The reasons for this were unrelated to EPCs or VEGF (both of which 
were higher at 6 months) and therefore uncertain. As postulated in 5.2.4, the 
CD34+CD45- fraction may include other progenitors e.g. of fibroblasts, and their 
demand in repair, probably from the blockage of angiogenesis, was also reduced. 
Once again this was the first study on this fraction of CD34+ cells and their reduction 
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may be more clinically relevant to the effect of anti-VEGF than measuring VEGF 
alone. That is, tumour excision reduced levels of VEGF in all groups but not in those 
receiving anti-VEGF. The higher levels at 6 months may be a rebound phenomenon, 
as bloods may have been taken after completing Bevacizumab and when the 
therapeutic effect (half-life of 20 days, range 11-50 days) at blocking VEGF was 
significantly diminished (467). Other authors with similar findings could not suggest 
this, presumably as they, like me, did not measure drug and VEGF levels together 
after treatment. Yang et al also reported a paradoxical increase in VEGF and 
plausibly suggested that the ELISAs measured both free and antibody-bound VEGF 
(468). I was unaware of any assay separately measure the two factors. 
 
With angiogenin found to be a good ‘identifier’ of CRC and its stage in this study, 
unsurprisingly it fell at 3 months but inexplicably rose to pre-treatment levels at 6 
months in all groups except in standard chemotherapy for whom levels exceeded 
that of the baseline. This result was not previously reported and, while more likely 
from residual tumour at 6 months, may also have arisen from the effects of treatment 
on other somatic cells (469). Levels of sE-sel and vWf also fell after surgery similar to 
that reported by Gil-Bazo et al and Sato et al respectively (14, 15). Unlike the other 
markers already discussed, the differences were not as apparent and showed no 
clear pattern. This may reflect the poorer capacity of these markers to measure EC 
activity, the damaging effects on ECs by standard chemotherapy with or without 
Bevacizumab, or the unpredictable disturbances to the EC from surgery.  
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In summary, within the limitations of the small numbers of each group, changes with 
some of the measured indices were highly significant though not entirely explicable. 
A fall in CD34+CD45- cells may have clinical importance as a better discriminator of 
the effectiveness of anti-VEGF treatment than EPCs or CECs, both of which fell at 3 
months and rose again at 6 months. Their measurements at two time points after 
treatment were not as informative as levels before surgery. 
 
 
Disease progression and survival are examined next. 
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3.2.2 The Endotheliome and Angiome in CRC Prognosis 
 
 
Abstract 
 
Background: Pre-treatment levels of the markers of the endotheliome and angiome 
individually may predict outcomes after CRC treatment. However their collective 
value was unknown. I hypothesized that the markers together and measured before 
surgery, were important determinants of outcomes than any single test.    
Methods: Peripheral blood from 154 participants with CRC was analyzed before 
surgery. CECs (CD34+CD45-CD146+) and EPCs (CD34+CD45-KDR+) were 
measured by 4-colour flow cytometry and the plasma makers by ELISA. 
Findings: Pre-surgery CECs and EPCs levels were higher in participants with 
recurrence in 2 years. However, Dukes’ and more so mAJCC stages were still the 
best independent predictors of progression free survival (PFS) and time to 
progression (TTP). Mathematical models that combined mAJCC stage with CECs 
and EPCs (when greater than median levels) may predict TTP within 2 years. With 
adjuvant therapy, there were no significant fold changes of CECs, EPCs or 
angiogenin in participants with poorer TTP or PFS outcomes. 
Conclusions: Models incorporating markers of the endotheliome before surgery with 
the CRC stage may better predict progression within 2 years than Dukes’ or mAJCC 
staging alone. As a clinical tool, the models may aid risk stratification and, alongside 
traditional determinants, decisions for adjuvant treatment. 
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Background 
 
Having described the importance of the markers of the angiome and endotheliome in 
CRC staging (sections 3.1.2 & 3.1.3), their value in determining outcomes was 
analyzed. Fewer CECs and EPCs in metastatic CRC were previously reported as 
good predictors of progression (28, 143, 201, 463). A fall in EPCs during treatment 
was associated with improved PFS (28, 147, 201) while Ronzoni et al proposed the 
pre-treatment levels, not the fold changes, as better surrogates (201). Disease 
progression was also associated with levels of VEGF (366), vWf (16, 470), 
angiogenin (364) and less so, sE-selectin ((369). The collective value of these factors 
in predicting outcomes after surgery was unknown. Therefore I hypothesized that, 
when measured before surgery, and regardless of adjuvant strategies, the markers 
together were important determinants of outcomes than any single test. 
 
 
Methods 
 
The markers measured in participants with CRC recruited to test hypotheses 1 to 3 
for the cross-sectional studies, were analyzed. That is, peripheral blood taken before 
surgery was tested by 4-colour flow cytometry for CECs (CD34+CD45-CD146+) and 
EPCs (CD34+CD45-KDR+); the plasma makers were quantified by ELISA assays 
(detailed in section 2.2, the exclusion criteria in section 2.1.3 and the methods of 
sections 3.1.2 and 3.1.4). Data on outcomes were prospectively collected over the 2-
year period after surgery (see details in section 2.3.2, page 102-106). 
3.2.2 Prognosis Study 
199 
	
Statistics 
Data was presented as mean and standard deviation (when normally distributed) or 
median and inter-quartile range (non-parametric distribution). The Chi-squared test 
was used for categorical data. Data was analysed using binary regression and Cox 
proportional hazards were estimated, and outcomes over time presented as Kaplan-
Meier plots. All analyses were performed on SPSS and figures produced by Prism 6 
package. A p<0.05 was taken to assume significance. 
 
Results 
 
Survival 
The cumulative 2-year mortality (OS) is shown on the Kaplan Meier chart, figure 44, 
and was consistent with previous reports (471). OS after 740 days for stages A, B, C 
and D were 100%, 92.6%, 89.8% and 46.9% respectively (p<0.001).  
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Figure 44: Kaplan Meier Plots of 2-year cumulative survival and Dukes’ Stage 
   
 
Progression 
 
Progression for this study, also referred to as TTP, was defined according to the 
widely accepted criteria of Eisenhauer et al (381, 382). It used ‘measurable’ evidence 
(X-rays, USS, CT, MRI, PET-CT or biopsy) of one of the following: 
• Local recurrence or metastases after surgery with curative intent and/or 
• For Dukes’ D, increasing tumour size of involved organs and/or new metastases, 
specifically of at least a 20% increase in the sum of diameters of lesions. 
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Those with disease progression within 2 years were found to have significantly higher 
levels of CECs and EPCs only (see table 41). However both were poor on ROC 
analysis. For CEC > 10 per ml. sensitivity was 59%, specificity 66%, and ROC area 
of 0.621 with p=0.351 LR=1.08; for EPCs > 12 per ml, sensitivity was 67%, specificity 
50%, and ROC area of 0.639 with p=0.110 LR=1.33). 
 
Further  analysis of the indices by binary logistic regression did not reveal any 
correlations with disease progression or histological features of poor prognosis (not 
shown). Only Dukes’ and mAJCC stages remained the best independent predictors 
of recurrence within 2 years (table 45). Both retained significance after adjustment for 
other indices i.e. Dukes’ stage OR was 2.28 (95% confidence interval 1.01-5.14), 
p=0.047; for mAJCC stage OR was 4.78 (1.98-11.55) and p<0.001.   
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Table 42: Pre-treatment markers and CRC progression within 2 years. 
 
 Preoperative Values 
 No Progression  Progression  P value 
Number 103 51  
Sex (male/female) 54/49 32/19 0.225 
Dukes’ stage 
n: Stage A/B/C/D 
17/48/37/1 2/6/12/31 <0.001 
Modified AJCC stage 
n: 1,2,3,4 1 
19/35/44/5 0/6/11/34 <0.001 
Treatment group 
n: A/C/S 2 
18/39/45 11/35/6 <0.001 
CEC cells/ml 10 (0 - 21) 19 (9-29) 0.019 
EPC cells/ml 20 (9-38) 30 (12-61) 0.004 
WCC (106/ml) 6.97 (2.01) 7.60 (1.94) 0.066 
EPC:CEC ratio 0.5 (0-1) 0.5 (0.1-1.0) 0.964 
vWf  [IU/dL] 116 (25) 125 (29) 0.060 
sE-sel [ng/mL] 28 (19-34) 25 (18-34) 0.566 
VEGF [pg/mL] 190 (30-560) 330 (30-778) 0.253 
Ang [ng/mL] 300 (101) 330 (93) 0.069 
 
Data presented as mean with standard deviation, median with interquartile range, or as number of 
patients, analysed by t test, Mann-Whitney or the chi-squared test respectively. 
1 I/IIa+ IIb/ IIIA+IIIB+IIIC‡ /IIIC* + IV.  
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Table 43: Measured Indices and CRC stage in predicting recurrence in 2 years. 
 Odd’s ratio 95% confidence 
interval 
P value 
    
Treatment group 0.86 0.42 – 1.78 0.688 
Dukes’ stage 2.30 1.00 – 5.30 0.049 
Modified AJCC stage 4.62 1.88 – 11.33 0.001 
Angiogenin 1.21 1.01 – 2.17 0.061 
EPCs 1.33 0.87 – 2.03 0.194 
CECs 1.08 0.73 – 1.61 0.700 
 
 
 
CECs and EPCs before surgery followed by adjuvant chemotherapy were higher in 
the progression group (p=0.015 and 0.012 respectively, table 43, figure 45). Once 
again, however,  only Dukes’ and mAJCC were more significant predictors by binary 
logistic regression (not shown), and with ORs similar to that of table 39. 
 
 
 
Table 44: Markers before surgery and 2 year recurrence with adjuvant therapy.  
 
No Progression 
n=85 
Progression 
n=24 P value 
    
CEC cells/ml 10 (0 - 21) 25 (8-48) 0.015 
EPC cells/ml 19 (0-36) 43 (12-55) 0.012 
WCC (106/ml) 6.99 (2.10) 7.72 (1.27) 0.157 
CD34+CD45- cells 0.8 (0.5-1.1) 0.7 (0.6-1.1) 0.559 
vWf  [IU/dL] 116 (26) 115 (11) 0.060 
sEsel [ng/mL] 27 (19-35) 28 (20-34) 0.594 
VEGF [pg/mL] 195 (30-618) 552 (53-1375) 0.196 
Ang [ng/mL] 312 (106) 313 (75) 0.974 
Data presented as mean with standard deviation, median with interquartile range Significance of 
p<0.05 by t-test or Mann-Whitney.  
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Figure 45: Box and Whisker Plots and ROC curves-  pre-treatment CECs (grey) 
and EPCs (red) to predict 2 year recurrence after adjuvant chemotherapy. 
 
		 	 	 	
 
CEC: p=0.015 (Mann-Whitney).   ROC area 0.638 (p=0.017). For > 12 cells/ml 
 Tukey Box & Whisker plots   Sensitivity=78%, specificity=49%, LR=1.8 
	
	
		 	 	 	
 
EPC: p=0.012 (Mann-Whitney)   ROC area 0.687 (p=0.012). For > 22 cells/ml: 
Tukey’s Box & Whisker plots   Sensitivity=78%, specificity=34%, LR=1.3 
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For adjuvant therapy, fold changes for CECs or EPCs were not significant (figure 46). 
 
Figure 46: Fold changes of CECs and EPCs after adjuvant chemotherapy. 
 
 
 
 
 
 
 
P= progression, N= no progression. Median shown as box, and IQR as interval bar. No significant 
differences  between progressive and non-progressive disease groups (Mann Whitney or t-test).   
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The relationship of the indices with other definitions of outcomes was analysed. 
Having examined progression (TTP) and survival (OS), PFS was also tested for the 
relationship with the indices relative to their median and  tertile levels. 
  
The progression free survival (PFS) rates after 740 days for Dukes’ stages A, B, C 
and D was 100%, 92.6%, 89.8% and 46.9% respectively (median 740, 418, 156 and 
116 days respectively, p<0.001). The PFS after 740 days for mAJCC stages 1 to 4 
were similar to Dukes’ stages: 100%, 92.6%, 91.1% and 50.0% respectively (mean 
times were 740, 418, 198, 110 days respectively, p<0.001). 
 
First, outcomes over the 740 days relative to the median levels of the indices were 
analysed. Significant outcomes for TTP and PFS were found with comparisons 
above and below the median values of CEC, EPC and angiogenin (see table 44). 
Kaplan Meier (cumulative survival) charts are in figure 46. Only CECs>12 /mL and 
EPCs >22 mL were significantly associated with poorer TTP and PFS over 2 years. 
Angiogenin > 308 ng/mL was also associated with poorer PFS outcomes only.   
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Table 45: Survival/progression analyses above/below median of indices. 
 
  
< > 
Median/
mean 
p values 
Number 
Time to 
Progression 
(TTP) 
Overall 
Survival 
(OS) 
Progression 
Free Survival 
(PFS) 
      
CEC 
(cells/mL) 
86 
68 
≤ 12 
> 12 
0.002 0.884 0.015 
EPC 
(cells/mL) 
79 
75 
≤ 21 
> 21 
0.008 0.554 0.017 
vWf 
(IU/dL) 
79 
75 
≤ 114 
> 114 
0.853 0.844 0.786 
sE-sel  
(ng/mL) 
81 
73 
≤ 27 
> 27 
0.172 0.304 0.098 
VEGF 
(pg/mL) 
78 
76 
≤ 195 
> 195 
0.455 0.947 0.541 
Angiogenin     
(ng/mL) 
77 
77 
≤ 308 
> 308 
0.088 0.095 0.020 
P values obtained from cumulative survival over time by Kaplan Meier method (log rank). WCC and 
CD34CD45- cells were excluded - no significant findings and not part of the hypothesis. 
 
The cumulative survival charts are shown for CECs and EPCs in figure 46.  
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Figure 47: Time to progression (TTP) over 2 years relative to median CEC 
(grey) and EPC (red) levels. 
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Next, the survival/progression over 2 years was analysed against tertiles of the 
measured indices (table 48). CECs (p=0.008) and EPCs (p=0.049) levels were not as 
significant by log rank analysis against their performance above and below median 
levels (p of 0.002 and 0.008 respectively, figure 46). However PFS was worse when 
angiogenin was >350ng/ml (see figure 48). 
 
Table 46: Survival and progression analyses by tertiles of measured indices 
   p value 
 Number Tertiles TTP OS PFS 
      
CEC 
(cells/mL) 
51 
49 
54 
< 7 
7 – 19 
> 19 
0.008 0.738 0.026 
EPC 
(cells/mL) 
47 
55 
52 
< 12 
12 – 35 
> 35 
0.049 0.273 0.396 
vWf 
(IU/dL) 
50 
51 
53 
< 108 
108 – 122 
> 122 
0.208 0.937 0.347 
sE-sel  
(ng/mL) 
48 
52 
54 
< 20 
21 – 30 
> 30 
0.350 0.382 0.214 
VEGF 
(pg/mL) 
50 
52 
52 
< 80 
80 – 499 
> 499 
0.190 0.362 0.123 
Angiogenin    
(ng/mL) 
51 
52 
51 
< 279 
279 – 350 
> 350 
0.021 0.032 0.002 
      
Tertiles were genrerated from SPSS and p values of cummulative survival by Kaplan Meier method. 
WCC and CD34+CD45- cells were excluded as there were no significant findings and were not part of 
the original hyoptheses. 
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Figure 48: Angiogenin tertiles and progression free survival (PFS). 
 
 
In summary, CECs and EPCs were significantly higher pre-surgery for participants 
with disease progression within 2 years but Dukes’ or modified AJCC stage remained 
the best independent predictors. CECs>12 /ml and EPCs >22 ml may be useful to 
predict progression (TTP), and angiogenin >350ng/ml poorer PFS outcomes. 
 
From the results above a mathematical model was developed to test whether the 
indices, when combined with Dukes and mAJCC stage improved their prognostic 
value by identifying those with potentially poorer TTPs and PFS. For TTP, levels with 
CECs>12/ml were assigned ‘1’ which was added to Dukes’ and mAJCC. Similarly 
this was also done for EPC (>22 cells/ml) and for PFS angiogenin levels >350ng/ml. 
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The composite stage was then tested against disease recurrence, death and all 
events (see table 48). For example EPCs of 30/ml, scored 1 and added to the stage, 
such as Dukes’ 3 (C) or mAJCC 4, giving a score of 4 and 5 respectively. 
 
Table 47: Performance of mathematical models against Dukes’ and AJCC in 
predicting time to progression and progression free survival. 
 
 MODEL r A p A  OR B p B  
        
 Time to Progression (TTP)  
        
 Model1       
 Dukes’ 0.611 <0.001  0.5 (0.1-2.1) 0.371  
 mAJCC 0.631 <0.001  4.3 (1.7-10.8) 0.002  
 Dukes’+CEC1 0.632 <0.001  2.0 (0.7-5.6) 0.189  
 Dukes’+EPC2 0.618 <0.001  2.3 (0.7-5.3) 0.116  
 Dukes’+CEC1+EPC2 0.608 <0.001  2.1 (1.2-3.8) 0.010  
        
 Model 2       
 mAJCC 0.631 <0.001  2.0 (1.1-5.8) 0.210  
 Dukes’ 0.612 <0.001  2.5 (1.0-5.6) 0.031  
 mAJCC+ CEC1 0.630 <0.001  2.0 (0.7-5.7) 0.189  
 mAJCC+ EPC2 0.636 <0.001  2.2 (0.8-6.3) 0.116  
 mAJCC+ CEC1+EPC2 0.612 <0.001  2.1 (1.1-3.8) 0.010  
        
        
 Progression Free Survival (PFS)  
        
 Dukes’ 0.584 <0.001  1.7 (0.5-6.6) 0.421  
 mAJCC 0.598 <0.001  3.5 (1.5-7.9) 0.003  
 Dukes’+Ang3 0.545 <0.001  1.2 (0.5-2.9) 0.686  
 mAJCC+Ang3 0.571 <0.001  1.5 (0.5-3.8) 0.203  
        
 
A Spearman’s correlation for r and p values. B Binary logistic regression for Odds Ratio (OR) and p 
values. 1 CECs>12 /ml. 2 EPCs >22 ml. 3 Angiogenin >350ng/ml.   
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As with disease recurrence, mAJCC was more predictive of TTP and PFS. However 
the model incorporating thresholds of CECs and EPCs (i.e. a score of 0 if <median or 
1 if >median) to the stage (1 to 4) was more predictive of TTP (p=.010 versus 
p=0.210 of mAJCC only). The Dukes’ model that combined the same thresholds did 
not perform (p=0.010) as well Dukes’ stage only (p=0.003).  
 
However on principal component analysis, those with above median values of CECs 
and EPCs, above upper tertiles of angiogenin and with poorer mAJCC stage had 
poorer PFS and TTP within 2 years than mAJCC or Dukes’ stage alone (figure 48). 
 
 
Figure 49: prinicipal component analysis of CRC recurrence in 2 years and the 
mathematical models of EPCs, CECs and angiogenin with CRC stage 
 
 
 
 
 Eigenvector Correlation 
mAJCC+EPC+CEC (F2) 0.261 0.957 
mAJCC+EPC+CEC+Ang (F1) 0.263 0.962 
mAJCC 0.241 0.884 
 
Scores of the indices (0 or 1) are added to the mAJCC stage (1 to 4). Score of 1 if angiogenin>upper 
tertile; 1 if CEC > median level; and 1 if EPC >median values. 
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Unfortunately the level of the score for any of these models with potentially 
informative outcomes could not be analysed as the number of subgroups (6 in total, 
but derived from 16 permutations) of these ‘mathematical stages’ were inadequately 
powered (r>0.40) and potentially open to significant type 1 or 2 errors.  Also, a point 
component analysis did not add any further information to the regression analysis. 
 
The temporal relationship of CECs and EPCs with TTP, and angiogenin with PFS 
was examined by the treatment modality. The numbers showing progression within 2 
years were generally small and therefore open to type 1 error. The results were 
however included as studies in the published literature also involved small but similar 
sized groups undergoing adjuvant treatment by standard chemotherapy with or 
without Avastin®. Generally there were no differences between the progression and 
non-progression groups (see figure 49). For progression in those who underwent 
Avastin® therapy, the fold changes of EPCs were significantly lower at 6 than 3 
months when compared to baseline (p=0.039). This was not found on standard 
chemotherapy. Therefore, the changes were influenced by anti-VEGF treatment. The 
relationship of PFS with tertiles of angiogenin was not reproduced on ratio analysis. 
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Figure 50: CECs and EPCs in TTP, and angiogenin in PFS for adjuvant 
chemotherapy with and without Avastin® (Bevacizumab). 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
P= progression & N= no 
progression, within 2 years. 
Median is shown as box, and 
IQR as interval bar. Only EPCs 
were higher with progression 
(TTP) while on avastin (p=0.039 
by Mann Whitney). Angiogenin 
showed no fold change patterns 
in PFS in either groups.	
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Discussion 
 
The measures of the endotheliome and angiome in my study were hypothesised to 
predict outcomes when tested before surgery. Having found ordered trends with 
Dukes’ and mAJCC stages, CECs, EPCs and angiogenin were further hypothesised 
to be markers of prognosis. A number of definitions of outcomes were reported for 
cancer therefore analysis was performed on several levels: progression (TTP), PFS, 
and OS. Oncologists often utilise the prognostic score put forward by Köhne et al for 
clinical trials to select patients for aggressive therapeutic strategies. The score 
incorporates the performance status [PS], number of metastatic sites, alkaline 
phosphatase [ALP] level, and white cell [WCC] count (472). This was not calculated 
in my study as participants with WCCs above 14x109 cells/L were excluded to avoid 
missed EC events on flow cytometry. That is, the assay was more likely to reach a 
target of 1 million with a highly populated specimen and less likely to analyse a 
sufficient volume to find rare events. Disease progression, proposed by Parulekar 
and Eisenhauer (382), and later revised under the RECIST guidelines (381), was 
defined as evidence (on radiology or histology) after resection (with curative intent) of 
recurrence or metastasis. To my knowledge my thesis was the first to show a 
correlation of CECs and EPCs with 2-year progression for CRC at any stage, 
although it was less predictive than Dukes’ or mAJCC staging systems.  
 
Published studies on cellular markers were mainly in metastatic CRC, and 
comparisons with my cohort were limited. Understandably with better long-term 
outcomes from CRC treatment (5 year survival improved by 10% over two decade), 
there was a clear attempt in the published literature to use EC markers to improve 
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predictions of and guidance on chemotherapy (3, 11, 14, 15). Lin et al promoted an 
indirect measure of early circulating endothelial progenitors (CEPs, not EPCs) by real 
time PCR (RT-PCR) measurement of CD133 mRNA in peripheral blood monocytes 
to replace cumbersome cell sorting techniques by IMS (351). While FC superseded 
RT-PCR over the years, theirs was the first to measure markers of CECs/CEPs 
relative to CRC stage and survival outcomes. Although they could not estimate the 
number of CEPs from CD133 mRNA quantification, they showed poorer survival and 
recurrent disease (ROC area 0.81, p<0.05) when levels were above the median 
threshold. This was a relatively small study and not powered to test its performance 
against each Dukes’ stage, though a significant difference of the combined Dukes’ 
A+B was found against C+D, (OR 17 [1.8-154.1]). Mehra et al found similar 
correlations with CD133 mRNA, and not CD146 mRNA, positive monocytes (CD146 
being the better marker of ECs), to metastasis and survival (473). Critically neither 
study measured the degree of CD133 loss in their monocyte fraction, if at all, as it 
was known to quickly downgrade with EPC maturity in the circulation (169). 
Assuming a correlation of the CD133 cellular expression with its mRNA precursor 
(though not proven by the authors) false positives may have arisen from tumour cells 
or, as with errors of CEC identification, from EC carcasses and/or circulating 
microparticles (391, 474).  
 
The effect of standard chemotherapy on the cellular markers and outcomes was also 
not previously reported. Goon et al found correlations with prognostic indices of non-
metastatic breast cancer, the highest CECs found in the poor prognostic group 
(PPG), though long-term outcomes were not reported (24). My study confirmed that 
while CECs and EPCs were significantly elevated before surgery, Dukes’ and the 
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mAJCC staging system remained the best predictors of outcomes as measured by 
TTP, PFS and OS. There were no publications of this kind to corroborate the 
findings, as most were limited to the temporal relationship before and during 
chemotherapy, specifically anti-VEGF, for mCRC only (28, 201). Understandably the 
traditional endpoints by CT scan to monitor response to chemotherapy both routinely 
and in the clinical trial setting could not differentiate responders until after treatment 
was initiated, and typically many months later. Anti-VEGF is more cytostatic than 
cytotoxic, but had a noticeable impact on progression and survival.  CT scan findings 
of non-progressive disease alone would not discriminate those with better PFS (201, 
468). Studies on CECs and EPCs as surrogate markers of responders to 
chemotherapy were encouraging. For mCRC, longer PFS was found in participants 
with lower CECs (< 40 cells/ml) before receiving the combination of first line 
chemotherapy (5-FU with folinic acid) and bevacizumab (201). A fall in CEPs below 
0.04 % after day 4 of Bevacizumab correlated to longer PFS (p<0.001) and OS 
(0.002), a valuable change that may identify better responders to anti-VEGF (28). 
 
Willet et al reported the first phase II study on adjuvant Bevacizumab for localised 
non-metastatic rectal cancer and found that higher CECs after treatment were 
significantly associated with poorer outcomes (475). A higher number of CECs was 
also noted with residual disease and with the inflammatory marker IL-6. The authors 
used a novel technique to measure intra-tumour interstitial pressures with a needle 
connected to the tubing of an endoscope channel, though the methodology required 
further evaluation. In theory this tested the leakiness of the EC and/or the disordered 
architecture in which higher pressures were found, a factor associated with poorer 
tumours (476). However, unlike their study, I found, along with EPCs, correlations 
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with VEGF continued from baseline to 3 months after surgery and again after 
adjuvant treatment.  The complete results of QUASAR 2 trial on the effect of 
Bevacizumab to 5-FU in the adjuvant setting were not available at submission of my 
thesis (477). However preliminary reports were of better PFS for stage II CRC. This 
contrasted with the AVANT and NSABP C-08 trials, as both showed no benefit of 
Bevacizumab with FOLFOX regimes for stage II and III CRC (477-479). 
 
The FNCLCC ACCORD trial of combining first-line chemotherapy with Bevacizumab 
for mCRC reported that higher CECs at baseline and after one cycle correlated to 
better 6-month PFS (for CEC> 23/ml log rank p=0.02) (349). Objective response rate 
(ORR i.e. at least 2 independent CT reports of reponse) also improved. ORR was not 
explored in my study, as it was not the policy of the NHS hospitals to examine CT 
scans by 2 or more radiologists. I found that only progression (TTP), not PFS 
(progression and/or mortality) associated with higher CECs across all 4 stages. The 
PFS analysis with CECs and EPCs in Dukes’ D only was not as reliable given the 
small subgroups involved (15 cases of good PFS versus 17 with poor PFS: p=0.282 
for CECs and 0.120 for EPCs by Mann Whitney).  
 
I would agree with Malka et al (349) and Willet et al (475) of the need for larger in-
depth studies. However, my findings suggested some value in measuring CECs and 
EPCs to identify those at risk of recurrent disease within 2 years after surgery (with 
curative intent) followed by adjuvant chemotherapy (for CECs ROC area=0.638, 
p=0.017 and EPCs ROC=0.867, p<0.001). Specifically, as preoperative test, above 
median levels may be valuable indicators for adjuvant therapy in those without poor 
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histological features such as lymph node spread, poor differentiation, vascular 
invasion or local invasion (section 1.4.2). 
 
I was unable to reproduce the relationship between VEGF and disease progression 
described by Poon et al, and could not offer plausible reasons for the differences 
(366). There may be more value in measuring tissue expression rather than serum 
concentration as proposed in the first meta-analysis of its role as a marker in CRC 
(284). Liu et al reported on their angiogenic assessment of mCRC by a panel of EC 
markers, including sE-selectin and vWf, which stratified survivors into low- and high-
risk groups before and after various chemotherapy regimes (470). Though not the 
authors’ intention, the study gave further evidence to the predictive value of 
measuring the endotheliome and angiome. Damin et al also reported links between 
baseline vWf to OS and PFS (16). I also found very high levels of vWf in Dukes’ D 
stage only but outcome analyses with or without treatment were unyielding. While 
there was growing evidence of the role of sE-selectin in promoting haematogenous 
metastasis via EC recognition of carbohydrate ligands and cancer survival by death 
receptor-3 mediated pathways, circulating levels had limited prognostic value (369, 
480). sE-selectin fell, though not significantly, after surgery, but was unpredictable 
after adjuvant therapy and as reported by Uner et al (78), not correlated to OS. The 
findings of Ito et al as a biomarker of CRC were not reproduced in my study (369). 
 
As shown in section 3.1.4, angiogenin was highly predictive of CRC and rose 
significantly with disease stage on trend analysis. Shimoyama et al showed sera 
levels of angiogenin reflected its distribution and genetic expression in CRC tissues 
(364). The mean serum angiogenin was significantly higher in CRC patients versus 
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healthy controls and significantly higher in mCRC. Though a small study it showed a 
correlation with high serum angiogenin and worse DFS at 5 years [p=0.03].  I also 
found a similar correlation with tertile levels above 350 ng/mL (p=0.002) but for PFS 
within 2 years, a finding not previously reported. Like EPCs and CECs, angiogenin 
were not better than Dukes’ or mAJCC at predicting TTP, PFS or OS.  
 
Overall, the markers chosen were not correlated to prognosis, which brought into 
question either the choice of markers or the value of multi-parameter assessment of 
EC activity. The recent study of Liu et al may offer a better panel including VCAM-1, 
TSP-1, IL-8, MMP-2 and angiogenin-2 for OS, and vWf with angiogenin-2 for PFS 
(470). It was however limited to mCRC and did not include cellular markers. In my 
study, combining EPCs and CECs with mAJCC, was better than mAJCC alone at 
predicting progression (by TTP) on mathematical modelling. That is, restaging by 
adding to the mAJCC stage (1-4) a score of 1 for CECs>12/mL and 1 for 
EPCs>22/mL, [OR (CI) of 2.1(1.1-3.8), p=0.010] performed slightly better against the 
mAJCC only [OR (CI) of 2.5(1.0-5.6), p=0.031]. When principal component analysis 
was applied to the mathematical models, the combination of mAJCC with tertiles of 
CECs, EPCs and angiogenin correlated to TTP and PFS. While the findings were 
promising, my study was not powered to determine the predictive value of this 
restaged model as it was scored out of 6 and derived from 16 possible permutations.  
 
In summary, CECs and EPCs were associated with poor TTP and angiogenin with 
poor PFS. Mathematical models combining angiogenin, CECs and EPCs, with the 
mAJCC may better predict TTP and PFS than mAJCC alone.  
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Chapter 4 
Conclusions 
 
4.1 Summary of findings 
 
In section 3.1.1, I found that circulating endothelial and progenitor cells were elevated 
in CRC regardless of its stage. Although CECs strongly correlated to EPCs and were 
comparable to the stable coronary artery disease (SCAD) group, EPCs were higher 
in CRC only and therefore a better biomarker of the disease.  
 
In section 3.1.2, I found that cellular markers had prognostic but not predictive value 
for disease severity as CECs and EPCs showed positive trends with increasing 
cancer differentiation, Dukes’ stage and mAJCC classification. 
 
In section 3.1.3, the relationship of the markers of endotheliome and angiome were 
analysed. VEGF and angiogenin were higher in CRC compared to controls. Only 
VEGF was linked to CEC and EPC levels. Angiogenin, more so than VEGF and 
EPCs, was the best biomarker of CRC. Angiogenin, independent of CECs and EPCs, 
had a positive trend with stage. Though the markers were not predictive of the stage, 
the relationship of angiogenin with Dukes’ remained after ordinal regression. 
 
In section 3.1.4, all measured indices fell after surgery (3 months) but some rose 
unpredictably at 6 months following adjuvant therapy.  CECs and EPCs rose 
regardless of the adjuvant regime. Standard chemotherapy, but not Bevacizumab, 
increased VEGF above post-surgery levels. Correlations between these three indices 
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at 6 months suggested disturbances to EC activity unrelated to tumour activity, 
assuming complete response to treatment. This may therefore have been the 
consequence of the adjuvant chemotherapy or unresponsive and undetected cancer. 
 
In section 3.1.5, pre-treatment indices were of some value in predicting outcomes. 
Higher pre-surgery levels of CECs, EPCs and angiogenin were associated with 
poorer time to progression (TTP) and progression free survival (PFS) at 2 years. 
However Dukes’ and more so mAJCC stages were the best independent predictors 
of both outcomes. Nevertheless, a mathematical model incorporating scores for the 
mAJCC stage, CECs and EPCs (above the median levels of this study) and 
angiogenin (above the upper tertile levels) may predict TTP and PFS within 2 years. 
For those on adjuvant treatment, there were no significant fold changes of markers 
that distinguished participants with poorer outcomes. 
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4.2 Recommendations for the future 
 
Over the last few decades, studies on CECs and EPCs contributed significantly to 
the understanding of angiogenesis in cancer and consequently their clinical value as 
measures of treatment outcomes. Yet, there was no consensus on their phenotypic 
identity. To move forward, and determine the importance of CECs and EPCs beyond 
the findings of my thesis, I propose my choices, as supported by other authors, to be 
the best definitions for studies using multi-channel flow cytometry (24, 139, 140). 
 
In this thesis I demonstrated the importance of the endotheliome and angiome in the 
vascular biology of CRC staging and, potentially, of its prognosis. Angiogenin may 
hold diagnostic value, while high levels of vWf, EPCs and CECs may reflect 
metastastic disease. However, these markers may have been influenced by 
cardiovascular disorders, such as coronary artery disease (CAD), though not 
significant on regression analysis. Both CRC and coronary disease occurred in 
patients at a similar age range, and may be concurrent, but not always detected. 
While I did not find any influence of CAD on the markers in CRC, a powered study of 
risk factors for CAD would better determine the influence of confounders on the 
measured markers. Though not initially intended in my study, CD34+CD45- cells 
overall were higher in SCAD than CRC, which may have both diagnostic and 
prognostic importance, and again require a large-scaled study. Further in vitro 
characterisation and differential content of these cells, other than EPCs, will support 
their distinct roles, if any, in SCAD as well as CRC. 
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Given I found increased levels in an ordered trend with CRC differentiation and 
stage, EPC may hold therapeutic advantages. Conceptually, vessel heterogeneity 
from disordered angiogenesis, promoted by hypoxia in rapidly growing tumour cells, 
effectively hampered drug delivery (481). Normalising these vessels, as seen with 
anti-angiogenic therapy, may overcome this problem (482). Therapeutic EPCs, given 
their role in vasculogenesis and potentially for vessel repair in CAD (483), may aid 
the normalisation process and therefore deserves further in vitro investigation. 
Alternatively, their affinity to tumour vasculature (209) may deliver targeted therapy, 
once engineered as vectors of anti-angiogenic drugs (484).  
 
I did not have the power to investigate the role of the endotheliome and angiome in 
predicting outcomes of the numerous modalities of adjuvant therapy. This, as well as 
the value of measuring levels before surgery versus at several time points during or 
after adjuvant therapy warrants a large-scaled comparative cohort study. 
Modifications to the array of markers may yield more information. For example, other 
EC-specific markers associated with CRC outcomes, could replace sE-selectin, such 
as NO or eNOS. Akbulut et al proposed an angiogenic index of VEGF and NO 
independently predicted survival and better DFS outcomes for operable CRC (49). 
 
Angiogenin, EPCs and CECs may determine long-term outcomes beyond 2 years. 
Their importance, particularly in the mathematical model incorporating their pre-
treatment levels with mAJCC stage, also need further evaluation, ideally by 5-year 
endpoints of progression (TTP, PFS) and survival (OS).  
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4.3 Conclusion 
 
 
The investigations of the chosen markers of endothelial activity further contributed to 
the understanding of the vascular biology of colorectal cancer and its staging. It may 
inform on concurrent dysfunction of the EC in undetected cardiovascular disease. 
Angiogenin was diagnostic of the CRC but required further evaluation against other 
cancers. EPCs, given the relationship to tumour differentiation and stage, may have 
therapeutic implications in anti-angiogenesis. Both, along with CECs and the mAJCC 
stage, predicted cancer progression within 2 years. The prognostic value may 
improve by expanding the panel to include other EC biomarkers, such as nitric oxide. 
Therefore the endotheliome and angiome is worthy of further study. 
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Appendix 1: QUASAR 2 Trial 
A multicentre international study of capecitabine ± bevacizumab as adjuvant 
treatment of colorectal cancer. 
EudraCT number:  2005-000629-32           Sponsor: University of Oxford 
Chief Investigator: Prof David Kerr 
 
This trial summary was downloaded from the The Oncology Clinical Trials Office 
(OCTO) website, Oxford. http://www.octo-oxford.org.uk. 
 
QUASAR 2 is a study comparing 'standard' chemotherapy using capecitabine, 
against capecitabine + Avastin® (bevacizumab) with the expectation that adding 
bevacizumab to capecitabine may have the potential for improved relapse free and 
overall survival compared to capecitabine alone. Initial results from the Cancer 
Research UK website suggested benefit to disease free survival to stage II disease. 
 
STUDY STATUS 
Recruitment into QUASAR 2 is now closed. 
Primary endpoint (3Y DFS stage II & III) target of 1892 patients: met 26 May 2010.  
Secondary endpoint (3Y DFS stage III only) target of 1411 stage III patients: 1206 
randomised by close of recruitment  (Oct 2010).  
Number of active sites: UK - 123, Non-UK - 61 (Sep 2010)  
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KEY DATES  
Accrual completed 13th October 2010 
Planned study completion: September 2014 
 STUDY SCHEMA 
 
 
INCLUSION CRITERIA 
• Histologically proven stage III (stage T2, T3 or T4) and stage II (any one or 
more of the following – stage T4, lymphatic invasion, vascular invasion, 
peritoneal involvement, poor differentiation, obstruction and perforation of the 
primary tumour during the pre-operative period) colorectal cancer (expected 
ratio 70%:30%). N.B Patients can be Stage II, T3 as long as they have one of 
the other poor prognostic features. For the purposes of stratification, rectal 
cancers will be anything below the peritoneal reflection.  
• Patients must have undergone complete resection of the primary tumour 
without evidence of residual disease. 
• Patients must be randomised to start treatment a minimum of 28 days and 
maximum of 70 days* after surgery. [If a subject has had a major surgical 
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procedure, open biopsy, or significant traumatic injury within 28 days prior to 
study treatment start, or there is the anticipated need for major surgical 
procedure during the course of the study they are not eligible]. 
• WHO Performance Status 0 or 1. 
• Male or female outpatients age >= 18 years. 
• Written informed consent given. 
• Life expectancy of >=5 years, in terms of non-cancer-related morbidity. 
 
EXCLUSION CRITERIA 
• Previous chemotherapy, immunotherapy or infra-diaphragmatic radiotherapy; 
or patients who are expected to require radiotherapy to these sites within the 
next 12 months, for any reason.  
• Received any investigational drug or agent/procedure, (i.e. participation in 
another treatment trial) within 4 weeks of randomisation.  
• Moderate or severe renal impairment [creatinine clearance <30ml/min 
(calculated according to Cockroft-Gault formula–see Appendix 4).  
• Any of the following laboratory values (tests must not have been carried out 
more than 2 weeks prior to randomisation): 
         a. Absolute neutrophil count (ANC) <1.5 x 109/L  
         b. Platelet count < 100 x 109/L  
         c. Total bilirubin > 1.5 ULN  
         d. ALT, AST > 2.5 x ULN  
         e. Alkaline phosphatase > 2.5 x ULN (ULN = Upper Limit of Normal)  
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• Patients requiring chronic use of full dose oral or parenteral anticoagulants, 
high dose aspirin (>325mg/day), anti-platelet drugs or known bleeding 
diathesis. Low dose aspirin is allowed.  Low dose clopidogrel (≤75mg) is 
allowed. 
• Proteinuria > 500 mg/24 hours.  
• Known coagulopathy.  
• Clinically significant cardiovascular disease [i.e. active; or <12 months since 
e.g. cerebrovascular accident, myocardial infarction, unstable angina, New 
York Heart Association (NYHA) grade II (see Appendix 14) or greater 
congestive heart failure, serious cardiac arrhythmia requiring medication; or 
uncontrolled hypertension].  
Concomitant treatment with sorivudine or its chemically related analogues 
such as brivudine.  
• Pregnant (positive pregnancy test within 7 days of starting treatment), or 
lactating women.  
• Sexually active patients of childbearing potential not using adequate 
contraception (male and female).  
• Previous malignancies other than adequately treated in situ carcinoma of the 
uterine cervix or basal or squamous cell carcinoma of the skin, unless there 
has been a disease free interval of at least 10 years.  
• Lack of physical integrity of the upper gastrointestinal tract, malabsorption 
syndrome or inability to take oral medication.  
• Chronic inflammatory bowel disease and/or bowel obstruction and/or active 
peptic ulcer, either of which have been active or required medication in the last 
2 years. 
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• History of uncontrolled seizures, central nervous system disorders or 
psychiatric disability judged by the investigator to be clinically significant 
precluding informed consent or interfering with compliance for oral drug intake.  
• Patients with known allergy to Chinese hamster ovary cell proteins or other 
recombinant human or humanized antibodies or to any excipients of 
bevacizumab formulation; or to any other study drugs.  
* Calculation of these dates is based on date of surgery being day 1.  
** Women of childbearing potential randomised to receive bevacizumab are required 
to have a serum pregnancy test at baseline (i.e. prior to starting treatment).  
Postmenopausal women must have been amenorrheic for at least 12 months to be 
considered of non-childbearing potential. 
 
STUDY OBJECTIVES 
Primary:  Disease free survival (DFS) 
Secondary:  Overall survival (OS) & side effect profile 
 
KEY DATES 
Planned accrual completion: September 2010 
Planned study completion: December 2013  
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Appendix 2: Diagnosis and Staging of CRC 
 
CRC is identified by tumour biopsy at colonoscopy or sigmoidoscopy (285). Along 
with a physical examination, therapy is guided by staging with colonoscopy (after 
sigmoidoscopy) for synchronous tumours, and/or radiology (CT, MRI, PET) to identify 
metastatic disease (314). Staging is an estimate of the penetration into the bowel 
wall and distant spread to determine the best method of treatment. It determines the 
extent of local invasion, lymph nodes involved and metastasis, if any (285). It may 
require abdominal ultrasound, PET scanning, and, in the case of rectal tumours, MRI 
and endo-anal ultrasound (314). MRI gave good global staging of rectal cancers, 
margin involvement, extramural venous invasion, indication for radiation treatment 
and pelvic node spread (286). Though few contraindications, there were limitations 
when correlating radiological with pathological findings postoperatively. Endorectal 
ultrasound has similar advantages except that it is user-dependent, gives little 
information on node status and cannot assess nodal or vascular invasion. CT and 
PET may determine distant spread to other organs specifically lymph nodes, liver 
and lungs (294). The future of the non-invasive assessment of angiogenesis/tumour 
vasculature probably lies with dynamic MRI with tumour EC specific contrast but the 
parameters to be assessed are still undecided (315). It would therefore follow that 
definitive staging can only be achieved after excision and with histopathology. The 
exceptions were endoscopic excision of a polyp cancer, and advanced disease not 
suitable for surgery (314). The two key methods of staging are the Dukes’ and AJCC-
TNM systems, as shown below. 
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Dukes’ system 
 
The classification, described in 1932 by Dr. Cuthbert Dukes, identified 4 stages (316) 
and was the forerunner to TMN. It is reported routinely in the UK as it informed 
prognosis and the need for further oncological treatment. 
 
 
Dukes’ Classification of CRC Stage based on histological staging 
 
Stage Description 
A Tumour confined to the intestinal wall 
B Tumour invading through the intestinal wall 
C With lymph node(s) involvement. This is further subdivided into: 
 C1 - apical node is not involved 
 C2 - apical lymph node is involved 
D With distant metastasis 
 
 
 
This has stood the test of time as stage correlated with 5-year survival (table 13).
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TNM system 
 
The most common staging system is the TNM (for Tumours/Nodes/Metastases) 
system, from the American Joint Committee on Cancer (AJCC), shown below. 
 
 
TNM Classification of Colorectal Cancer 
T N M 
Level of invasion of the bowel wall Nodes 
involved 
Metastases 
      
T0  no evidence of tumour  N0 No 
Nodes 
M0 No metastases 
      
Tis Cancer in situ tumour without 
invasion 
N1 1 to 3 
Nodes 
M1 Metastases 
      
T1 Invasion through muscularis 
mucosa into submucosa 
N2 4 or more   
      
T2 Invasion through the muscularis 
propria into subserosa but not to 
neighbouring tissues 
    
      
T3 Invasion through the muscularis 
propria into subserosa but not to 
neighbouring tissues 
    
      
T4 Invasion of surrounding structures 
or on the free external surface of 
the bowel  
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TNM is usually quoted as a stage I, II, III and IV, roughly equivalent to Dukes’ A, B, 
C, and D respectively. The higher the stage the more advanced the CRC and, 
therefore, more likely have a poorer outcome or 5 year survival (below). 
 
Dukes', AJCC-TNM Stage and 5-Year Survival Rates 
Dukes' Dukes’ 5 yr survival % 
AJCC 
Stage T N M 
AJCC 5 yr 
survival % 
na na 0 Tis N0 M0 — 
A 93 I T1, T2 N0 M0 97 
B 77 IIA T3 N0 M0 88 
  IIB T4 N0 M0 72 
C 47 IIIA T1, T2 N1 M0 88 
  IIIB T1, T2 N2 M0 68 
  IIIB T3 N1 M0 69 
  IIIC T3 N2 M0 47 
  IIIC T4 N1 M0 51 
  IIIC T4 N2 M0 27 
D 8 IV Any T Any N M1 8 
 
The American Joint Committee on Cancer (AJCC) TNM staging for Tumour, Nodes, 
Metastases for colorectal cancer (2, 317)  
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With permission from the Royal College of Pathologists 
Reference: Williams GT, Quirke P, Shepherd NA on behalf of the RCPath Cancer Services Working 
Group. Dataset for colorectal cancer (2nd edition). London: The Royal College of Pathologists; 2007) 	
	
Appendix 3 
273 
	
Appendix 3: Standard Operating Procedure for the enumeration of 
EPCs and CECs 
 
A. Introduction 
 
This method described the enumeration of: 
• KDR+, CD34+, CD45- cells for endothelial progenitor cells, and 
• CD146+, CD34+, CD45- cells for circulating endothelial cells. 
This enumeration demanded an accurate WCC from the Bayer Advia® Analyser. 
 
B. Materials (and Supplier): 
 
1. BD “FACS Flow” Running solution. (Becton Dickinson, UK) 
2. BD “FACS Clean” Cleaning Solution (Becton Dickinson, UK) 
3. 3 ml BD Falcon tubes (Becton Dickinson, UK) 
4. BD Lysing solution (Becton Dickinson, UK) 
5. Sterile Phosphate Buffered Saline solution, 0.5L bottles (Gibco) 
6. CD45 -FITC conjugated monoclonal antibody (Becton Dickinson, UK) 
7. CD146 – PE conjugated monoclonal antibody (Becton Dickinson, UK) 
8. CD34 –PerCP conjugated monoclonal antibody (Becton Dickinson, UK) 
9. VEGFR2 (KDR)-APC conjugated monoclonal antibody (R&D Systems) 
10. Clear pipette tips (Alpha Laboratories Limited) 
11. Yellow pipette tips (Alpha Laboratories Limited). 
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C. Health and Safety / COSHH (Control of Substances Hazardous to Health) issues 
 
• Lasers 
• Danger of electric shocks 
• Assume bloods may be biohazardous 
 
D. Detailed method 
 
A full blood count (Bayer Advia) was obtained on the same sample of blood to be 
used for flow cytometry to back-calculate CEC/EPC numbers to whole blood. 
 
a. Lysing/fixative solution.  
This was made with 50mls of 10x concentrated FACS Lysing Solution (containing 
formaldehyde, stored at room temperature). It was diluted with 450ml distilled 
water in a 500ml bottle and was not used if older than a month. 
 
b. Blood sample preparation 
2. The vacutainer of EDTA or citrate blood sample was gently vortexed.  With 
yellow tip pipette 0.2mL of blood was added to a 3 mL BD Falcon tube.   
3. Using a different micropipette each time to avoid cross-contamination, 10µL 
each of CD45, CD146, CD34, KDR fluorochrome labelled antibodies with a 
yellow tip micropipette was added. This was flushed into and out of pipette tip to 
ensure thorough mixing and then gently vortexed. The mixture was incubated in 
the dark at room temperature for 20 minutes. 
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4. Using a 1ml pipette 3 ml of pre-diluted BD lysing/fixing solution was added. The 
solution was incubated for 15 minutes in the dark (e.g. inside a box) and then 
centrifuged at 200g for 5 minutes. 
5. The supernatant was decanted and 3 ml of PBS solution is added. With gentle 
vortex the pellet was re-suspended and the solution centrifuged once again at 
200g for 5 minutes. The supernatant was then discarded.  
6. The pellet was re-suspended with 0.5 ml of PBS solution by flushing into and 
out of the clear pipette tip and by gentle vortex to ensure it was thoroughly 
mixed.  The sample was stored in dark at 4oC until ready to be analysed (note 
sample must be processed within three days). 
 
c. Running blood sample. 
1. The CellQuest Pro software was opened and the required settings were 
applied. 
2. The link to the BD FACSCalibur™ was established by clicking ‘Connect to 
Cytometer’, located under the ‘Acquire’ menu. When completed proper shut 
down procedures of the computer and the BD FACSCalibur™, as per the 
manufacturers’ guidance, were observed.     
3. Under the ‘Cytometer’ menu the ‘Instrument Settings’ of the compensations 
and threshold were changed by clicking on the open icon of the window of the 
folders to set the appropriate instrument settings. The system was updated to 
the preferred settings for the acquisition, followed by ‘Set’ and ‘Done’. 
4. The ‘Acquire’ menu was clicked once more followed by the ‘show browser’.   
5. ‘Change’ the directory was clicked to specify the location folder. 
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6. A ‘new folder’ was created if needed. 
7. The sample (in a 3 mL BD Falcon tube) was mixed thoroughly and positioned 
onto the SIP by opening swing arm at bottom right of the cytometer. The swing 
arm was replaced under the tube when ready. 
8. The setup box was un-ticked. The “RUN” and “HIGH” was then clicked.  
9. Both the ‘Run’ and ‘High’ on the control panel of the cytometer were set for a 
target of ≤ 1500 events per second adjusting to ‘Med’ or ‘Low’ as necessary. 
10. On the browser menu, ‘Acquire’ was clicked. Typically the sample ran for ~ 7 
minutes, depending on the cell number.  Total events and five windows of 
detected events were displayed on the screen throughout the process and ran 
until 1,000,000 events were achieved or no sample left was left.  
11. The acquisition was observed closely for blockages (which happened very 
rarely) as suggested when plots did not show any progress and the counters 
did not display any events per second. 
12. If a block was suspected the acquisition was paused and the sample from the 
SIP replaced with water and run for 5 minutes. Once resolved the acquisition 
with the sample on the sip was continued. If the problem persisted assistance 
was sought from the senior scientific staff or the manufacturer. 
13. Once obtained both an electronic and a hard copy were obtained. 
14. Step 11 was repeated for the next sample (again re-suspended with vortex). 
15. The sheath and waste fluid level were checked regularly, refilled and emptied 
respectively as required. 
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E. Interpretation (example given) 
 
7. The WBC count by Bayer Advia was determined e.g. 4.71 x106/mL 
8. The first showed the FSC/SSC plot, which gated almost all cells (R1).  
9. The SSC/CD45 and SSC/CD34 plots determined R3, highly positive ‘CD34 
events’ e.g. n=176 in the gate statistics out of 612,840 total WBC events on FC. 
 
 
Gating for CEC and EPC enumeration 
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10. The R2 of SSC/CD45 with R3 SSC/CD34 collected ‘CD34 cells’, i.e. n=114. 
Hence 114/612840 = 1.860 x 10-4 WBCs are CD34 cells. From the WBC of the 
Advia i.e. 4.71 x 106 cells/ml, there were 876 CD34+ve cells/ml in the venous 
blood. These cells were called CD34+CD45- cells. 
 
11. On the plot of KDR PE vs CD45 PerCP the CD34+ve events were scanned for 
KDR and CD45. The events, i.e. 2, in the upper left quadrant were KDR+ but 
CD45- and therefore were EPCs. Thus 2/114 of the CD34+ve cells were EPCs, 
(or 2/114th of 876) = 15 EPCs/mL. 
 
 
Plot derived from R3 of KDR positive CD 45 negative events (EPC). 
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12. Similarly, on the plot of CD146 FITC vs CD 45PerCP, CECs were low for CD45 
and high for CD146, i.e. 1 event. Therefore, 1/114 of the CD34+ve cells were 
CECs. That is 1/114 of 876 CD34+ cells/mL, or 8 CECs/mL. 
 
 
 
Plot derived from R3 of CD 146 positive and CD 45 negative events (CEC). 
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Instrument Settings for the FACSCalibur® Flow Cytometry Enumeration of  
CECs and EPCs 
 
 
 
  
Cytometer Type:  FACSCalibur
    
D e t e c t o r s / A m p s :
Param    Detector Voltage  AmpGain  Mode     
P1       FSC      E00      1.70     Lin      
P2       SSC      457      1.00     Lin      
P3       FL1      540      1.00     Log      
P4       FL2      600      1.00     Log      
P5       FL3      744      1.00     Log      
P6       FL2-A             1.00     Lin      
P7       FL4      819               Log      
    
T h r e s h o l d :
Primary Parameter:  FSC
Value:  0        
    
Secondary Parameter:  None
    
C o m p e n s a t i o n :
FL1 - 0.7 % FL2
FL2 - 34.0 % FL1
FL2 - 0.0 % FL3
FL3 - 27.5 % FL2
FL3 - 2.9 % FL4
FL4 - 3.8 % FL3
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Appendix 4: Standard Operating Procedure for vWf ELISA Assay 
 
A. Introduction 
 
The method was modified from Short el al (375) and used by my colleagues in 
previous cancer and cardiovascular studies (24, 89, 375). 
 
Synopsis 
This was the standard ELISA for the measurement of von Willebrand factor (vWf) 
using commercial antisera from the Danish company Dako. 
 
Brief Method 
7. The microtitre plate was coated with 100 µl of diluted primary antiserum (30 µl in 
20.5 ml coating buffer pH 9.6) at room temperature (RT) for >60 minutes. 
8. The plate was washed 3 times in PBS/tween, 100 µl of 1/40 serum or plasma in 
pbs/tween was added along with the standards and incubated for >60 minutes. 
9. The wash was repeated 3 times and 100 µl secondary antiserum was added i.e. 
the peroxidase-labelled conjugate (30 µl in 20.5 ml PBS/tween), and incubated for 
>45 minutes at room temperature. 
10. The plate was washed and 100 µl substrate (OPD, hydrogen peroxide, pH 5 
citrate buffer) was added. The colour developed almost immediately. 
11. This was stopped with 50 µl acid, read at 492 nm and concentrations determined 
against the standard curve. 
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Expected values:  in citrated normal plasma are in the region of a mean of 100 with a 
standard deviation 30 IU/dL. Typical values in stable atherosclerosis are 130 IU/dL 
and acute coronary syndromes often 150 IU/dL. Data is generally of normal 
distribution.                   
 
B. Materials 
 
1. Coating Buffer 
 
Reagents 
• Sodium carbonate or Na2CO3 (Sigma).  
• Sodium hydrogen carbonate (NaHCO3) also known as sodium bicarbonate 
(Sigma).  
• Distilled water (Sigma-Aldrich). 
 
Method 
To 500 ml of distilled water 0.795 g (795 mg) sodium carbonate and 1.465 g 
(1,465 mg) sodium hydrogen carbonate were added and placed on rotary mixer 
with magnetic stir bar. At room temperature the salts took around 5 minutes to 
dissolve (as carbonates are relatively insoluble). Generally the pH was very stable 
when stored at 4oC. 
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Biohazard/COSHH: There were no major concerns unless a few kilos/litres are 
consumed orally. Spills were washed off with water and good laboratory practice 
was maintained. 
 
2. Primary Antiserum 
This is rabbit anti-human vWf polyclonal antiserum stored at 4oC (DakoCytomation). 
 
3. Microtitre plates & Yellow and Blue Tips 
Flat-bottomed 96 well microtitre high binding plates (Immunlon 2, Thermo Electron 
Corporation). 
 
4. Wash Buffer 
Reagents 
• Phosphate buffer saline tablets (Sigma). 
• Tween 20 (Sigma). 
• Distilled water (Sigma-Aldrich). 
Method 
To one litre of water 5 tablets of buffer and 0.5 ml Tween were added. This was 
placed on rotamixer with bar and stirred until tablets dissolved. The solution was 
stored at room temperature. 
Biohazard/COSHH: There were no major concerns unless a few kilos/litres are 
consumed orally. Spills with were washed off with water and good laboratory 
practice was maintained. 
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Secondary Antiserum 
This is rabbit anti-human vWf polyclonal antiserum conjugated to horse radish 
peroxidise and stored at 4oC (DakoCytomation). 
 
Substrate 
Reagents 
• Citrate Phosphate Buffer 
- Citric acid (anhydrous), C3H4OH (COOH)3 (Sigma C). 
- Sodium hydrogen phosphate (Na2HPO4) or anhydrous Sodium phosphate 
(Sigma S). 
• Ortho-phenylene diamine (Sigma P).  
• Hydrogen peroxide (Sigma H). 
• Distilled water (Sigma-Aldrich). 
Method for Substrate: citrate buffer plus OPD plus peroxide 
To 500 ml distilled water 3.65 g citric acid and 4.73 g sodium hydrogen 
phosphate were added. If it did not dissolve immediately the pH of 5.3 was 
ensured and adjusted with concentrated acid or concentrated sodium hydroxide 
solution. The buffer was stored at 4oC in the refrigerator. 
To 20 ml citrate phosphate buffer one OPD tablet with 10 µL hydrogen peroxide 
was added and properly mixed (the tablet dissolve in a few minutes). The buffer 
when at room temperature aided more rapid colour development. 
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Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Good laboratory practice was maintained. 
 
Stop Solution 
Hydrochloric acid 1 mol/L (Sigma). 
Biohazard/COSHH: Considerable. Contact with skin/clothes were avoided, spills 
washed off with water and good laboratory practice was maintained. 
 
 
C. DETAILED METHOD 
 
1. Coating microtitre plates 
With a micropipette and a yellow tip 30 µL primary antibody was added to 
approximately 20.5 mls coating buffer, mixed well and poured into a trough. Using an 
eight-channel micropipette with yellow tips, 100 µL was applied to each well of two 
microtitre plates. This was incubated on the bench for at least 1 hour or in the 
refrigerator overnight. 
2. Wash 
Using the eight-channel washing manifold (Sigma), the unbound antiserum was 
washed 3 times with >250 µL PBS/tween. The plates were blotted out on tissue 
paper between steps. 
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3. Samples of plasma, serum or tissue culture fluid 
The samples were thawed in warm water but never for long, to take the chill off (as 
small aliquots thawed quickly even from -70oC).  
vWf is extracted commercially from frozen plasma as cryoprecipitate and therefore 
undissolved precipitates were avoided. 
A 1/40 dilution of plasma was made by adding 10 µL to 390 µL PBS/Tween or 
equivalent. Generally, it was best to lay out the 80 empty, screw-top vials in a rack 
and add 390 µL (blue tip) to each en masse. Then the 10 µl were individually added 
and mixed with up-and-down tip washing.  
 
4. Standards 
These standards were referenced against a WHO standard from the National 
Institute for Biological Standards and Controls (NIBSC), Blanche Lane, South 
Mimms, Potters Bar, Hertfordshire EN6 3QH. They provided a lyophilised ampoule of 
plasma with a defined mass of vWf that could be made up in water to a desired 
concentration e.g. 100 IU/dL.  
These were stored in an Eppendorf tube at -70oC. One vial was thawed in warm 
water and different aliquots were added to 780 µL of dilution buffer as follows. 
a. The Top Standard was created by adding 90 µL of plasma to 780 µL of dilution 
buffer. This ultimately gave a result of 180 IU/dL 
b. The Second Standard was made by adding 60 µL of plasma to 780 µL of dilution 
buffer. This ultimately gave a result of 130 IU/dL 
c. The Third Standard was made by adding 30 µL of plasma to 780 µL of dilution 
buffer. This ultimately gave a result of 90 IU/dL  
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d. The Fourth Standard: 10 µL of plasma was added to 780 µL of dilution buffer to 
ultimately give a result of 65 IU/dL 
e. The Bottom Standard: 5 µL of plasma was added to 780 µL of dilution buffer to 
ultimately give a result of 50 IU/dL 
f. A Blank was made by adding 0 µL of plasma to 780 µL of dilution buffer to 
ultimately give a result of 0 IU/dL 
g. Two wells were left empty (e.g. row D, columns 11 and 12) as blanks 
h. 100 µL sample or standard was added to each well in duplicate.  
i. The Universal control, were also placed in duplicate e.g. row E of columns 11 
and 12.  
j. The plates were incubated at room temperature for minimum of one hour.  
 
5. Wash Again 
The wash procedure was repeated as in step 2 above. 
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6. Conjugate 
Using a micropipette and a yellow tip 35 µL of secondary peroxidase-conjugated 
antibody was added to approximately 20 mls wash buffer (e.g. PBS/tween, green 
Stago buffer) in a tube. This was mixed well and with an eight-channel micropipette 
with yellow tips 100 µL was added to each well of the two microtitre plates. 
The plates were incubated at room temperature for minimum of 45 minutes.  
NB: tips were immediately discarded, as a mere 1 molecule of contaminating enzyme 
would turn the substrate yellow prematurely. 
 
7. Wash Again 
As for step 2 but performed very thoroughly at this stage. Delays were avoided as the 
blanks may become positive giving high backgrounds. 
 
8. Colour Development 
100 µL of substrate was added in a controlled manner, and then, almost immediately, 
the 50 uL acid stop solution at the same speed in the same direction (i.e. both right to 
left).  This was achieved by applying stop solution as soon as the substrate was 
added to the last wells of the second plate.  
When to stop the reaction was a learned skill but generally determined when a 
gradient between all the standards could be differentiated and the blanks were still 
blank. Delays of more than 30 seconds for the colour to develop may have caused 
the enzyme to quickly consume all the substrate and produce a plateau of the 
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dose/response curve. If the reaction was slow the substrate buffer was most likely 
not of the correct pH and adjusted accordingly as already described.  
 
9. Reading and Calculation 
This was performed on an ELISA reader after start-up procedures were observed 
and read at a wavelength of 492 nm. A curve from the standards (IU/dL) was plotted 
from which the optical densities was determined. 
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Appendix 5: Standard Operating Procedure ELISA for soluble e-selectin 
 
A. Introduction 
 
Synopsis 
This was the standard ELISA for measurement of soluble E-Selectin\CD62E (sE-Sel) 
using the duoset from R&D. The method and quantities described were for two plates 
(~75 samples), which required one day for completion. My colleagues in 
cardiovascular disease and breast cancer studies have used it extensively. (22, 24). 
 
Brief method 
7. The microtitre plates were coated with 112ul of capture primary antibody in PBS 
buffer and incubated in the fridge (4oC) overnight or 1.5 hours at room 
temperature (RT). 
8. The plates were washed, 100 ul serum/plasma (diluted 1/5 i.e. 20 plasma plus 80 
blue or pbs-tween buffer) with standards (top ‘prepared’ at 50 ng/mL) were added 
and incubated for 1.5 hours at room temperature. 
The ‘Universal’ plasma was also prepared. 
9. The plates were washed again, 112 ul detection antibody (one vial in 20 mls 1% 
BSA PBS for two plates) was added and incubated for 1.5 hours at RT. 
10. Again the plates were washed, 100 ul Streptavidin-HRP conjugate (diluted 1/200 
in PBS, i.e. 100 ul plus 20 mls) was added and incubated for a minimum of 20 
minutes at room temperature in the dark. 
Appendix 5 
291 
	
11. The plate was washed again and 100ul of substrate (made up from equal 
volumes of reagents A and B) was added. This went blue after 3 – 5 minutes. 
The key definition was a clear gradation of blue colour from the top to the blank. 
12. The reaction was stopped with 75ul Acid (a yellow reaction) and the optical 
density was read at 450 nm. A curve of standards was generated and used to 
determine the concentrations.  
13. The expected values were about 20-40ng/mL and the Universal at 40 ng/mL. 
 
B. Materials 
 
1. Wash Buffer 
Reagents 
• Phosphate buffer saline tablets (Sigma) 
• Tween 20 (Sigma) 
• Distilled water (Sigma- Aldrich) 
Method 
To one litre of water 5 tablets and 0.5 ml Tween with a pastette was added and 
placed on rotamixer with stir bar until tablets dissolved. This was stored at room 
temperature. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Spills were washed off with water and good laboratory practice was 
maintained. 
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2. Primary capture antibody: 
One aliquot (obtained from R&D systems) was defrosted and diluted in a total volume 
20ml PBS buffer to make a working solution for 2 plates.  
 
3. Recombinant standard: 
Each vial in the DuoSet contained 190ng/ml when reconstituted with 0.5ml of 1% 
BSA PBS. To the vial 500 ul of 1% BSA PBS was added, vortexed gently and 
incubated at room temperature for 15 minutes. The required top standard for an ideal 
standard curve was 10ng/ml prepared with 52.6ul from a standard’s vial and 947.4ul 
of 1% BSA PBS. 
 
The standard was double diluted in 1% BSA PBS in the wells of the plate as follows: 
(i) 200 ul (of 10ng/ml) was placed in each of wells 11 and 12 of row A. 
(ii) 100 ul in wells of rows B to H of columns 11 and 12.  
(iii) Wells A to G were double diluted down; the leftover 100 ul was discarded. 
(iv) It followed that 11H and 12H were blanks. 
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4. Controls 
• Internal control (Universal Plasma): This was a pool of plasma aliquots of 60 ul 
and 500 ul volumes. This was treated as one of the plasma samples i.e. dilution of 
20 ul with 80 ul blue or pbs-tween buffer. 
• Control 1 (8ng/ml): This was prepared fresh from the standard vial to verify the 
accuracy of the points on the standard curve obtained by double dilution. From the 
standard vial 42.1ul was added to 957.9ul of 1% BSA PBS. 
• Control 2 (1ng/ml): From the standard vial 5.2 ul was added to 994.8ul of 1% BSA 
PBS. 
• Control 3 (0.5ng/ml): From the standard vial 2.6ul was added to 994.8ul of 1% 
BSA PBS.  
The controls were placed above the blank and the universal below the blank. 
 
5. Secondary detection antibody: 
For this assay, one aliquot (R&D System) was defrosted to make a 20ml in 1% BSA 
PBS for two plates. 
 
6. Streptavidin HRP conjugate 
This was stored at 4oC and diluted to 1/1000 with PBS e.g. 100 ul to 20ml PBS for 
two plates. 
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7.  Substrate 
The R&D System substrate reagent pack was stored at 4oC, contained two 
different reagents in glass bottles, A and B, and mixed in equal amounts 
immediately before use. 
 
8.  Stop Solution: 
Hydrochloric acid 1 mol/L (Sigma). 
Biohazard/COSHH: Considerable. Contact with skin/clothes was avoided, spills 
washed off with water and good laboratory practice was maintained. 
 
C. Detailed Methods 
1. Using a micropipette and a yellow tip, one aliquot of defrosted primary antibody 
to approximately 20 mls PBS buffer was added. Using an eight-channel 
micropipette with yellow tips, 100 µL was added to each well of two microtitre 
plates. These were placed in covered boxes, refrigerated overnight OR incubated 
on the bench for two hours. 
2. With the eight-channel washing manifold (Sigma), unbound antiserum was 
washed out with three lots of >250 µL PBS/tween and blotted between steps. 
3. The 34 plasma samples per plate (in duplicates) along with the universal were 
defrosted and left in fridge overnight. 
4. Into the plate wells 80 uL of blue PBS buffer and 20 ul of plasma were placed. 
5. Top Standard (10ng/ml): rEsel were prepared as above and 200 ul added to 
wells of columns 11 and 12.  To wells B-H columns 11 and 12 was added 100 ul 
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buffer. The standards were double dilute in 100 ul volumes down the plate 
leaving wells 11H and 12 H as blanks. 
6. The plates were rested for a minute to enable homogenisation. 
7. The plates were incubated for 2 hours at room temperature and washed again. 
8. One aliquot of secondary antibody was defrosted and made to 20ml solution in 
1%BSA PBS for two plates. To each well 100 ul of the detection antibody was 
added. 
9. The plates were incubated for 2 hours at room temperature in the lunch box and 
washed. 
10. To each well 100ul of streptavidin-HRP diluted 1/200 in PBS was added. 
Generally this was 100 ul + 20mls buffer. From the fridge reagents A and B were 
brought to room temperature on the bench. 
11. The plates were incubated for 30 minutes at room temperature in the dark. 
12. Excess enzymes were thoroughly washed with THREE cycles. 
13. Equal volumes of substrate components A+B in were placed on a tray and 100 ul 
added to each well. The blue colour developed quite rapidly. 
14. After 3 - 5 minutes, a clear gradient between the top and bottom standard was 
established. The stop reagent i.e. 75 uL acid, was added to each well. The blue 
colour went lemon yellow. Using the ELISA plate reader at 450 nm a standard 
curve was generated from which concentrations were determined. 
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Appendix 6: Standard Operating Procedure ELISA for VEGF 
 
A. Introduction 
 
Synopsis 
Vascular endothelial growth factor (VEGF) is a multi-functional peptide capable of 
inducing angiogenesis and may have effects on endothelial integrity. It has been 
implicated in neovascularisation in adult pathophysiology. This ELISA uses 
commercial antibody and used by my colleagues in previous studies (24, 485, 486). 
 
Brief Method: 
8. Microtitre plates were coated with 100µl of primary antisera (40µl of 40µg/ml in 
10ml coating buffer for 1 plate) and stored overnight in the fridge. 
9. Plates were washed and blocked with 100µl /well of 5% Marvel (1g in 20mls PBS-
T for 2 plates) for 1 hour at room temperature. 
10. Plates were washed, 100µl of neat plasma and recombinant standards added and 
incubated for 2 hours at room temperature. Standards were diluted tenfold with 
fresh tips for each sample. 
11. Plates were washed; 100µl of 500ng/ml of biotinylated anti-human VEGF antibody 
(100µl of 5 µg/ml in 10ml PBS) was added and incubated for 2 hours at RT. 
12. Plates were washed; extravidin peroxidase (100µl/well) was added and incubated 
for 45 minutes at room temperature. 
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13. tes were washed; 100µl substrate (Solutions A and B) was added and incubated 
for 30 minutes at room temperature. The blue colour developed. 
14. Reaction was stopped with 50µl/well acid, the colour changed yellow and the 
concentration after reading at 450 nm.  
Expected values: Data was usually non-parametrically distributed. Controls generally 
had median values of about 30-50pg/ml (but wide IQRs, at times exceeding 
200pg/ml). Patients’ median values generally were 100 to over 200pg/ml. 
 
B. Materials 
 
1. Coating Buffer 
Reagents 
• Sodium carbonate [Na2CO3] (Sigma).  
• Sodium hydrogen carbonate (NaHCO3), or sodium bicarbonate (Sigma). 
NB: both these are anhydrous - ensure you do not order a hydrated species. 
• Distilled water (Sigma-Aldrich). 
Method 
To 500 ml distilled water 0.795 g (=795 mg) sodium carbonate and 1.465 g 
(=1,465 mg) sodium hydrogen carbonate) was added and placed on rotary mixer 
with magnetic stir bar. At room temperature the salts took ~5 minutes or so to 
dissolve (carbonates are relatively insoluble). The solution was stored at 4oC. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Good laboratory practice was maintained. 
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2. Primary Antiserum 
The primary antiserum is goat anti-human VEGF antibody (R&D systems). A vial was 
reconstituted with 1ml PBS (gave a stock of 1mg/ml) and 40µl aliquots (gives 40µg) 
made and stored at –70oC freezer until used. To this 10mls of coating buffer 
(carbonate) was added to give a 4µg/ml solution, i.e. the working concentration and 
enough for 1 plate. 
 
3. Microtitre plates; Yellow and Clear Tips 
Flat-bottomed 96 well microtitre plates (Immunlon 2). 
 
4. Wash Buffer 
Reagents 
• Phosphate buffer saline tablets (Sigma) 
• Tween 20 (Sigma). 
• Distilled water (Sigma- Aldrich) 
 
Appendix 6 
299 
	
Method 
To one litre of water, add 5 tablets and 0.5 ml Tween (with a pastette) was 
added, placed on rotamixer with stir bar and mixed until tablets dissolved. This 
was stored at room temperature. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Good laboratory practice was maintained. 
 
5. Secondary Antiserum 
The secondary antiserum is biotinylated goat anti-human VEGF polyclonal antiserum 
i.e. conjugated to biotin (R&D systems). 
The vial was reconstituted with 1ml of PBS-0.1% BSA (which gave stock of 50µg/ml), 
portioned into 100µl aliquots (giving 5000ng) and stored at –70oC freezer until used.  
To get a 5000ng/10mls or 500ng/ml solution 10mls of PBS-T was added.  
 
6. Steptavidin-HRP conjugate 
Streptavidin binds to biotin, thus amplifying the signal. HRP = horse radish 
peroxidase (R&D Systems). Alternatively extravidin peroxidase may be use (Sigma). 
It was stored at 4 0C. 
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7. Substrate 
This was formed by mixing solutions A and B from R&D Systems. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Good laboratory practice was maintained. 
 
8. Standards 
Standards were obtained from R&D systems. It was present in 100 ul aliquots each 
containing 1000 ng of protein. To get a 200 ng/ml concentration 400 ul of PBS tween 
was added. This was further diluted for the final concentration of 100 ng/mL. 
 
9.  Stop Solution 
Hydrochloric acid 1 mol/L (Sigma). 
Biohazard/COSHH: Considerable. Contact with skin/clothes was avoided, spills 
washed off with water and good laboratory practice was maintained. 
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C. Detailed Method 
1. Coating microtitre plates: With a micropipette and a yellow tip, 40 µl of primary 
antibody aliquots was transferred to 10 mls coating buffer. Using an eight-
channel micropipette with yellow tips 100 µL was placed in each well of the 
microtitre plate.  This was incubated at 4oC overnight. 
2. Wash: Using the eight-channel washing manifold (Sigma), the unbound 
antiserum was washed with three lots of >250 µL PBS/tween. Plates were blot 
out on tissue paper between each step. 
3. Samples: Plasma AND standards were thawed in warm water, but never for long, 
just to take the chill off (from –70oC small aliquots quickly thawed). To each well 
100µl of neat plasma was added and tips changed with each sample. 
4. The Standard Curve: The standard consisted of a small amount of pre-aliquoted 
rVEGF and stored at -70oC. For four plates 2 mls of 3000 pg/mL was used. 
a. From the standard, 1ml was added to 2 ml of PBS/tween to make 3mls at 
1000 pg/mL. 
b. From a, 1 mL was added to 2 ml of PBS tween to make 3 mls at 333 pg/mL. 
c. From b, 1 mL was added to 2 ml of PBS tween to make 3 mls at 111 pg/mL.  
d. From c, 1 mL was added to 2 ml of PBS tween to make 3 mls at 37 pg/mL. 
e. From d, 1 mL was added to 2 ml of PBS tween to make 3 mls at 12 pg/mL. 
f. From e, 1 mL was added to 2 ml of PBS tween to make 3 mls at 4 pg/mL. 
g. From f, 1 mL was added to 2 ml of PBS tween to make 3 mls at 1 pg/mL. 
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Thus this gave eight tubes; 100 µl was added to each of rows A – H, columns 11 
and 12 for the standard curve. The plates were placed in a covered box as 
before and incubated for 2 hours at room temperature. 
5. Wash and secondary detection antibody: Wash was performed as above.  The 
secondary Ab was pre- aliquoted and stored at -70oC. This was transferred to 
10mls of PBS-T, mixed well and 100µl was added to each well with an 8-channel 
pipette. The plates were incubated at room temperature for 2 hours. 
6. Wash: as above. 
7. Peroxidase: With a micropipette and a yellow tip, 10µl of extravidin peroxidase 
was added to approximately 10mls of PBS-T and, using an eight-channel 
micropipette with yellow tips, 100 µL were put into each well. The plates were 
incubated in a covered box and incubated on the bench for 45 minutes. All tips 
were discarded immediately as a mere 1 molecule of contaminating enzyme will 
activate the substrate.  
8. Colour Development: The R&D Systems reagents A and B were used at room 
temperature for quicker development. Once mixed 100 µL was added in a 
controlled manner, and then the acid at the same speed in the same direction 
(eg. both right to left).  This was achieved by applying stop solution as soon as 
the substrate was added to the last wells of the second plate. When to stop the 
reaction was a learned skill but generally determined when a gradient between 
all the standards could be differentiated and the blanks were still blank. Delays of 
longer than 30 seconds for the colour to develop were avoided as the enzyme 
would have quickly consumed all the substrate and given a plateau of the 
Appendix 6 
303 
	
dose/response curve. The initial blue colour turned yellow with the acid. Slow 
reactions suggested that the substrate buffer was not of the correct pH and this 
was adjusted accordingly. 
 
9. Reading and Calculation: The wavelength of 450 nm on optical reader was used 
and a standard curve using 4-6 log versus optical densities was constructed. 
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Appendix 7: Standard Operating Procedure ELISA for Angiogenin 
 
A. Introduction 
 
Synopsis: 
Angiogenin is a potent angiogenic protein whose concentration in serum is elevated 
in patients affected by various types of cancers. Mechanisms by which angiogenin 
induces neovascularization are yet to be elucidated, though this protein interacts with 
endothelial and smooth muscle cells, stimulates a second messenger cascade, 
induces cell proliferation, mediates cell adhesion, activates proteases and induces 
cell invasion.  This SOP has been developed and results reported by my colleagues 
in breast cancer and cardiovascular disease (24, 378, 487). 
 
Brief Method: 
7. Microtitre plate wells were coated with 100µl of primary antiserum at room 
temperature (RT) for 90 minutes or at 4oC overnight. 
8. Plates were washed, plasma added and recombinant standards diluted in 
PBS/tween for 90 minutes at room temperature. 
9. Plates were washed again, 100µl of biotinylated anti-human angiogenin antibody 
(one vial for 10ml PBS-T) added to each well for 90 minutes at RT. 
10. Plates were washed again, 100µl/well of streptavidin-HRP (50µl strep-HRP in 
10mls of PBS-T for 1 plate) was added and incubated for at least 20 minutes at 
room temperature avoiding direct light. 
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11. Plates were washed again, 100µl warm substrate solution (5mls A + 5mls B for 1 
plate) were added. The colour developed in less than 5 minutes. 
12. The reaction was stopped with 50µl/well of acid and read at 450 nm. 
Expected values:  
Data was non-parametric, controls generally had median values of about 5mcg/ml. 
 
B. MATERIALS 
 
1. Primary Antiserum 
The primary antiserum was mouse anti-human Angiogenin antibody (R&D systems). 
A vial was reconstituted with 1ml of PBS (to give 360 µg/ml) and divided into 18 
aliquots of 55µl or 20 µg and stored at -700C until used. To get 2 µg/ml (enough for 1 
plate), 10mls of PBS-T was added.  
 
2. Coating Buffer 
Reagents 
• Sodium carbonate [Na2CO3] (Sigma).  
• Sodium hydrogen carbonate (NaHCO3), also known as sodium bicarbonate 
(Sigma). 
• Distilled water (Sigma-Aldrich). 
Method 
To 500 ml distilled water 0.795 g (=795 mg) sodium carbonate and 1.465 g 
(=1,465 mg) sodium hydrogen carbonate) was added and placed on rotary mixer 
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with magnetic stir bar. At room temperature the salts took ~5 minutes or so to 
dissolve (carbonates are relatively insoluble). The solution was stored at 4oC. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Spills were washed off with water and good laboratory practice 
was maintained. 
 
3. Microtitre plates; Yellow and Clear Tips 
Flat-bottomed 96 well microtitre plates (Immunlon 2). 
 
4. Wash Buffer 
Reagents 
• Phosphate buffer saline tablets (Sigma) 
• Tween 20 (Sigma). 
• Distilled water (Sigma- Aldrich) 
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Method 
To one litre of water, add 5 tablets and 0.5 ml Tween (with a pastette) was 
added, placed on rotamixer with stir bar and mixed until tablets dissolved. This 
was stored at room temperature. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Spills were washed off with water and good laboratory practice 
was maintained. 
 
5. Secondary Antiserum 
The secondary antiserum was biotinylated mouse anti-human Angiogenin antibody 
(R&D systems). One vial was reconstituted with 1ml of PBS 0.1% BSA (to give a 
stock of 50µg/ml), divided into aliquots of 100µl or 5000ng and stored at -70oC 
freezer until used. To get 500ng/ml (enough for 1 plate) 10mls of PBS-T was added.  
 
6. Steptavidin-HRP conjugate 
To 100µl of this conjugate 20mls of PBS-T was added. This gave enough for 2 plates 
or 50µl into 10mls of PBS-T for 1 plate. This was stored at 4 0C. 
 
7. Substrate 
This was formed by mixing solutions A and B from R&D Systems. 
Biohazard/COSHH: There were no major concerns unless a few litres were 
consumed orally. Good laboratory practice was maintained. 
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8. Standards 
Standards were obtained from R&D systems. To one vial 500µl of PBS was added to 
give stock of 50ng/ml (or 25 000pg in 500µl). This was divided into 20 µl aliquots 
containing 1000pg each and stored at -700C until used.  Adding 1980µl of PBS-T to 
each aliquot (i.e.: 1 in 10 dilution) gave a working top standard concentration of 
500pg/ml (4 plates in duplicates). 
 
9.  Stop Solution 
Hydrochloric acid 1 mol/L (Sigma). 
Biohazard/COSHH: Considerable. Contact with skin/clothes was avoided, spills 
washed off with water and good laboratory practice was maintained. 
 
C. METHOD 
1. Coating microtitre plates: With a micropipette and a yellow tip, 55 µl of primary 
antibody aliquots was mixed with approximately 10 mls of PBS. Using an eight-
channel micropipette with yellow tips, 100 µL was placed into each well of the 
microtitre plate. Plates were incubated in a covered box overnight at 4oC. 
2. Wash: Using the eight-channel washing manifold (Sigma), the unbound 
antiserum was washed with three lots of >250 µL PBS/tween and blot out on 
tissue paper between steps. 
3. Samples: i.e. plasma and standards were thawed in warm water but never for 
long, just to take the chill off. The plasma was diluted to 1:2010 as follows: 10µl 
of serum/plasma was mixed with 2000µl of PBS-T (i.e. a 1:201 dilution) in a small 
screw-top plastic tube; with the lid secure it was mixed well by inversion. From 
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this diluted plasma 10µl was placed into the each of three wells of a microtitre 
plate and 90µl of PBS-T to give a final dilution of 1:2010. 
4. Standards: The Standard Angiogenin is kept in the -700C.  
(a) To one vial 1980 µl of PBS tween was added.  
(b) From this 200 µl was placed in wells of columns 11 and 12 of row A.  
(c) 100 µl of PBS-tween was placed in wells of columns 11 and 12, rows B to H. 
(d) Column 11 and 12 were double diluted in 100 µl aliquots from rows A to F. 
(e) It follows that wells 11 and 12 in rows G and H were blanks. 
(f) The universal control was placed in one of the empty wells. 
The plates were replaced in the covered box as before and incubated for at least 
1.5 hours at room temperature. All leftover tubes, vials and tips were discarded. 
5. Wash and Secondary (Detection) Antibody: The plates were washed as above 
(C2). The 55µl aliquots of secondary Ab was transferred to 10mls of PBS-T, 
mixed, 100µl put into each well with an 8-channel pipette and incubated at room 
temperature for 2 hours. 
6. Wash and Conjugate: The plates were washed as above (C2). Using a 
micropipette and a yellow tip, 50µl of streptavidin-HRP was added to 10mls of 
PBS-T. With an eight-channel micropipette with yellow tips, 100 µL was placed to 
each well.  The plates were incubated in the covered box on the bench for a 
minimum of 20 minutes avoiding direct light. The tips were discarded immediately 
as a mere 1 molecule of contaminating enzyme will activate the substrate. 
7. Wash: This was performed FOUR times and thoroughly to avoid positive blanks. 
8. Colour Development: 
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(i) The substrate (equal amounts of Solution A and B) was mixed and brought to 
room temperature. The acid stop solution was placed into its own trough. 
(ii) In a controlled manner 100µl of substrate was added from right to left. That is 
standards developed first. Exactly when to stop the reaction was a learned 
skill. Generally, it was when a gradient was differentiated between all the 
standards and the blanks were still blank.  
(iii) When there was a good gradient down the standard, the stop acid was 
added at the same speed in the same direction (e.g. both right to left).  This 
often meant the reaction was stopped on completing the addition of the 
substrate to the second plate.  
(iv) To stop the reaction 50µl of concentrated was added which changed the blue 
colour to bright yellow.  
9. Reading and Calculation: The ELISA reader the wavelength was set to 450 
nm and a standard curve was generated to determine the concentrations. 
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Appendix 8: Treatment of CRC 
 
A summary of the treatment strategy for CRC is shown  below and adapted from 
guidelines of National Institute for Clinical excellence [NICE] and Association of 
Coloproctology of Great Britain and Ireland [ACPGBI 2007] (285, 318) . 
 
 
Summary of the Treatment Strategy of Colorectal Cancer 
 
 
 
MDT- all patients are discussed in the Multi-Disciplinary Team (primarily of Oncologists, Radiologists, 
Surgeons, Histopathologists, Gastroenterologists, Nurse Specialist) weekly meeting to determine their 
best therapeutic strategy at all stages of the patient’s treatment. 
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Surgery  
 
Surgery, whether laparoscopic or open, is the cornerstone for cure in localised 
disease (285). Curative resections were based on histological and surgical 
confirmation of complete excision as follows (319-321):  
• Distal margins of 5 cm, 2cm for rectal cancers 
• At least 10 to 12 lymph node 
• En-bloc resection of involved organs with no microscopic cancer at the margins 
• For rectal cancer, total excision of the mesorectum (TME) with inferior mesenteric 
nodes and clear circumferential and distal margins. 
 
The liver, more so than the lung, was the most common site of relapse after surgery. 
Resection of liver and lung metastases may substantially improve 5- and 10-year 
survival rates. Improvements in liver surgery along with chemotherapy before and 
after surgery versus surgery alone reduced the risk of relapse. Chemotherapy for 
inoperable liver metastases may render them resectable (322, 323).  
 
Palliative resections may be required to relieve obstruction or improve quality of life 
for advanced and debilitating disease (318). 
  
Appendix 8 
313 
	
Neoadjuvant treatment 
 
This refers to treatment before surgery and typically applies to rectal cancers. The 
meta-analysis of the Colorectal Cancer Collaborative Group concluded both 
preoperative (from 22.5% to 12.5%; p<0.001) and postoperative radiotherapy (25.8% 
to 16.7% p=0.001) reduced local recurrence but the benefit to overall survival was 
marginal (62% vs 63% deaths; p=0.06) (314). Analysing a number of trials in the last 
decade, the Association of Coloproctologists of Great Britain & Ireland recommend 
two strategies: preoperative short course radiotherapy [SCRT] followed by Total 
Mesorectal Excision (TME) surgery or preoperative long course chemotherapy and 
radiotherapy followed thereafter by surgery (285). 
 
Poor results (i.e. local recurrence rates > 10%) are seen with surgery alone, or long 
course postoperative radiotherapy alone (314). The best results were from short 
course preoperative radiotherapy and high quality TME (285). However the long-term 
complications from radiotherapy against the benefits of reducing local recurrence and 
the marginal effect on disease free and overall survival were uncertain. 
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Adjuvant treatment 
 
There are well-established predictive factors for local recurrence after resection and 
hence the need for adjuvant chemotherapy i.e. therapy after surgery (285, 318): 
 
• indeterminate or positive resection margin. 
• lymph node spread. 
• extramural vascular invasion. 
• bowel obstruction at presentation.  
• poor differentiation. 
• less than 10 lymph nodes in the resected specimen. 
• CT,PET, or US scan evidence of metastases. 
 
Ideally radiotherapy is offered preoperatively for rectal cancers but if omitted 
postoperative long course treatment is combined with chemotherapy. Adjuvant 
fluoropyrimidine (Capecitibine or 5-FU) alone or oxaliplatin with 5-FU and folinic acid, 
are offered for of node-positive disease following putatively curative surgery (294).  
 
In node positive disease (Dukes’ C or stage III) 6 months of 5-FU or capecitibine 
reduces mortality by 30% i.e. a 10-15% survival gain. However, beyond this many 
adjuvant trials have not matched the overall survival (OS) benefit at 5 years with the 
3 year disease free survival [DFS] (324).  
 
Adjuvant chemotherapy for Dukes’ B or stage II CRC is controversial given the small 
gains in survival when studies combined stages II and III. However high-risk patients 
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are offered treatment based on the QUASAR study in which OS improved for those 
≤70 years of age [risk reduction of 18% (stage III) and 3·6% (stage II)] (325, 326).   
 
The addition of adjuvant biological or immunotherapy with either edrecolomab 
(monoclonal antibody to epithelial cell adhesion molecule) or bevacizumab 
(humanised monoclonal antibody against VEGF) to chemotherapy did not improve 
DFS of stage II or III disease (327). The QUASAR 2 trial (Bevacuzimab with 
capecitabine vs capecitabine alone for stage II and III disease) conducted in the UK 
has recently closed and the results pending (Appendix 1, page 257). Full details of all 
chemotherapy regimes are tabulated on page 311. 
 
Relapse following surgery, regardless of adjuvant chemotherapy, occurs within 2 
years (328, 329). Intensive follow-up improves survival in a third of patients by 
detecting and radically treating metastases (commonly liver or lung) (314). 
Surveillance involved clinical review, CT scan every year for the first 3 years, and 
colonoscopy a year after surgery and then 3 to 5 yearly (285, 306). Monitoring CEA 
was not routine as it was neither sensitive for nor specific to CRC (314).  
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Adjunct Chemotherapy 
 
This therapy is either part of a trial or for palliation (306).  Palliative chemotherapy 
may improve survival, symptoms, quality of life, and resectability of liver or lung 
metastases (294). 5-FU with irinotecan, oxaliplatin, and targeted regimes has 
increased survival from 1 to roughly 2 years (330, 331). For survival, the sequence of 
the regime, either for initial therapy or for progression of the disease, was not as 
crucial as treatment with all active agents at any given period (332).  
 
The main advance in managing mCRC is the addition of targeted therapies (333). 
Though shown to have relatively little survival benefit, they include Cetuximab 
[human EGFR monoclonal antibody], bevacizumab [human VEGF monoclonal 
antibody], and panitumumab [human EGFR monoclonal antibody], (294). 
Bevacizumab theoretically is a modifier of the endotheliome and angiome, as it 
‘normalises’ the vasculature and hence improves drug delivery to the growing 
tumours (334). When administered with irinotecan and fluorouracil, the OS in the 
responders of untreated mCRC improved by 4·7 months (333, 335, 336).  
 
 
In summary, the staging of CRC has improved with radiological techniques but, in the 
absence of obvious distant spread, is only accurate after resection. Adjuvant and 
adjunct treatment is also monitored radiologically (CT/PET/MRI). However, the 
sensitivity for diagnosing recurrence and/or metastasis on CT is only 70% (specificity 
of 94%). At present invasion into blood vessels, described histologically, is the only 
‘vascular marker’ of prognostic value and identified post-resection.  
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Chemotherapy regimes 
 
Dukes Standard Chemotherapy Regimes 
  
A None 
  
  
B Modified de Gromant regime (488) 
Leucovorin [folinic acid] + 5-fluorouracil [5-FU] (2). 
5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) 
as a 46–48 hr continuous infusion. Repeat every 2 weeks equivalent to 12 cycles or 6 
months. 
   
or Capecitibine [Xeloda] - rarely used by the hospitals in my study. 
Days 1–14: Capecitabine 1,250mg/m2 orally twice daily. Repeat cycle every 3 weeks for 8 
cycles over approximately 6 months. 
   
   
C FOLFOX (488-490) 
Leucovorin [folinic acid] + 5-fluorouracil [5-FU] + oxaliplatin [Eloxatin] 
Day 1: Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 
5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) 
as a 46–48 hr continuous infusion. Repeat every 2 weeks. 
* FOLFOX is superior to 5-FU alone in Stage III patients. 
   
or CapeOX (490, 491) 
Capecitibine [Xeloda] + Oxaliplatin [Eloxatin] 
Capecitibine 1000 mg/m2 PO BID on days 1-14. Oxaliplatin 130 mg/m2 IV over 2 hours on 
day 1. Twenty one day cycle x 8 cycles. 
   
or As for Dukes’ B depending on age and/or coomordities. 
   
   
D Modified de Gromant regime 
   
or FOLFOX 
   
or CapeOX 
   
or FOLFOXIRI  
FOLFOX and irinotecan 
Used by the oncologist if no response to the above regimes. 
   
   
   
 Anti-VEGF Regimes 
   
D 
 
Modified de Gromant regime + Bevacuximab (Avastin®) (492) 
5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) 
as a 46–48 hr continuous infusion. Bevacizumab 5mg/kg every 2 weeks. Repeat biweekly.  
   
B or C QUASAR 2 Trial: Capecitibine vs Capecitibine + Bevacuximab (Avastin®)  
Group 1 - capecitabine (equivalent to standard chemo). Capecitabine tablets twice a day 
(12 hours apart) for 2 weeks out of every 3. None given in the 3rd week. Each 3 week block 
is one cycle of chemotherapy or 8 cycles over about 6 months altogether. 
Group 2 - capecitabine and bevacizumab. capecitabine As for group 1. On day 1 of each 3 
week cycle bevacizumab IV (5mg/kg). In total 8 cycles of capecitabine over about 6 months 
and 16 cycles of bevacizumab or about 12 months altogether. 
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Summary of Treatment of Operable Rectal Cancer 
MRI/CT Stage Histology Pre-Surgery Surgery 
Post-Surgery 
Chemo Radio Chemo Radio Adjunct 
Stage I low risk 
• T1 or 2 
• <3 cm 
• <30% of the 
bowel 
circumference 
• CRM clear 
Moderately 
or  
Well 
differentiated 
- - Local 
excision of 
tumour 
[TART, 
TEM] 
- - - 
Stage I high risk  
• not fulfilling low-
risk criteria 
• CRM clear 
Lymphatic 
+/or 
vascular 
invasion  
+/or  
poorly 
differentiated 
- SCRT Rectal 
Resection 
+/- LCRT - 
Stage II to III 
• CRM clear AND 
• T3N0 OR 
• T4N0 OR 
• Any T,N1 or 2 
 +/- SCRT Rectal 
Resection 
+/- 
CRT 
+/-
CRT 
+/- 
Stage IV 
• +/- CRM  
 CRT CRT Rectal 
Resection 
CRT CRT +/- 
 
MRI- Magnetic Resonance Imaging; Chemo- chemotherapy; Radio- Radiotherapy; TART- Transanal 
Resection of Tumour; TEM- Transanal Endoscopic Microsurgery; SCRT- short Course Radiotherapy; 
CRT- Chemo- Radio- therapy; CRM- Circumferential resection margin.  
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Appendix 9: Regression analysis of patient and tumour factors in CRC stage. 
 
Table A: Univariate and Multivariate regression analysis of patient and tumour factors 
with Dukes’ Stage. 
 
 Univariate  Multivariate 
Versus Dukes’ Stage R2 p   OR 95 % CI p  
         
CEC 0.091 0.159  1.0 1.0 - 1.0 0.032 
EPC -0.119 0.096  1.0 1.0 - 1.0 0.219 
CD34+CD45- cells -0.110 0.115  1.0 1.0 - 1.0 0.189 
WCC 0.086 0.173  1.0 1.0 - 1.1 0.295 
BMI -0.131 0.074  1.0 0.9 - 1.0 0.244 
Sex 0.097 0.143  1.1 0.8 - 1.6 0.408 
Age -0.018 0.424  1.0 1.0 - 1.0 0.712 
Screen detected 0.009 0.461  1.0 0.6 - 1.8 0.929 
Hypertension -0.095 0.115  0.8 0.5 - 1.2 0.225 
Diabetes Mellitus -0.031 0.368  1.1 0.6 - 1.9 0.787 
Ischemic heart disease -0.098 0.114  0.6 0.4 - 1.0 0.065 
First Degree Relative  0.057 0.268  1.1 0.7 - 1.6 0.791 
ACE Inhibitor -0.034 0.355  1.3 0.8 - 2.1 0.251 
ARB -0.051 0.288  1.0 0.5 - 2.2 0.996 
Beta Blocker -0.004 0.481  1.4 0.9 - 2.2 0.148 
Calcium Channel Blocker 0.011 0.451  1.3 0.8 - 2.1 0.345 
Systolic BP -0.018 0.421  1.0 1.0 - 1.0 0.501 
Heart Rate -0.007 0.468  1.0 1.0 - 1.0 0.400 
Saturation 0.020 0.614  1.1 1.0 - 1.3 0.133 
Temperature 0.079 0.192  1.0 0.9 - 1.2 0.583 
Tumour Diameter 0.126 0.084  1.0 1.0 - 1.0 0.635 
Tumour Differentiation 0.092 0.156  1.0 0.8 - 1.3 0.697 
Vascular Invasion 0.131 0.076  1.1 0.8 - 1.7 0.545 
Tumour Site -0.072 0.215  1.0 0.9 - 1.0 0.265 
Number of nodes* 0.376 0.001  1.2 1.1 - 1.3 0.001 
         
 
P values of <0.05. R2 by Pearson’s correlation. OR=Odds Ratio. Tumour perforation and involved 
resection margins were excluded given their very small numbers. Model fit was R2=0.334, p=.013. 
ARB- angiotensin receptor blocker. BMI- Body mass index. BP- blood pressure. * Number of involved 
nodes- correlation was likely as Dukes’ stage C included positive nodes by location, not number 
involved. However, there was minimal difference when number of involved nodes was excluded.  
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Table B: Univariate and Multivariate regression analysis of patient and tumour 
factors with modified AJCC (mAJCC) Stage. 
 
 Univariate  Multivariate 
Versus mAJCC Stage R2 p  OR 95 % CI p 
       
CECml 0.089 0.139  1.0 1.0  1.0 0.166 
EPCml -0.024 0.387  1.0 1.0 - 1.0 0.984 
CD34+CD45- cells -0.056 0.246  1.0 1.0 - 1.0 0.303 
WCC 0.139 0.043  1.1 1.0 - 1.2 0.236 
Sex -0.027 0.373  1.0 0.7 - 1.4 0.936 
Age -0.026 0.375  1.0 1.0 - 1.0 0.877 
BMI -0.136 0.047  0.9 0.9 - 1.0 0.049 
Screen detected -0.062 0.223  0.8 0.4 - 1.6 0.597 
Hypertension -0.052 0.330  0.6 0.4 - 1.0 0.330 
Ischaemic hear disease -0.064 0.150  0.6 0.4 - 1.0 0.062 
First Degree relative 0.019 0.407  0.9 0.6 - 1.4 0.770 
ACE inhibitor 0.014 0.431  1.1 0.7 - 1.8 0.593 
ARB -0.040 0.314  1.0 0.5 - 2.2 0.958 
Beta blocker -0.026 0.374  1.4 0.8 - 2.2 0.198 
Calcium channel blocker 0.097 0.106  1.8 1.1 - 3.0 0.325 
Diabetes Mellitus 0.081 0.161  1.5 0.9 - 2.5 0.147 
Systolic BP 0.001 0.497  1.0 1.0 - 1.0 0.602 
HR -0.056 0.245  1.0 1.0 - 1.0 0.346 
Saturation 0.126 0.061  1.1 0.9 - 1.2 0.252 
Temperature 0.123 0.066  1.2 1.0 - 1.4 0.096 
Tumour Diameter 0.181 0.013  1.0 1.0 - 1.0 0.075 
Differentiation -0.020 0.406  0.9 0.7 - 1.2 0.422 
Vascular Invasion 0.020 0.405  1.0 0.7 - 1.6 0.975 
Tumour Site -0.085 0.150  1.0 0.9 - 1.0 0.456 
         
 
P values of <0.05. R2 by Pearson’s correlation. Model fit was R2=0.212, p=.108. Tumour perforation 
and involved resection margins were excluded given their very small numbers. ARB- angiotensin 
receptor blocker. BMI- Body mass index. BP- blood pressure. Number of nodes involved as nodal 
status is a factor of AJCC staging and were therefore excluded. AJCC was modified by pooling 
T4N2M0 with stage 4 disease (Stage 1-4 were equivalent to Dukes’ A to D), as both had similar life-
expectancies. 
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